Polymorphs and salts of 1,6-naphthidine compounds and their uses in cancer treatment

By combining compound 1 with MAPK pathway inhibitors in multiple crystal forms, the problems of low specificity and off-target effects of existing BRAF-targeted kinase inhibitors have been solved, achieving highly efficient targeted therapy for BRAF gene mutation-driven cancers.

CN123125212APending Publication Date: 2026-11-17BLACK DIAMOND THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202580029528.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-24
Filing Date
2025-04-23
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing B-Raf-targeting kinase inhibitors have low specificity and off-target effects in the treatment of B-Raf mutation-driven cancers, and cannot effectively target specific BRAF/B-Raf mutations, leading to treatment failure or relapse.

Method used

Compound 1 is provided in various crystal forms and its solvates, hydrates or pharmaceutically acceptable salts for use in combination with MAPK pathway inhibitors to target the oncogenic form caused by BRAF gene mutations.

Benefits of technology

It improves the therapeutic effect on cancers driven by BRAF gene mutations, enhances the targeting of B-Raf, reduces off-target effects, and provides a more effective treatment option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123125212A_ABST
    Figure CN123125212A_ABST
Patent Text Reader

Abstract

This disclosure provides compound 1: (compound 1), its solvate, its hydrate, and pharmaceutically acceptable salts thereof. This disclosure also provides methods for preparing said forms and uses of said forms, for example, in the prevention or treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Related applications

[0001] This application claims priority and benefit to U.S. Provisional Application No. 63 / 637,945, filed April 24, 2024, which is incorporated herein by reference in its entirety.

[0002] Reference to the electronic sequence list The contents of the electronic sequence list (ASET-042_001WO_ST26_SequenceListing.xml; size: 2,530 bytes; and creation date: April 18, 2025) are incorporated herein by reference in their entirety. Background Technology

[0003] The human gene encoding the protein B-Raf is known. BRAF Specific mutations in B-Raf drive oncogenic activity in a variety of different cancers. Targeted inactivation of the mutant B-Raf protein through the administration of protein kinase inhibitors has been used to treat many different cancers in patients. However, there exists a subset of patients who either do not respond to these treatments, eventually relapse, or experience secondary lesions / pathway rebound. More specifically, many existing B-Raf-targeting kinase inhibitors either exhibit low specificity for B-Raf, leading to undesirable off-target effects, or only target… BRAF A specific subset of / B-Raf mutations. Therefore, there has long been a need in the field to target mutations caused by / B-Raf. BRAF Novel therapies for specific carcinogenic forms of B-Raf resulting from gene mutations or alterations. This disclosure provides for the prevention or treatment of diseases with... BRAF The crystal form of compound 1 in patients with cancer caused by oncogenic mutations in the gene and B-Raf protein. Summary of the Invention

[0004] In some respects, this disclosure provides a compound 1: The crystal form of its solvate, its hydrate, or its pharmaceutically acceptable salt.

[0005] In some aspects, this disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of compound 1, its solvate, its hydrate or a pharmaceutically acceptable salt thereof in a crystal form, and a pharmaceutically acceptable excipient.

[0006] In some aspects, this disclosure provides a method for treating or preventing cancer in a subject, the method comprising administering to the subject compound 1, its solvate, its hydrate or a pharmaceutically acceptable salt thereof in a crystalline form (e.g., in a therapeutically effective amount).

[0007] In some aspects, this disclosure provides a method for treating a subject with cancer, the method comprising administering to the subject compound 1, its solvate, its hydrate or a pharmaceutically acceptable salt thereof in a crystalline form (e.g., in a therapeutically effective amount).

[0008] In some aspects, this disclosure provides a compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof for the treatment or prevention of cancer in a subject.

[0009] In some aspects, this disclosure provides a compound 1 for treating cancer in a subject, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof in crystal form.

[0010] In some respects, this disclosure provides the use of compound 1, its solvates, its hydrates or pharmaceutically acceptable salts in crystal form in the manufacture of a medicament for the treatment or prevention of cancer in a subject.

[0011] In some respects, this disclosure provides the use of compound 1, its solvates, its hydrates or pharmaceutically acceptable salts in crystal form in the manufacture of a medicament for treating cancer in a subject.

[0012] In some aspects, this disclosure provides a combination comprising compound 1, its solvate, its hydrate or a pharmaceutically acceptable salt thereof, and one or more MAPK pathway inhibitors.

[0013] In some aspects, this disclosure provides a method for treating or preventing cancer in a subject, the method comprising administering to the subject a combination comprising compound 1, its solvate, its hydrate or a pharmaceutically acceptable salt thereof (e.g., at a therapeutically effective amount) and one or more MAPK pathway inhibitors (e.g., at a therapeutically effective amount).

[0014] In some aspects, this disclosure provides a method of treating a subject with cancer, the method comprising administering to the subject a combination comprising compound 1, its solvate, its hydrate or a pharmaceutically acceptable salt thereof (e.g., at a therapeutically effective amount) and one or more MAPK pathway inhibitors (e.g., at a therapeutically effective amount).

[0015] In some aspects, this disclosure provides a combination for treating or preventing cancer in a subject, the combination comprising compound 1, its solvate, its hydrate or a pharmaceutically acceptable salt thereof, and one or more MAPK pathway inhibitors.

[0016] In some aspects, this disclosure provides a combination for treating cancer in a subject, the combination comprising compound 1, its solvate, its hydrate or a pharmaceutically acceptable salt thereof, and one or more MAPK pathway inhibitors.

[0017] In some aspects, this disclosure provides the use of a combination of compound 1, its solvate, its hydrate or a pharmaceutically acceptable salt thereof, and one or more MAPK pathway inhibitors in the manufacture of a medicament for the treatment or prevention of cancer in a subject.

[0018] In some aspects, this disclosure provides the use of a combination of compound 1, its solvate, its hydrate or a pharmaceutically acceptable salt thereof, and one or more MAPK pathway inhibitors in the manufacture of a medicament for treating cancer in a subject.

[0019] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. In this specification, the singular form includes the plural form unless the context clearly requires otherwise. Although methods and materials similar to or equivalent to those described herein may be used to practice or test this disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated herein by reference. No prior art to the claimed inventions is acknowledged in any references cited herein. In case of conflict, this specification, including the definitions, shall prevail. Furthermore, materials, methods, and examples are illustrative only and are not intended to be restrictive. In case of conflict between the chemical structures and names of compounds disclosed herein, the chemical structures shall prevail.

[0020] Other features and advantages of this disclosure will become apparent from the following detailed description and claims. Attached Figure Description

[0021] Figure 1 An XRPD plot of compound 1 in form A is shown.

[0022] Figure 2 The DSC thermogram of compound 1 in form A was depicted.

[0023] Figure 3 The TGA thermogram of compound 1 in form A was depicted.

[0024] Figure 4 The form A of compound 1 is described. 1 H-NMR spectrum.

[0025] Figure 5 DVS isotherms and kinetic plots of compound 1 in form A were depicted.

[0026] Figure 6 An XRPD diagram of form D of compound 1 was depicted.

[0027] Figure 7 The DSC thermogram of compound 1 in form D was depicted.

[0028] Figure 8 The TGA thermogram of compound 1 in form D was depicted.

[0029] Figure 9 The form D of compound 1 is described 1 H-NMR spectrum.

[0030] Figure 10 The DVS isotherm and kinetic plot of compound 1 in form D were depicted.

[0031] Figure 11 An XRPD plot of compound 1 in form I was depicted.

[0032] Figure 12 The DSC thermogram of form I of compound 1 was depicted.

[0033] Figure 13 The TGA thermogram of form I of compound 1 was depicted.

[0034] Figure 14 The form I of compound 1 was described 1 H-NMR spectrum.

[0035] Figure 15 An XRPD diagram of form J of compound 1 was depicted.

[0036] Figure 16 The DSC thermogram of compound 1 in form J was depicted.

[0037] Figure 17 The TGA thermogram of compound 1 in form J was depicted.

[0038] Figure 18 The form J of compound 1 is described 1 H-NMR spectrum.

[0039] Figure 19 The DVS isotherm and kinetic plot of compound 1 in form J were depicted.

[0040] Figure 20 An XRPD plot of compound 1 in form L was depicted.

[0041] Figure 21 The DSC thermogram of compound 1 in form L was depicted.

[0042] Figure 22 The TGA thermogram of compound 1 in form L was depicted.

[0043] Figure 23The form L of compound 1 was described 1 H-NMR spectrum.

[0044] Figure 24 DVS isotherms and kinetic plots were drawn for form L of compound 1.

[0045] Figure 25 An XRPD diagram of form C of compound 1 was depicted.

[0046] Figure 26 The DSC thermogram of compound 1 in form C was depicted.

[0047] Figure 27 The TGA thermogram of compound 1 in form C was depicted.

[0048] Figure 28 The form C of compound 1 is described. 1 H-NMR spectrum.

[0049] Figure 29 An XRPD diagram of form D of compound 1 was depicted.

[0050] Figure 30 The DSC thermogram of compound 1 in form D was depicted.

[0051] Figure 31 The TGA thermogram of compound 1 in form D was depicted.

[0052] Figure 32 The form D of compound 1 is described 1 H-NMR spectrum.

[0053] Figure 33 An XRPD diagram of form E of compound 1 was depicted.

[0054] Figure 34 The DSC thermogram of compound 1 in form E was depicted.

[0055] Figure 35 The TGA thermogram of compound 1 in form E was depicted.

[0056] Figure 36 The form E of compound 1 is described 1 H-NMR spectrum.

[0057] Figure 37 An XRPD plot of compound 1 in form F was depicted.

[0058] Figure 38 The DSC thermogram of compound 1 in form F was depicted.

[0059] Figure 39The TGA thermogram of compound 1 in form F was depicted.

[0060] Figure 40 The form F of compound 1 was described. 1 H-NMR spectrum.

[0061] Figure 41 An XRPD diagram of compound 1 in form G was depicted.

[0062] Figure 42 The DSC thermogram of compound 1 in form G was depicted.

[0063] Figure 43 The TGA thermogram of compound 1 in form G was depicted.

[0064] Figure 44 The form G of compound 1 is described 1 H-NMR spectrum.

[0065] Figure 45 An XRPD diagram of form H of compound 1 was depicted.

[0066] Figure 46 The DSC thermogram of compound 1 in form H was depicted.

[0067] Figure 47 The TGA thermogram of compound 1 in form H was depicted.

[0068] Figure 48 The form H of compound 1 is described 1 H-NMR spectrum.

[0069] Figure 49 An XRPD plot of compound 1 in form I was depicted.

[0070] Figure 50 The DSC thermogram of form I of compound 1 was depicted.

[0071] Figure 51 The TGA thermogram of form I of compound 1 was depicted.

[0072] Figure 52 The form I of compound 1 was described 1 H-NMR spectrum.

[0073] Figure 53 The DSC thermogram of compound 1 in form I was depicted after the solid was heated to 170 °C.

[0074] Figure 54 An XRPD diagram of form J of compound 1 was depicted.

[0075] Figure 55The DSC thermogram of compound 1 in form J was depicted.

[0076] Figure 56 The TGA thermogram of compound 1 in form J was depicted.

[0077] Figure 57 The form J of compound 1 is described 1 H-NMR spectrum.

[0078] Figure 58 An XRPD plot of form K of compound 1 was depicted.

[0079] Figure 59 The DSC thermogram of form K of compound 1 was depicted.

[0080] Figure 60 The TGA thermogram of form K of compound 1 was depicted.

[0081] Figure 61 The form K of compound 1 is described 1 H-NMR spectrum.

[0082] Figure 62 An XRPD plot of compound 1 in form L was depicted.

[0083] Figure 63 The DSC thermogram of compound 1 in form L was depicted.

[0084] Figure 64 The TGA thermogram of compound 1 in form L was depicted.

[0085] Figure 65 The form L of compound 1 was described 1 H-NMR spectrum.

[0086] Figure 66 An XRPD diagram of form M of compound 1 was depicted.

[0087] Figure 67 The DSC thermogram of compound 1 in form M was depicted.

[0088] Figure 68 The TGA thermogram of compound 1 in form M was depicted.

[0089] Figure 69 The form M of compound 1 is described 1 H-NMR spectrum.

[0090] Figure 70 An XRPD plot of form N of compound 1 was depicted.

[0091] Figure 71 The DSC thermogram of form N of compound 1 was depicted.

[0092] Figure 72 The TGA thermogram of form N of compound 1 was depicted.

[0093] Figure 73 The form N of compound 1 is described 1 H-NMR spectrum.

[0094] Figure 74 An XRPD diagram of form O of compound 1 was depicted.

[0095] Figure 75 The DSC thermogram of compound 1 in form O was depicted.

[0096] Figure 76 The TGA thermogram of compound 1 in form O was depicted.

[0097] Figure 77 The form O of compound 1 is described 1 H-NMR spectrum.

[0098] Figure 78 An XRPD plot of compound 1 in form P was depicted.

[0099] Figure 79 The DSC thermogram of compound 1 in form P was depicted.

[0100] Figure 80 The TGA thermogram of compound 1 in form P was depicted.

[0101] Figure 81 The form P of compound 1 is described 1 H-NMR spectrum.

[0102] Figure 82 An XRPD plot of form B of compound 1 was depicted.

[0103] Figure 83 The DSC thermogram of compound 1 in form B was depicted.

[0104] Figure 84 The TGA thermogram of compound 1 in form B was depicted.

[0105] Figure 85 The form B of compound 1 is described 1 H-NMR spectrum.

[0106] Figure 86 TGA thermograms of compositions containing the amorphous form of compound 1 and PVP VA64 were depicted.

[0107] Figure 87TGA thermograms of compositions containing the amorphous form of compound 1 and HPMC ASMG were depicted.

[0108] Figure 88 TGA thermograms of compositions containing the amorphous form of compound 1 and HPMC E3 were depicted.

[0109] Figure 89 TGA thermograms of compositions containing the amorphous form of compound 1 and Eudragit E100 were depicted.

[0110] Figure 90 TGA thermograms of compositions containing the amorphous form of compound 1 and Eudragit L100-55 were depicted.

[0111] Figure 91 The mDSC thermograms of the composition containing the amorphous form of compound 1 and PVP VA64 were depicted.

[0112] Figure 92 The mDSC thermograms of the composition containing the amorphous form of compound 1 and HPMC ASMG were depicted.

[0113] Figure 93 The mDSC thermograms of the composition containing the amorphous form of compound 1 and HPMC E3 were depicted.

[0114] Figure 94 The mDSC thermograms of the composition containing the amorphous form of compound 1 and Eudragit E100 were depicted.

[0115] Figure 95 The mDSC thermograms of the composition containing the amorphous form of compound 1 and Eudragit L100-55 were depicted.

[0116] Figure 96 The mDSC thermograms of the composition containing the amorphous form of compound 1 and PVP VA64 were depicted.

[0117] Figure 97 The mDSC thermograms of the composition containing the amorphous form of compound 1 and Soluplus were depicted.

[0118] Figure 98 The mDSC thermograms of the composition containing the amorphous form of compound 1 and Kollidon 12 PF were depicted.

[0119] Figure 99 The mDSC thermograms of the composition containing the amorphous form of compound 1 and HPMC ASMG were depicted.

[0120] Figure 100 The XRPD diagrams of the following compounds are depicted from top to bottom: a composition containing the amorphous form of compound 1 and Eudragit L100-55; a composition containing the amorphous form of compound 1 and Eudragit E100; a composition containing the amorphous form of compound 1 and HPMCE3; a composition containing the amorphous form of compound 1 and HPMC ASMG; a composition containing the amorphous form of compound 1 and PVP VA64; and crystalline compound 1 (form A). Detailed Implementation

[0121] It is not intended to be theoretically constrained, and it should be understood that the crystal forms disclosed herein may have one or more advantages, for example, compared to other forms of the compound. For instance, the crystal forms disclosed herein (e.g., form A) may have greater stability (e.g., thermodynamic stability, stability with minimal water adsorption under high heat and high humidity, and / or long-term stability), as illustrated in the examples described below.

[0122] It should be understood that, as used herein, the term "compound 1" refers to a compound having the following structure: (Compound 1) Compound 1 or a pharmaceutically acceptable salt thereof may be prepared by any suitable technique known in the art or as described in PCT application number PCT / US2022 / 076164 (incorporated herein by reference).

[0123] In some aspects, this disclosure provides a crystal form of compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof.

[0124] In some implementations, the crystal form is the crystalline form.

[0125] In some embodiments, the crystal form is the crystal form (e.g., crystalline form) of compound 1, its solvate, or its hydrate.

[0126] In some implementations, the crystal form is the crystal form of compound 1 (e.g., crystalline form).

[0127] In some embodiments, the crystal form is the crystal form (e.g., crystalline form) of the solvate (e.g., the isosolvent) of compound 1.

[0128] In some embodiments, the crystal form is the crystal form of the hydrate of compound 1 (e.g., crystalline form).

[0129] In some embodiments, the crystal form is the crystal form (e.g., crystalline form) of compound 1 or a pharmaceutically acceptable salt thereof.

[0130] In some implementations, the crystal form is the crystal form (e.g., crystalline form) of a pharmaceutically acceptable salt of compound 1.

[0131] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof, in the form A.

[0132] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof, in form B.

[0133] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof, in the form of C.

[0134] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof, in the form of D.

[0135] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof, in the form of E.

[0136] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof, in the form of F.

[0137] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof, in the form of G.

[0138] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof, in the form of H.

[0139] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof in form I.

[0140] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof.

[0141] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof, in the form of K.

[0142] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof, in the form of L.

[0143] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof, in the form M.

[0144] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof, in the form of N.

[0145] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof.

[0146] In some implementations, the crystal form is compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof, in the form of P.

[0147] In some respects, this disclosure provides a method for preparing crystalline forms of compound 1, its solvates, its hydrates, or pharmaceutically acceptable salts thereof.

[0148] Form A In some implementations, the crystal form is compound 1, its salt, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof, in form A.

[0149] In some implementations, the crystal form is form A of compound 1.

[0150] X-ray powder diffraction (XRPD) characterization In some embodiments, form A is characterized by an X-ray diffraction (“XRPD”) pattern of a signal (e.g., a peak) contained at 13.2±0.2, 22.3±0.2, and 25.3±0.2 °2θ (e.g., 13.2±0.1, 22.3±0.1, and 25.3±0.1 °2θ (e.g., 13.2, 22.3, and 25.3 °2θ)) using Cu Kα radiation.

[0151] In some embodiments, the XRPD plot of form A further includes at least one signal (e.g., a peak) selected from 18.5±0.2, 19.4±0.2 and 24.8±0.2 °2θ (e.g. 18.5±0.1, 19.4±0.1 and 24.8±0.1 °2θ (e.g. 18.5, 19.4 and 24.8 °2θ)) using Cu Kα radiation.

[0152] In some embodiments, the XRPD plot of Form A further includes at least two signals (e.g., peaks) selected from 18.5±0.2, 19.4±0.2 and 24.8±0.2 °2θ (e.g. 18.5±0.1, 19.4±0.1 and 24.8±0.1 °2θ (e.g. 18.5, 19.4 and 24.8 °2θ)) using Cu Kα radiation.

[0153] In some embodiments, the XRPD plot of Form A further includes a signal (e.g., a peak) at 18.5±0.2, 19.4±0.2, and 24.8±0.2 °2θ (e.g., 18.5±0.1, 19.4±0.1, and 24.8±0.1 °2θ (e.g., 18.5, 19.4, and 24.8 °2θ) using Cu Kα radiation.

[0154] In some embodiments, the XRPD plot of form A further includes at least one signal (e.g., a peak) using Cu Kα radiation selected from 12.8±0.2, 18.5±0.2, 19.4±0.2 and 24.8±0.2 °2θ (e.g. 12.8±0.1, 18.5±0.1, 19.4±0.1 and 24.8±0.1 °2θ (e.g. 12.8, 18.5, 19.4 and 24.8 °2θ)).

[0155] In some embodiments, the XRPD plot of Form A further includes at least two signals (e.g., peaks) selected from 12.8±0.2, 18.5±0.2, 19.4±0.2 and 24.8±0.2 °2θ (e.g. 12.8±0.1, 18.5±0.1, 19.4±0.1 and 24.8±0.1 °2θ (e.g. 12.8, 18.5, 19.4 and 24.8 °2θ)) using Cu Kα radiation.

[0156] In some embodiments, the XRPD plot of Form A further includes a signal (e.g., a peak) at 12.8±0.2, 18.5±0.2, 19.4±0.2 and 24.8±0.2 °2θ (e.g. 12.8±0.1, 18.5±0.1, 19.4±0.1 and 24.8±0.1 °2θ (e.g. 12.8, 18.5, 19.4 and 24.8 °2θ) using Cu Kα radiation.

[0157] In some embodiments, form A is characterized by an X-ray diffraction (“XRPD”) pattern using Cu Kα radiation containing at least three signals (e.g., peaks) selected from 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2 and 25.3±0.2 °2θ (e.g. 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1 and 25.3±0.1 °2θ (e.g. 13.2, 18.5, 19.4, 22.3, 24.8 and 25.3 °2θ)).

[0158] In some embodiments, the XRPD plot of form A includes at least four signals (e.g., peaks) selected from 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2 and 25.3±0.2 °2θ (e.g. 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1 and 25.3±0.1 °2θ (e.g. 13.2, 18.5, 19.4, 22.3, 24.8 and 25.3 °2θ) using Cu Kα radiation.

[0159] In some embodiments, the XRPD plot of form A includes at least five signals (e.g., peaks) selected from 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2 and 25.3±0.2 °2θ (e.g. 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1 and 25.3±0.1 °2θ (e.g. 13.2, 18.5, 19.4, 22.3, 24.8 and 25.3 °2θ) using Cu Kα radiation.

[0160] In some embodiments, the XRPD plot of form A contains a signal (e.g., a peak) at 12.8±0.2, 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2, and 25.3±0.2 °2θ (e.g., 12.8±0.1, 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1, and 25.3±0.1 °2θ (e.g., 12.8, 13.2, 18.5, 19.4, 22.3, 24.8, and 25.3 °2θ) using Cu Kα radiation.

[0161] In some embodiments, form A is characterized by an X-ray diffraction (“XRPD”) pattern using Cu Kα radiation containing at least three signals (e.g., peaks) selected from 12.8±0.2, 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2 and 25.3±0.2 °2θ (e.g. 12.8±0.1, 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1 and 25.3±0.1 °2θ (e.g. 12.8, 13.2, 18.5, 19.4, 22.3, 24.8 and 25.3 °2θ)).

[0162] In some embodiments, the XRPD plot of form A includes at least four signals (e.g., peaks) selected from 12.8±0.2, 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2 and 25.3±0.2 °2θ (e.g. 12.8±0.1, 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1 and 25.3±0.1 °2θ (e.g. 12.8, 13.2, 18.5, 19.4, 22.3, 24.8 and 25.3 °2θ) using Cu Kα radiation.

[0163] In some embodiments, the XRPD plot of form A includes at least five signals (e.g., peaks) selected from 12.8±0.2, 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2 and 25.3±0.2 °2θ (e.g. 12.8±0.1, 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1 and 25.3±0.1 °2θ (e.g. 12.8, 13.2, 18.5, 19.4, 22.3, 24.8 and 25.3 °2θ) using Cu Kα radiation.

[0164] In some embodiments, the XRPD plot of form A contains a signal (e.g., a peak) at 12.8±0.2, 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2, and 25.3±0.2 °2θ (e.g., 12.8±0.1, 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1, and 25.3±0.1 °2θ (e.g., 12.8, 13.2, 18.5, 19.4, 22.3, 24.8, and 25.3 °2θ) using Cu Kα radiation.

[0165] In some implementations, form A is characterized by being substantially similar to Figure 1 The XRPD spectrum shown is the XRPD spectrum.

[0166] In some implementations, Form A is characterized by an XRPD plot containing signals (e.g., peaks) at approximately the locations shown in the table below. It should be understood that the values ​​in the table are approximate and are subject to instrument and experimental variations.

[0167] Table 1: List of exemplary XRPD signals of Form A Differential Scanning Calorimetry (DSC) Characterization In some embodiments, Form A is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 208 ± 20 °C (e.g., 208 ± 10 °C (e.g., 208 ± 5 °C (e.g., 208 ± 4 °C (e.g., 208 ± 3 °C (e.g., 208 ± 2 °C (e.g., 208 ± 1 °C (e.g., 208 ± 0.5 °C))))))))

[0168] In some implementations, Form A is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 208 °C.

[0169] In some embodiments, form A is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of about 93 ± 9 J / g (e.g., 93 ± 8 J / g (e.g., 93 ± 7 J / g (e.g., 93 ± 6 J / g (e.g., 93 ± 5 J / g (e.g., 93 ± 4 J / g (e.g., 93 ± 3 J / g (e.g., 93 ± 2 J / g)))))))

[0170] In some implementations, form A is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 93 J / g.

[0171] In some implementations, form A is characterized by being substantially similar to Figure 2 The DSC spectrum shown is the DSC spectrum.

[0172] Thermogravimetric analysis (TGA) characterization In some embodiments, Form A exhibits a weight loss of about 0.05% to about 0.5% as measured by TGA at temperatures ranging from about 35 ± 20 °C (e.g., 35 ± 10 °C, e.g., 35 ± 5 °C, e.g., 35 ± 4 °C, e.g., 35 ± 3 °C, e.g., 35 ± 2 °C, e.g., 35 ± 1 °C, e.g., 35 ± 0.5 °C) to about 200 ± 20 °C (e.g., 200 ± 10 °C, e.g., 200 ± 5 °C, e.g., 200 ± 4 °C, e.g., 200 ± 3 °C, e.g., 200 ± 2 °C, e.g., 200 ± 1 °C, e.g., 200 ± 0.5 °C)).

[0173] In some implementations, Form A exhibits a weight loss of about 0.28% at temperatures ranging from about 35°C to about 200°C, as measured by TGA.

[0174] In some implementations, form A is characterized by being substantially similar to Figure 3 The TGA spectrum shown is the TGA spectrum.

[0175] In some implementations, the purity of form A is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0176] In some implementations, the purity of form A is greater than 99.0%, greater than 99.1%, greater than 99.2%, greater than 99.3%, greater than 99.4%, greater than 99.5%, greater than 99.6%, greater than 99.7%, greater than 99.8%, or greater than 99.9%.

[0177] In some implementations, after being placed in an open container at 25°C / 92.5%RH for one week, the purity of Form A is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0178] In some implementations, after being placed in an open container at 40°C / 75% RH for one week, the purity of form A is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0179] In some implementations, after being placed in a closed container at 60°C for one week, the purity of form A is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0180] In some implementations, form A is non-hygroscopic.

[0181] In some implementations, Form A experiences water absorption rates of less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% at 95% RH.

[0182] In some implementations, form A has a crystallinity of more than 50%, more than 55%, more than 60%, more than 65%, 70%, more than 75%, more than 80%, more than 85%, more than 90%, or more than 95%.

[0183] In some implementations, Form A has a crystallinity of more than 50%, more than 55%, more than 60%, more than 65%, 70%, more than 75%, more than 80%, more than 85%, more than 90%, or more than 95% after being compressed at 2 MPa for 5 minutes.

[0184] In some implementations, form A has a crystallinity of more than 50%, more than 55%, more than 60%, more than 65%, 70%, more than 75%, more than 80%, more than 85%, more than 90%, or more than 95% after being compressed at 5 MPa for 5 minutes.

[0185] In some implementations, Form A has a crystallinity of more than 50%, more than 55%, more than 60%, more than 65%, 70%, more than 75%, more than 80%, more than 85%, more than 90%, or more than 95% after being compressed at 10 MPa for 5 minutes.

[0186] In some implementations, Form A has a crystallinity of more than 50%, more than 55%, more than 60%, more than 65%, 70%, more than 75%, more than 80%, more than 85%, more than 90%, or more than 95% after being manually ground with a mortar and pestle for 1 minute.

[0187] In some implementations, Form A has a crystallinity of more than 50%, more than 55%, more than 60%, more than 65%, 70%, more than 75%, more than 80%, more than 85%, more than 90%, or more than 95% after being manually ground with a mortar and pestle for 2 minutes.

[0188] In some implementations, Form A has a crystallinity of more than 50%, more than 55%, more than 60%, more than 65%, 70%, more than 75%, more than 80%, more than 85%, more than 90%, or more than 95% after being manually ground with a mortar and pestle for 5 minutes.

[0189] In some embodiments, Form A, after being moistened with water and manually ground with a mortar and pestle, has a crystallinity of more than 50%, more than 55%, more than 60%, more than 65%, 70%, more than 75%, more than 80%, more than 85%, more than 90%, or more than 95%.

[0190] In some embodiments, form A, after being moistened with ethanol and manually ground with a mortar and pestle, has a crystallinity of more than 50%, more than 55%, more than 60%, more than 65%, 70%, more than 75%, more than 80%, more than 85%, more than 90%, or more than 95%.

[0191] In some embodiments, form A has a solubility of more than 80 μg / mL, more than 90 μg / mL, more than 100 μg / mL, more than 110 μg / mL, more than 120 μg / mL, or more than 130 μg / mL in a pH 1.2 HCl solution (0.1 N) over 2 hours.

[0192] In some embodiments, form A has a solubility of more than 60 μg / mL, more than 70 μg / mL, more than 80 μg / mL, more than 90 μg / mL, or more than 95 μg / mL in a pH 1.2 HCl solution (0.1 N) over 24 hours.

[0193] In some implementations, form A has a solubility in SGF (pH 2.0) of more than 60 μg / mL, more than 70 μg / mL, more than 80 μg / mL, more than 90 μg / mL, more than 100 μg / mL, or more than 110 μg / mL within 2 hours.

[0194] In some implementations, form A has a solubility in SGF (pH 2.0) of more than 60 μg / mL, more than 70 μg / mL, more than 80 μg / mL, more than 90 μg / mL, more than 100 μg / mL, or more than 110 μg / mL over 24 hours.

[0195] In some implementations, form A has a solubility in FeSSIF-v1 (pH 5.0) of more than 1 μg / mL, more than 2 μg / mL, more than 4 μg / mL, more than 6 μg / mL, more than 8 μg / mL, or more than 10 μg / mL over 2 hours.

[0196] In some implementations, form A has a solubility in FeSSIF-v1 (pH 5.0) of more than 5 μg / mL, more than 10 μg / mL, more than 15 μg / mL, or more than 20 μg / mL over 24 hours.

[0197] Form B In some implementations, the crystal form is compound 1, its salt, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof, in form B.

[0198] In some implementations, the crystal form is form B of compound 1.

[0199] X-ray powder diffraction (XRPD) characterization In some implementations, form B is characterized by being substantially similar to Figure 82 The XRPD spectrum shown is the XRPD spectrum.

[0200] Differential Scanning Calorimetry (DSC) Characterization In some embodiments, Form B is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 208 ± 20 °C (e.g., 208 ± 10 °C (e.g., 208 ± 5 °C (e.g., 208 ± 4 °C (e.g., 208 ± 3 °C (e.g., 208 ± 2 °C (e.g., 208 ± 1 °C (e.g., 208 ± 0.5 °C))))))))

[0201] In some implementations, Form B is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 208 °C.

[0202] In some embodiments, form B is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of about 86 ± 9 J / g (e.g., 86 ± 8 J / g (e.g., 86 ± 7 J / g (e.g., 86 ± 6 J / g (e.g., 86 ± 5 J / g (e.g., 86 ± 4 J / g (e.g., 86 ± 3 J / g (e.g., 86 ± 2 J / g)))))))).

[0203] In some implementations, form B is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 86 J / g.

[0204] In some implementations, form B is characterized by being substantially similar to Figure 83 The DSC spectrum shown is the DSC spectrum.

[0205] Thermogravimetric analysis (TGA) characterization In some embodiments, Form B exhibits a weight loss of about 0.5% to about 4.0% as measured by TGA at temperatures ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C, e.g., 34 ± 5 ​​°C, e.g., 34 ± 4 °C, e.g., 34 ± 3 °C, e.g., 34 ± 2 °C, e.g., 34 ± 1 °C, e.g., 34 ± 0.5 °C) to about 180 ± 20 °C (e.g., 180 ± 10 °C, e.g., 180 ± 5 °C, e.g., 180 ± 4 °C, e.g., 180 ± 3 °C, e.g., 180 ± 2 °C, e.g., 180 ± 1 °C, e.g., 180 ± 0.5 °C))

[0206] In some implementations, Form B exhibits a weight loss of about 2.3% at temperatures ranging from about 34°C to about 180°C, as measured by TGA.

[0207] In some implementations, form B is characterized by being substantially similar to Figure 84 The TGA spectrum shown is the TGA spectrum.

[0208] Form C In some implementations, the crystal form is compound 1, its salt, its solvate, or its hydrate, in the form of C.

[0209] In some embodiments, the crystal form is a salt of compound 1, its solvate, or its hydrate, in the form of C.

[0210] In some embodiments, the crystal form is the hydrochloride salt of compound 1, its solvate, or its hydrate, in the form C.

[0211] In some embodiments, the crystal form is the hydrochloride form C of compound 1.

[0212] In some embodiments, the hydrochloride salt comprises compound 1 and hydrochloric acid in a ratio of about 1:1. In some embodiments, the hydrochloride salt comprises compound 1 and hydrochloric acid in a ratio of about 1:2. In some embodiments, the hydrochloride salt comprises compound 1 and hydrochloric acid in a ratio of about 2:1.

[0213] X-ray powder diffraction (XRPD) characterization In some implementations, form C is characterized by being substantially similar to Figure 25 The XRPD spectrum shown is the XRPD spectrum.

[0214] Differential Scanning Calorimetry (DSC) Characterization In some embodiments, form C is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 56.6 ± 20 °C (e.g., 56.6 ± 10 °C (e.g., 56.6 ± 5 °C (e.g., 56.6 ± 4 °C (e.g., 56.6 ± 3 °C (e.g., 56.6 ± 2 °C (e.g., 56.6 ± 1 °C (e.g., 56.6 ± 0.5 °C))))))))

[0215] In some implementations, form C is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 56.6 °C.

[0216] In some embodiments, form C is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 188 ± 20 °C (e.g., 188 ± 10 °C (e.g., 188 ± 5 °C (e.g., 188 ± 4 °C (e.g., 188 ± 3 °C (e.g., 188 ± 2 °C (e.g., 188 ± 1 °C (e.g., 188 ± 0.5 °C))))))))

[0217] In some implementations, form C is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 188 °C.

[0218] In some embodiments, form C is characterized by having a DSC curve with an endothermic signal (e.g., a peak) associated with an enthalpy of about 4.09 ± 0.4 J / g (e.g., 4.09 ± 0.3 J / g (e.g., 4.09 ± 0.2 J / g (e.g., 4.09 ± 0.1 J / g (e.g., 4.09 ± 0.08 J / g (e.g., 4.09 ± 0.06 J / g (e.g., 4.09 ± 0.04 J / g (e.g., 4.09 ± 0.02 J / g))))))))

[0219] In some implementations, form C is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 4.09 J / g.

[0220] In some embodiments, form C is characterized by having a DSC curve with an endothermic signal (e.g., a peak) associated with an enthalpy of about 111 ± 12 J / g (e.g., 111 ± 10 J / g (e.g., 111 ± 8 J / g (e.g., 111 ± 6 J / g (e.g., 111 ± 4 J / g (e.g., 111 ± 3 J / g (e.g., 111 ± 2 J / g (e.g., 111 ± 1 J / g)))))))).

[0221] In some implementations, form C is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 111 J / g.

[0222] In some implementations, form C is characterized by being substantially similar to Figure 26 The DSC spectrum shown is the DSC spectrum.

[0223] Thermogravimetric analysis (TGA) characterization In some embodiments, form C exhibits a weight loss of about 0.05% to about 2.5% in the temperature range of about 33 ± 20 °C (e.g., 33 ± 10 °C (e.g., 33 ± 5 °C (e.g., 33 ± 4 °C (e.g., 33 ± 3 °C (e.g., 33 ± 2 °C (e.g., 33 ± 1 °C (e.g., 33 ± 0.5 °C) ...

[0224] In some implementations, form C exhibits a weight loss of about 0.9% at temperatures ranging from about 33°C to about 100°C, as measured by TGA.

[0225] In some embodiments, form C exhibits a weight loss of about 1% to about 7% in the temperature range of about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C) ...

[0226] In some implementations, form C exhibits a weight loss of about 4.4% at temperatures ranging from about 100°C to about 200°C, as measured by TGA.

[0227] In some implementations, form C is characterized by being substantially similar to Figure 27 The TGA spectrum shown is the TGA spectrum.

[0228] Form D In some implementations, the crystal form is compound 1, its salt, its solvate, or its hydrate, in the form of D.

[0229] In some embodiments, the crystal form is the salt of compound 1, its solvate, or its hydrate, in the form of D.

[0230] In some embodiments, the crystal form is the hydrochloride salt of compound 1, its solvate, or its hydrate, in form D.

[0231] In some embodiments, the crystal form is the hydrochloride salt form D of compound 1.

[0232] In some embodiments, the hydrochloride salt comprises compound 1 and hydrochloric acid in a ratio of about 1:1. In some embodiments, the hydrochloride salt comprises compound 1 and hydrochloric acid in a ratio of about 1:2. In some embodiments, the hydrochloride salt comprises compound 1 and hydrochloric acid in a ratio of about 1:3. In some embodiments, the hydrochloride salt comprises compound 1 and hydrochloric acid in a ratio of about 2:1.

[0233] X-ray powder diffraction (XRPD) characterization In some embodiments, form D is characterized by an X-ray diffraction (“XRPD”) pattern of a signal (e.g., a peak) contained at 7.7±0.2, 21.2±0.2, and 26.3±0.2 °2θ (e.g., 7.7±0.1, 21.2±0.1, and 26.3±0.1 °2θ (e.g., 7.7, 21.2, and 26.3°2θ)) using Cu Kα radiation.

[0234] In some embodiments, the XRPD plot of form D further includes at least one signal (e.g., a peak) using Cu Kα radiation selected from 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2θ (e.g., 27.8±0.1, 28.7±0.1, and 30.2±0.1 °2θ (e.g., 27.8, 28.7, and 30.2 °2θ)).

[0235] In some embodiments, the XRPD plot of form D further includes at least two signals (e.g., peaks) selected from 27.8±0.2, 28.7±0.2 and 30.2±0.2 °2θ (e.g. 27.8±0.1, 28.7±0.1 and 30.2±0.1 °2θ (e.g. 27.8, 28.7 and 30.2 °2θ)) using Cu Kα radiation.

[0236] In some embodiments, the XRPD plot of form D further includes a signal (e.g., a peak) at 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2θ (e.g., 27.8±0.1, 28.7±0.1, and 30.2±0.1 °2θ (e.g., 27.8, 28.7, and 30.2 °2θ) using Cu Kα radiation.

[0237] In some embodiments, form D is characterized by an X-ray diffraction (“XRPD”) pattern using Cu Kα radiation containing at least three signals (e.g., peaks) selected from 7.7±0.2, 21.2±0.2, 26.3±0.2, 27.8±0.2, 28.7±0.2 and 30.2±0.2 °2θ (e.g. 7.7±0.1, 21.2±0.1, 26.3±0.1, 27.8±0.1, 28.7±0.1 and 30.2±0.1 °2θ (e.g. 7.7, 21.2, 26.3, 27.8, 28.7 and 30.2 °2θ)).

[0238] In some embodiments, the XRPD plot of form D includes at least four signals (e.g., peaks) selected from 7.7±0.2, 21.2±0.2, 26.3±0.2, 27.8±0.2, 28.7±0.2 and 30.2±0.2 °2θ (e.g. 7.7±0.1, 21.2±0.1, 26.3±0.1, 27.8±0.1, 28.7±0.1 and 30.2±0.1 °2θ (e.g. 7.7, 21.2, 26.3, 27.8, 28.7 and 30.2 °2θ)) using Cu Kα radiation.

[0239] In some embodiments, the XRPD plot of form D includes at least five signals (e.g., peaks) selected from 7.7±0.2, 21.2±0.2, 26.3±0.2, 27.8±0.2, 28.7±0.2 and 30.2±0.2 °2θ (e.g. 7.7±0.1, 21.2±0.1, 26.3±0.1, 27.8±0.1, 28.7±0.1 and 30.2±0.1 °2θ (e.g. 7.7, 21.2, 26.3, 27.8, 28.7 and 30.2 °2θ)) using Cu Kα radiation.

[0240] In some embodiments, the XRPD plot of form D contains a signal (e.g., a peak) at 7.7±0.2, 21.2±0.2, 26.3±0.2, 27.8±0.2, 28.7±0.2 and 30.2±0.2 °2θ (e.g. 7.7±0.1, 21.2±0.1, 26.3±0.1, 27.8±0.1, 28.7±0.1 and 30.2±0.1 °2θ (e.g. 7.7, 21.2, 26.3, 27.8, 28.7 and 30.2 °2θ) using Cu Kα radiation.

[0241] In some implementations, form D is characterized by being substantially similar to Figure 6 Or the XRPD diagram shown in 29.

[0242] In some implementations, form D is characterized by an XRPD plot containing signals (e.g., peaks) at approximately the locations shown in the table below. It should be understood that the values ​​in the table are approximate and are subject to instrument and experimental variations.

[0243] Table 2: List of exemplary XRPD signals of form D Differential Scanning Calorimetry (DSC) Characterization In some embodiments, form D is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 61.5 ± 20 °C (e.g., 61.5 ± 10 °C (e.g., 61.5 ± 5 °C (e.g., 61.5 ± 4 °C (e.g., 61.5 ± 3 °C (e.g., 61.5 ± 2 °C (e.g., 61.5 ± 1 °C (e.g., 61.5 ± 0.5 °C)))))))

[0244] In some implementations, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 61.5 °C.

[0245] In some embodiments, form D is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 141 ± 20 °C (e.g., 141 ± 10 °C (e.g., 141 ± 5 °C (e.g., 141 ± 4 °C (e.g., 141 ± 3 °C (e.g., 141 ± 2 °C (e.g., 141 ± 1 °C (e.g., 141 ± 0.5 °C))))))))

[0246] In some implementations, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 141 °C.

[0247] In some embodiments, form D is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 67 ± 20 °C (e.g., 67 ± 10 °C (e.g., 67 ± 5 °C (e.g., 67 ± 4 °C (e.g., 67 ± 3 °C (e.g., 67 ± 2 °C (e.g., 67 ± 1 °C (e.g., 67 ± 0.5 °C))))))))

[0248] In some implementations, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 67 °C.

[0249] In some embodiments, form D is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 145 ± 20 °C (e.g., 145 ± 10 °C (e.g., 145 ± 5 °C (e.g., 145 ± 4 °C (e.g., 145 ± 3 °C (e.g., 145 ± 2 °C (e.g., 145 ± 1 °C (e.g., 145 ± 0.5 °C))))))))

[0250] In some implementations, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 145 °C.

[0251] In some embodiments, form D is characterized by having a DSC curve with an endothermic signal (e.g., a peak) associated with an enthalpy of approximately 8.48 ± 0.8 J / g (e.g., 8.48 ± 0.7 J / g (e.g., 8.48 ± 0.6 J / g (e.g., 8.48 ± 0.5 J / g (e.g., 8.48 ± 0.4 J / g (e.g., 8.48 ± 0.3 J / g (e.g., 8.48 ± 0.2 J / g (e.g., 8.48 ± 0.1 J / g))))))))

[0252] In some implementations, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 8.48 J / g.

[0253] In some embodiments, form D is characterized by having a DSC curve with an endothermic signal (e.g., a peak) associated with an enthalpy of about 354 ± 35 J / g (e.g., 354 ± 30 J / g (e.g., 354 ± 25 J / g (e.g., 354 ± 20 J / g (e.g., 354 ± 15 J / g (e.g., 354 ± 10 J / g (e.g., 354 ± 5 ​​J / g (e.g., 354 ± 3 J / g)))))))

[0254] In some implementations, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 354 J / g.

[0255] In some embodiments, form D is characterized by having a DSC curve with an endothermic signal (e.g., a peak) associated with an enthalpy of about 16.2 ± 2 J / g (e.g., 16.2 ± 1.5 J / g (e.g., 16.2 ± 1 J / g (e.g., 16.2 ± 0.8 J / g (e.g., 16.2 ± 0.6 J / g (e.g., 16.2 ± 0.4 J / g (e.g., 16.2 ± 0.2 J / g (e.g., 16.2 ± 0.1 J / g))))))))

[0256] In some implementations, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 16.2 J / g.

[0257] In some embodiments, form D is characterized by having a DSC curve with an endothermic signal (e.g., a peak) associated with an enthalpy of about 255 ± 25 J / g (e.g., 255 ± 20 J / g (e.g., 255 ± 15 J / g (e.g., 255 ± 10 J / g (e.g., 255 ± 5 J / g (e.g., 255 ± 4 J / g (e.g., 255 ± 2 J / g (e.g., 255 ± 1 J / g))))))))

[0258] In some implementations, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 255 J / g.

[0259] In some implementations, form D is characterized by being substantially similar to Figure 7 Or the DSC spectrum shown in 30.

[0260] Thermogravimetric analysis (TGA) characterization In some embodiments, Form D exhibits a weight loss of about 0.1% to about 5% as measured by TGA at temperatures ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C, e.g., 34 ± 5 ​​°C, e.g., 34 ± 4 °C, e.g., 34 ± 3 °C, e.g., 34 ± 2 °C, e.g., 34 ± 1 °C, e.g., 34 ± 0.5 °C) to about 90 ± 20 °C (e.g., 90 ± 10 °C, e.g., 90 ± 5 °C, e.g., 90 ± 4 °C, e.g., 90 ± 3 °C, e.g., 90 ± 2 °C, e.g., 90 ± 1 °C, e.g., 90 ± 0.5 °C)).

[0261] In some implementations, form D exhibits a weight loss of about 1.8% at temperatures ranging from about 34°C to about 90°C, as measured by TGA.

[0262] In some embodiments, Form D exhibits a weight loss of about 10% to about 25% in the temperature range of about 90 ± 20 °C (e.g., 90 ± 10 °C (e.g., 90 ± 5 °C (e.g., 90 ± 4 °C (e.g., 90 ± 3 °C (e.g., 90 ± 2 °C (e.g., 90 ± 1 °C (e.g., 90 ± 0.5 °C) ...

[0263] In some implementations, form D exhibits a weight loss of about 17% at temperatures ranging from about 90°C to about 170°C, as measured by TGA.

[0264] In some embodiments, Form D exhibits a weight loss of about 0.1% to about 5% in the temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ...

[0265] In some implementations, form D exhibits a weight loss of about 2.6% at temperatures ranging from about 34°C to about 100°C, as measured by TGA.

[0266] In some embodiments, form D exhibits a weight loss of about 8% to about 25% in the temperature range of about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C) ...

[0267] In some implementations, form D exhibits a weight loss of about 15% at temperatures ranging from about 100°C to about 200°C, as measured by TGA.

[0268] In some implementations, form D is characterized by being substantially similar to Figure 8 Or the TGA spectrum shown in 31.

[0269] In some implementations, the purity of form D is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0270] In some implementations, the purity of form D is greater than 99.0%, greater than 99.1%, greater than 99.2%, greater than 99.3%, greater than 99.4%, greater than 99.5%, greater than 99.6%, greater than 99.7%, greater than 99.8%, or greater than 99.9%.

[0271] In some implementations, after being placed in an open container at 25°C / 92.5%RH for one week, the purity of form D is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0272] In some implementations, after being placed in an open container at 40°C / 75% RH for one week, the purity of form D is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0273] In some implementations, after being placed in a closed container at 60°C for one week, the purity of form D is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0274] In some embodiments, form D has a solubility of more than 80 μg / mL, more than 100 μg / mL, more than 120 μg / mL, more than 140 μg / mL, or more than 160 μg / mL in a pH 1.2 HCl solution (0.1 N) over 2 hours.

[0275] In some embodiments, form D has a solubility of more than 50 μg / mL, more than 60 μg / mL, more than 70 μg / mL, more than 80 μg / mL, or more than 90 μg / mL in a pH 1.2 HCl solution (0.1 N) over 24 hours.

[0276] In some implementations, form D has a solubility in SGF (pH 2.0) of more than 60 μg / mL, more than 70 μg / mL, more than 80 μg / mL, more than 90 μg / mL, more than 100 μg / mL, more than 110 μg / mL, or more than 120 μg / mL over 2 hours.

[0277] In some implementations, form D has a solubility in SGF (pH 2.0) of more than 60 μg / mL, more than 70 μg / mL, more than 80 μg / mL, more than 90 μg / mL, more than 100 μg / mL, or more than 110 μg / mL over 24 hours.

[0278] In some implementations, form D has a solubility in FaSSIF-v1 (pH 6.5) of more than 1 μg / mL, more than 2 μg / mL, more than 3 μg / mL, more than 4 μg / mL, more than 5 μg / mL, or more than 7 μg / mL over 2 hours.

[0279] In some implementations, form D has a solubility of 2 μg / mL, more than 4 μg / mL, more than 6 μg / mL, more than 8 μg / mL, more than 10 μg / mL, or more than 12 μg / mL in FaSSIF-v1 (pH 6.5) over 24 hours.

[0280] In some implementations, form D has a solubility in FeSSIF-v1 (pH 5.0) of more than 50 μg / mL, more than 100 μg / mL, more than 150 μg / mL, more than 200 μg / mL, or more than 250 μg / mL over 2 hours.

[0281] In some implementations, form D has a solubility of 10 μg / mL, more than 20 μg / mL, more than 30 μg / mL, or more than 40 μg / mL in FeSSIF-v1 (pH 5.0) over 24 hours.

[0282] In some embodiments, form D has a solubility in water of more than 60 μg / mL, more than 80 μg / mL, more than 100 μg / mL, more than 120 μg / mL, more than 140 μg / mL, or more than 160 μg / mL within 2 hours.

[0283] In some embodiments, form D has a solubility in water of more than 60 μg / mL, more than 80 μg / mL, more than 100 μg / mL, more than 120 μg / mL, more than 140 μg / mL, or more than 160 μg / mL within 24 hours.

[0284] Form E In some implementations, the crystal form is compound 1, its salt, its solvate, or its hydrate, in the form of E.

[0285] In some embodiments, the crystal form is a salt of compound 1, its solvate, or its hydrate, in the form E.

[0286] In some embodiments, the crystal form is the sulfate of compound 1, its solvate, or its hydrate, in the form E.

[0287] In some implementations, the crystal form is the sulfate form E of compound 1.

[0288] In some embodiments, the sulfate comprises compound 1 and sulfuric acid in a ratio of about 1:1. In some embodiments, the sulfate comprises compound 1 and sulfuric acid in a ratio of about 1:2. In some embodiments, the sulfate comprises compound 1 and sulfuric acid in a ratio of about 2:1.

[0289] X-ray powder diffraction (XRPD) characterization In some implementations, form E is characterized by being substantially similar to Figure 33 The XRPD spectrum shown is the XRPD spectrum.

[0290] Differential Scanning Calorimetry (DSC) Characterization In some embodiments, form E is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 65.9 ± 20 °C (e.g., 65.9 ± 10 °C (e.g., 65.9 ± 5 °C (e.g., 65.9 ± 4 °C (e.g., 65.9 ± 3 °C (e.g., 65.9 ± 2 °C (e.g., 65.9 ± 1 °C (e.g., 65.9 ± 0.5 °C))))))))

[0291] In some implementations, form E is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 65.9 °C.

[0292] In some embodiments, form E is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 200 ± 20 °C (e.g., 200 ± 10 °C (e.g., 200 ± 5 °C (e.g., 200 ± 4 °C (e.g., 200 ± 3 °C (e.g., 200 ± 2 °C (e.g., 200 ± 1 °C (e.g., 200 ± 0.5 °C)))))))).

[0293] In some implementations, form E is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 200 °C.

[0294] In some embodiments, form E is characterized by having a DSC curve with an endothermic signal (e.g., a peak) associated with an enthalpy of approximately 19.3 ± 2.0 J / g (e.g., 19.3 ± 1.5 J / g (e.g., 19.3 ± 1.0 J / g (e.g., 19.3 ± 0.8 J / g (e.g., 19.3 ± 0.6 J / g (e.g., 19.3 ± 0.4 J / g (e.g., 19.3 ± 0.2 J / g (e.g., 19.3 ± 0.1 J / g))))))))

[0295] In some implementations, form E is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 19.3 J / g.

[0296] In some embodiments, form E is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of approximately 64.3 ± 6.5 J / g (e.g., 64.3 ± 4.0 J / g (e.g., 64.3 ± 2.0 J / g (e.g., 64.3 ± 1.0 J / g (e.g., 64.3 ± 0.8 J / g (e.g., 64.3 ± 0.6 J / g (e.g., 64.3 ± 0.4 J / g (e.g., 64.3 ± 0.2 J / g))))))))

[0297] In some implementations, form E is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 64.3 J / g.

[0298] In some implementations, form E is characterized by being substantially similar to Figure 34 The DSC spectrum shown is the DSC spectrum.

[0299] Thermogravimetric analysis (TGA) characterization In some embodiments, form E exhibits a weight loss of about 0.05% to about 4.5% in the temperature range of about 33 ± 20 °C (e.g., 33 ± 10 °C (e.g., 33 ± 5 °C (e.g., 33 ± 4 °C (e.g., 33 ± 3 °C (e.g., 33 ± 2 °C (e.g., 33 ± 1 °C (e.g., 33 ± 0.5 °C) ...

[0300] In some implementations, form E exhibits a weight loss of about 1.3% at temperatures ranging from about 33°C to about 100°C, as measured by TGA.

[0301] In some implementations, form E is characterized by being substantially similar to Figure 35 The TGA spectrum shown is the TGA spectrum.

[0302] Form F In some implementations, the crystal form is compound 1, its salt, its solvate, or its hydrate, in the form of F.

[0303] In some embodiments, the crystal form is the salt of compound 1, its solvate, or its hydrate, in the form of F.

[0304] In some embodiments, the crystal form is the phosphate of compound 1, its solvate, or its hydrate, in the form of F.

[0305] In some implementations, the crystal form is F, the phosphate form of compound 1.

[0306] In some embodiments, the phosphate comprises compound 1 and phosphoric acid in a ratio of about 1:1. In some embodiments, the phosphate comprises compound 1 and phosphoric acid in a ratio of about 1:2. In some embodiments, the phosphate comprises compound 1 and phosphoric acid in a ratio of about 2:1.

[0307] X-ray powder diffraction (XRPD) characterization In some implementations, form F is characterized by being substantially similar to Figure 37 The XRPD spectrum shown is the XRPD spectrum.

[0308] Differential Scanning Calorimetry (DSC) Characterization In some embodiments, form F is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 72.2 ± 20 °C (e.g., 72.2 ± 10 °C (e.g., 72.2 ± 5 °C (e.g., 72.2 ± 4 °C (e.g., 72.2 ± 3 °C (e.g., 72.2 ± 2 °C (e.g., 72.2 ± 1 °C (e.g., 72.2 ± 0.5 °C))))))))

[0309] In some implementations, form F is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 72.2 °C.

[0310] In some embodiments, form F is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 159 ± 20 °C (e.g., 159 ± 10 °C (e.g., 159 ± 5 °C (e.g., 159 ± 4 °C (e.g., 159 ± 3 °C (e.g., 159 ± 2 °C (e.g., 159 ± 1 °C (e.g., 159 ± 0.5 °C))))))))

[0311] In some implementations, form F is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 159 °C.

[0312] In some embodiments, form F is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of approximately 64.4 ± 6.5 J / g (e.g., 64.4 ± 5.0 J / g (e.g., 64.4 ± 4.0 J / g (e.g., 64.4 ± 3.0 J / g (e.g., 64.4 ± 2.0 J / g (e.g., 64.4 ± 1.0 J / g (e.g., 64.4 ± 0.8 J / g (e.g., 64.4 ± 0.5 J / g))))))))

[0313] In some implementations, form F is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 64.4 J / g.

[0314] In some embodiments, form F is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of approximately 33.6 ± 3.5 J / g (e.g., 33.6 ± 3.0 J / g (e.g., 33.6 ± 2.5 J / g (e.g., 33.6 ± 2.0 J / g (e.g., 33.6 ± 1.5 J / g (e.g., 33.6 ± 1.0 J / g (e.g., 33.6 ± 0.5 J / g (e.g., 33.6 ± 0.3 J / g))))))))

[0315] In some implementations, form F is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 33.6 J / g.

[0316] In some implementations, form F is characterized by being substantially similar to Figure 38 The DSC spectrum shown is the DSC spectrum.

[0317] Thermogravimetric analysis (TGA) characterization In some embodiments, form F exhibits a weight loss of about 0.5% to about 7.5% in the temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ...

[0318] In some implementations, form F exhibits a weight loss of about 3.6% at temperatures ranging from about 34°C to about 100°C, as measured by TGA.

[0319] In some implementations, form F is characterized by being substantially similar to Figure 39 The TGA spectrum shown is the TGA spectrum.

[0320] Form G In some implementations, the crystal form is compound 1, its salt, its solvate, or its hydrate, in the form of G.

[0321] In some embodiments, the crystal form is a salt of compound 1, its solvate, or its hydrate, in the form of G.

[0322] In some embodiments, the crystal form is the phosphate of compound 1, its solvate, or its hydrate, in the form G.

[0323] In some implementations, the crystal form is the phosphate form G of compound 1.

[0324] In some embodiments, the phosphate comprises compound 1 and phosphoric acid in a ratio of about 1:1. In some embodiments, the phosphate comprises compound 1 and phosphoric acid in a ratio of about 1:2. In some embodiments, the phosphate comprises compound 1 and phosphoric acid in a ratio of about 2:1.

[0325] X-ray powder diffraction (XRPD) characterization In some implementations, form G is characterized by being substantially similar to Figure 41 The XRPD spectrum shown is the XRPD spectrum.

[0326] Differential Scanning Calorimetry (DSC) Characterization In some embodiments, form G is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 75.1 ± 20 °C (e.g., 75.1 ± 10 °C (e.g., 75.1 ± 5 °C (e.g., 75.1 ± 4 °C (e.g., 75.1 ± 3 °C (e.g., 75.1 ± 2 °C (e.g., 75.1 ± 1 °C (e.g., 75.1 ± 0.5 °C)))))))

[0327] In some implementations, form G is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 75.1 °C.

[0328] In some embodiments, form G is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of approximately 58.4 ± 6.0 J / g (e.g., 58.4 ± 5.0 J / g (e.g., 58.4 ± 4.0 J / g (e.g., 58.4 ± 3.0 J / g (e.g., 58.4 ± 2.0 J / g (e.g., 58.4 ± 1.5 J / g (e.g., 58.4 ± 1.0 J / g (e.g., 58.4 ± 0.5 J / g))))))))

[0329] In some implementations, form G is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 58.4 J / g.

[0330] In some implementations, form G is characterized by being substantially similar to Figure 42 The DSC spectrum shown is the DSC spectrum.

[0331] Thermogravimetric analysis (TGA) characterization In some embodiments, form G exhibits a weight loss of about 2.0% to about 7.5% in the temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ...

[0332] In some implementations, form G exhibits a weight loss of approximately 4.1% at temperatures ranging from approximately 34°C to approximately 100°C, as measured by TGA.

[0333] In some implementations, form G is characterized by being substantially similar to Figure 43 The TGA spectrum shown is the TGA spectrum.

[0334] Form H In some implementations, the crystal form is compound 1, its salt, its solvate, or its hydrate in the form of H.

[0335] In some embodiments, the crystal form is the salt of compound 1, its solvate, or its hydrate in the form of H.

[0336] In some embodiments, the crystal form is the methanesulfonate of compound 1, its solvate, or its hydrate in the form of H.

[0337] In some embodiments, the crystal form is the methanesulfonate form H of compound 1.

[0338] In some embodiments, the methanesulfonate comprises compound 1 and methanesulfonic acid in a ratio of about 1:1. In some embodiments, the methanesulfonate comprises compound 1 and methanesulfonic acid in a ratio of about 1:2. In some embodiments, the methanesulfonate comprises compound 1 and methanesulfonic acid in a ratio of about 2:1.

[0339] X-ray powder diffraction (XRPD) characterization In some implementations, form H is characterized by being substantially similar to Figure 45 The XRPD spectrum shown is the XRPD spectrum.

[0340] Differential Scanning Calorimetry (DSC) Characterization In some embodiments, form H is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 72.4 ± 20 °C (e.g., 72.4 ± 10 °C (e.g., 72.4 ± 5 ​​°C (e.g., 72.4 ± 4 °C (e.g., 72.4 ± 3 °C (e.g., 72.4 ± 2 °C (e.g., 72.4 ± 1 °C (e.g., 72.4 ± 0.5 °C))))))))

[0341] In some implementations, form H is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 72.4 °C.

[0342] In some embodiments, form H is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 163 ± 20 °C (e.g., 163 ± 10 °C (e.g., 163 ± 5 °C (e.g., 163 ± 4 °C (e.g., 163 ± 3 °C (e.g., 163 ± 2 °C (e.g., 163 ± 1 °C (e.g., 163 ± 0.5 °C))))))))

[0343] In some implementations, form H is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 163 °C.

[0344] In some embodiments, form H is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of approximately 49.3 ± 5.0 J / g (e.g., 49.3 ± 4.5 J / g (e.g., 49.3 ± 4.0 J / g (e.g., 49.3 ± 3.5 J / g (e.g., 49.3 ± 3.0 J / g (e.g., 49.3 ± 2.5 J / g (e.g., 49.3 ± 2.0 J / g (e.g., 49.3 ± 1.0 J / g))))))))

[0345] In some implementations, form H is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 49.3 J / g.

[0346] In some embodiments, form H is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of approximately 59.1 ± 6.0 J / g (e.g., 59.1 ± 4.0 J / g (e.g., 59.1 ± 3.0 J / g (e.g., 59.1 ± 2.0 J / g (e.g., 59.1 ± 1.5 J / g (e.g., 59.1 ± 1.0 J / g (e.g., 59.1 ± 0.5 J / g (e.g., 59.1 ± 0.3 J / g))))))))

[0347] In some implementations, form H is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 59.1 J / g.

[0348] In some implementations, form H is characterized by being substantially similar to Figure 46 The DSC spectrum shown is the DSC spectrum.

[0349] Thermogravimetric analysis (TGA) characterization In some embodiments, form H exhibits a weight loss of about 0.1% to about 5% in temperatures ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C, e.g., 34 ± 5 ​​°C, e.g., 34 ± 4 °C, e.g., 34 ± 3 °C, e.g., 34 ± 2 °C, e.g., 34 ± 1 °C, e.g., 34 ± 0.5 °C) to about 100 ± 20 °C (e.g., 100 ± 10 °C, e.g., 100 ± 5 °C, e.g., 100 ± 4 °C, e.g., 100 ± 3 °C, e.g., 100 ± 2 °C, e.g., 100 ± 1 °C, e.g., 100 ± 0.5 °C))

[0350] In some implementations, form H exhibits a weight loss of about 2.4% at temperatures ranging from about 34°C to about 100°C, as measured by TGA.

[0351] In some implementations, form H is characterized by being substantially similar to Figure 47 The TGA spectrum shown is the TGA spectrum.

[0352] Form I In some implementations, the crystal form is compound 1, its salt, its solvate, or its hydrate, in form I.

[0353] In some embodiments, the crystal form is a salt of compound 1, its solvate, or its hydrate, in form I.

[0354] In some embodiments, the crystal form is the benzenesulfonate of compound 1, its solvate, or its hydrate in form I.

[0355] In some embodiments, the crystal form is the benzenesulfonate form I of compound 1.

[0356] In some embodiments, the benzenesulfonate comprises compound 1 and benzenesulfonic acid in a ratio of about 1:1. In some embodiments, the benzenesulfonate comprises compound 1 and benzenesulfonic acid in a ratio of about 1:2. In some embodiments, the benzenesulfonate comprises compound 1 and benzenesulfonic acid in a ratio of about 2:1.

[0357] X-ray powder diffraction (XRPD) characterization In some embodiments, Form I is characterized by an X-ray diffraction (“XRPD”) pattern of a signal (e.g., a peak) contained in Cu Kα radiation at 12.4±0.2, 16.6±0.2, and 23.4±0.2 °2θ (e.g., 12.4±0.1, 16.6±0.1, and 23.4±0.1 °2θ (e.g., 12.4, 16.6, and 23.4 °2θ)).

[0358] In some embodiments, the XRPD plot of Form I further includes at least one signal (e.g., a peak) selected from 19.3±0.2, 26.3±0.2 and 27.2±0.2 °2θ (e.g. 19.3±0.1, 26.3±0.1 and 27.2±0.1 °2θ (e.g. 19.3, 26.3 and 27.2 °2θ)) using Cu Kα radiation.

[0359] In some embodiments, the XRPD plot of Form I further includes at least two signals (e.g., peaks) selected from 19.3±0.2, 26.3±0.2 and 27.2±0.2 °2θ (e.g. 19.3±0.1, 26.3±0.1 and 27.2±0.1 °2θ (e.g. 19.3, 26.3 and 27.2 °2θ)) using Cu Kα radiation.

[0360] In some embodiments, the XRPD plot of Form I further includes a signal (e.g., a peak) at 19.3±0.2, 26.3±0.2, and 27.2±0.2 °2θ (e.g., 19.3±0.1, 26.3±0.1, and 27.2±0.1 °2θ (e.g., 19.3, 26.3, and 27.2 °2θ) using Cu Kα radiation.

[0361] In some embodiments, Form I is characterized by an X-ray diffraction (“XRPD”) pattern using Cu Kα radiation containing at least three signals (e.g., peaks) selected from 12.4±0.2, 16.6±0.2, 19.3±0.2, 23.4±0.2, 26.3±0.2 and 27.2±0.2 °2θ (e.g. 12.4±0.1, 16.6±0.1, 19.3±0.1, 23.4±0.1, 26.3±0.1 and 27.2±0.1 °2θ (e.g. 6.7, 12.1, 15.1, 17.5, 24.2 and 24.6 °2θ)).

[0362] In some embodiments, the XRPD plot of Form I includes at least four signals (e.g., peaks) selected from 12.4±0.2, 16.6±0.2, 19.3±0.2, 23.4±0.2, 26.3±0.2 and 27.2±0.2 °2θ (e.g. 12.4±0.1, 16.6±0.1, 19.3±0.1, 23.4±0.1, 26.3±0.1 and 27.2±0.1 °2θ (e.g. 6.7, 12.1, 15.1, 17.5, 24.2 and 24.6 °2θ) using Cu Kα radiation.

[0363] In some embodiments, the XRPD plot of Form I includes at least five signals (e.g., peaks) selected from 12.4±0.2, 16.6±0.2, 19.3±0.2, 23.4±0.2, 26.3±0.2 and 27.2±0.2 °2θ (e.g. 12.4±0.1, 16.6±0.1, 19.3±0.1, 23.4±0.1, 26.3±0.1 and 27.2±0.1 °2θ (e.g. 6.7, 12.1, 15.1, 17.5, 24.2 and 24.6 °2θ) using Cu Kα radiation.

[0364] In some embodiments, the XRPD plot of Form I includes a signal (e.g., a peak) at 12.4±0.2, 16.6±0.2, 19.3±0.2, 23.4±0.2, 26.3±0.2 and 27.2±0.2 °2θ (e.g. 12.4±0.1, 16.6±0.1, 19.3±0.1, 23.4±0.1, 26.3±0.1 and 27.2±0.1 °2θ (e.g. 6.7, 12.1, 15.1, 17.5, 24.2 and 24.6 °2θ) using Cu Kα radiation.

[0365] In some implementation schemes, Form I is characterized by being substantially similar to Figure 11 Or the XRPD diagram shown in 49.

[0366] In some implementations, Form I is characterized by an XRPD plot containing signals (e.g., peaks) at approximately the locations shown in the table below. It should be understood that the values ​​in the table are approximate and subject to instrument and experimental variations.

[0367] Table 3: List of Exemplary XRPD Signals for Form I Differential Scanning Calorimetry (DSC) Characterization In some embodiments, Form I is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 233 ± 20 °C (e.g., 233 ± 10 °C (e.g., 233 ± 5 °C (e.g., 233 ± 4 °C (e.g., 233 ± 3 °C (e.g., 233 ± 2 °C (e.g., 233 ± 1 °C (e.g., 233 ± 0.5 °C))))))))

[0368] In some implementations, Form I is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 233 °C.

[0369] In some embodiments, Form I is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 128 ± 20 °C (e.g., 128 ± 10 °C (e.g., 128 ± 5 °C (e.g., 128 ± 4 °C (e.g., 128 ± 3 °C (e.g., 128 ± 2 °C (e.g., 128 ± 1 °C (e.g., 128 ± 0.5 °C))))))))

[0370] In some implementations, Form I is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 128 °C.

[0371] In some embodiments, Form I is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 235 ± 20 °C (e.g., 235 ± 10 °C (e.g., 235 ± 5 °C (e.g., 235 ± 4 °C (e.g., 235 ± 3 °C (e.g., 235 ± 2 °C (e.g., 235 ± 1 °C (e.g., 235 ± 0.5 °C))))))))

[0372] In some implementations, Form I is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 235 °C.

[0373] In some embodiments, Form I is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of about 96 ± 9 J / g (e.g., 96 ± 8 J / g (e.g., 96 ± 7 J / g (e.g., 96 ± 6 J / g (e.g., 96 ± 5 J / g (e.g., 96 ± 4 J / g (e.g., 96 ± 2 J / g (e.g., 96 ± 1 J / g)))))))).

[0374] In some implementations, Form I is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 96 J / g.

[0375] In some embodiments, Form I is characterized by having a DSC curve with an endothermic signal (e.g., a peak) associated with an enthalpy of about 40 ± 4 J / g (e.g., 40 ± 3 J / g (e.g., 40 ± 2 J / g (e.g., 40 ± 1 J / g (e.g., 40 ± 0.75 J / g (e.g., 40 ± 0.5 J / g (e.g., 40 ± 0.2 J / g (e.g., 40 ± 0.1 J / g)))))))).

[0376] In some implementations, Form I is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 40 J / g.

[0377] In some embodiments, Form I is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of about 88 ± 9 J / g (e.g., 88 ± 8 J / g (e.g., 88 ± 7 J / g (e.g., 88 ± 6 J / g (e.g., 88 ± 5 J / g (e.g., 88 ± 4 J / g (e.g., 88 ± 2 J / g (e.g., 88 ± 1 J / g)))))))).

[0378] In some implementations, Form I is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 88 J / g.

[0379] In some implementation schemes, Form I is characterized by being substantially similar to Figure 12 Or the DSC spectrum shown in 50.

[0380] Thermogravimetric analysis (TGA) characterization In some embodiments, Form I exhibits a weight loss of about 0.1% to about 2% as measured by TGA at temperatures ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C, 34 ± 5 ​​°C, 34 ± 4 °C, 34 ± 3 °C, 34 ± 2 °C, 34 ± 1 °C, 34 ± 0.5 °C) to about 230 ± 20 °C (e.g., 230 ± 10 °C, 230 ± 5 °C, 230 ± 4 °C, 230 ± 3 °C, 230 ± 2 °C, 230 ± 1 °C, 230 ± 0.5 °C)).

[0381] In some implementations, Form I exhibits a weight loss of about 0.5% at temperatures ranging from about 34°C to about 230°C, as measured by TGA.

[0382] In some implementation schemes, Form I is characterized by being substantially similar to Figure 13 Or the TGA spectrum shown in 51.

[0383] In some implementations, Form I has a purity greater than 99.0%, greater than 99.1%, greater than 99.2%, greater than 99.3%, greater than 99.4%, greater than 99.5%, greater than 99.6%, greater than 99.7%, greater than 99.8%, or greater than 99.9%.

[0384] Form J In some implementations, the crystal form is the form J of compound 1, its salt, its solvate, or its hydrate.

[0385] In some embodiments, the crystal form is the salt of compound 1, its solvate, or its hydrate J.

[0386] In some embodiments, the crystal form is the toluenesulfonate salt of compound 1, its solvate, or its hydrate J.

[0387] In some embodiments, the crystal form is the toluenesulfonate form J of compound 1.

[0388] In some embodiments, the toluenesulfonate comprises compound 1 and p-toluenesulfonic acid in a ratio of about 1:1. In some embodiments, the toluenesulfonate comprises compound 1 and p-toluenesulfonic acid in a ratio of about 1:2. In some embodiments, the toluenesulfonate comprises compound 1 and p-toluenesulfonic acid in a ratio of about 2:1.

[0389] X-ray powder diffraction (XRPD) characterization In some embodiments, form J is characterized by an X-ray diffraction (“XRPD”) pattern of a signal (e.g., a peak) contained at 6.7±0.2, 12.1±0.2, and 15.1±0.2 °2θ (e.g., 6.7±0.1, 12.1±0.1, and 15.1±0.1 °2θ (e.g., 6.7, 12.1, and 15.1°2θ)) using Cu Kα radiation.

[0390] In some embodiments, the XRPD plot of form J further includes at least one signal (e.g., a peak) selected from 17.5±0.2, 24.2±0.2 and 24.6±0.2 °2θ (e.g. 17.5±0.1, 24.2±0.1 and 24.6±0.1 °2θ (e.g. 17.5, 24.2 and 24.6 °2θ)) using Cu Kα radiation.

[0391] In some embodiments, the XRPD plot of form J further includes at least two signals (e.g., peaks) selected from 17.5±0.2, 24.2±0.2 and 24.6±0.2 °2θ (e.g. 17.5±0.1, 24.2±0.1 and 24.6±0.1 °2θ (e.g. 17.5, 24.2 and 24.6 °2θ)) using Cu Kα radiation.

[0392] In some embodiments, the XRPD plot of form J further includes a signal (e.g., a peak) at 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2θ (e.g., 17.5±0.1, 24.2±0.1, and 24.6±0.1 °2θ (e.g., 17.5, 24.2, and 24.6 °2θ) using Cu Kα radiation.

[0393] In some embodiments, form J is characterized by an X-ray diffraction (“XRPD”) pattern using Cu Kα radiation containing at least three signals (e.g., peaks) selected from 6.7±0.2, 12.1±0.2, 15.1±0.2, 17.5±0.2, 24.2±0.2 and 24.6±0.2 °2θ (e.g. 6.7±0.1, 12.1±0.1, 15.1±0.1, 17.5±0.1, 24.2±0.1 and 24.6±0.1 °2θ (e.g. 6.7, 12.1, 15.1, 17.5, 24.2 and 24.6 °2θ)).

[0394] In some embodiments, the XRPD plot of form J includes at least four signals (e.g., peaks) selected from 6.7±0.2, 12.1±0.2, 15.1±0.2, 17.5±0.2, 24.2±0.2 and 24.6±0.2 °2θ (e.g. 6.7±0.1, 12.1±0.1, 15.1±0.1, 17.5±0.1, 24.2±0.1 and 24.6±0.1 °2θ (e.g. 6.7, 12.1, 15.1, 17.5, 24.2 and 24.6 °2θ) using Cu Kα radiation.

[0395] In some embodiments, the XRPD plot of form J includes at least five signals (e.g., peaks) selected from 6.7±0.2, 12.1±0.2, 15.1±0.2, 17.5±0.2, 24.2±0.2 and 24.6±0.2 °2θ (e.g. 6.7±0.1, 12.1±0.1, 15.1±0.1, 17.5±0.1, 24.2±0.1 and 24.6±0.1 °2θ (e.g. 6.7, 12.1, 15.1, 17.5, 24.2 and 24.6 °2θ) using Cu Kα radiation.

[0396] In some embodiments, the XRPD plot of form J contains a signal (e.g., a peak) at 6.7±0.2, 12.1±0.2, 15.1±0.2, 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2θ (e.g., 6.7±0.1, 12.1±0.1, 15.1±0.1, 17.5±0.1, 24.2±0.1, and 24.6±0.1 °2θ (e.g., 6.7, 12.1, 15.1, 17.5, 24.2, and 24.6 °2θ) using Cu Kα radiation.

[0397] In some implementations, form J is characterized by being substantially similar to Figure 15 Or the XRPD diagram shown in 54.

[0398] In some implementations, form J is characterized by an XRPD plot containing signals (e.g., peaks) at approximately the locations shown in the table below. It should be understood that the values ​​in the table are approximate and subject to instrument and experimental variations.

[0399] Table 4: List of Exemplary XRPD Signals of Form J Differential Scanning Calorimetry (DSC) Characterization In some embodiments, form J is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 204 ± 20 °C (e.g., 204 ± 10 °C (e.g., 204 ± 5 ​​°C (e.g., 204 ± 4 °C (e.g., 204 ± 3 °C (e.g., 204 ± 2 °C (e.g., 204 ± 1 °C (e.g., 204 ± 0.5 °C))))))))

[0400] In some implementations, form J is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 204 °C.

[0401] In some embodiments, form J is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of about 76 ± 8 J / g (e.g., 76 ± 7 J / g (e.g., 76 ± 6 J / g (e.g., 76 ± 5 J / g (e.g., 76 ± 4 J / g (e.g., 76 ± 3 J / g (e.g., 76 ± 2 J / g (e.g., 76 ± 1 J / g)))))))).

[0402] In some implementations, form J is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 76 J / g.

[0403] In some embodiments, form J is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 205 ± 20 °C (e.g., 205 ± 10 °C (e.g., 205 ± 5 °C (e.g., 205 ± 4 °C (e.g., 205 ± 3 °C (e.g., 205 ± 2 °C (e.g., 205 ± 1 °C (e.g., 205 ± 0.5 °C))))))))

[0404] In some implementations, form J is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 205 °C.

[0405] In some embodiments, form J is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of about 62 ± 6 J / g (e.g., 62 ± 5 J / g (e.g., 62 ± 4 J / g (e.g., 62 ± 3 J / g (e.g., 62 ± 2 J / g (e.g., 62 ± 1 J / g (e.g., 62 ± 0.75 J / g (e.g., 62 ± 0.5 J / g)))))))).

[0406] In some implementations, form J is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 62 J / g.

[0407] In some implementations, form J is characterized by being substantially similar to Figure 16 Or the DSC spectrum shown in 55.

[0408] Thermogravimetric analysis (TGA) characterization In some embodiments, Form J exhibits a weight loss of about 0.1% to about 2% in the temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C, e.g., 34 ± 5 ​​°C, e.g., 34 ± 4 °C, e.g., 34 ± 3 °C, e.g., 34 ± 2 °C, e.g., 34 ± 1 °C, e.g., 34 ± 0.5 °C) to about 200 ± 20 °C (e.g., 200 ± 10 °C, e.g., 200 ± 5 °C, e.g., 200 ± 4 °C, e.g., 200 ± 3 °C, e.g., 200 ± 2 °C, e.g., 200 ± 1 °C, e.g., 200 ± 0.5 °C)))))), as measured by TGA.

[0409] In some implementations, form J exhibits a weight loss of about 0.7% at temperatures ranging from about 34°C to about 200°C, as measured by TGA.

[0410] In some embodiments, Form J exhibits a weight loss of about 0.1% to about 2.5% in temperatures ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C, e.g., 34 ± 5 ​​°C, e.g., 34 ± 4 °C, e.g., 34 ± 3 °C, e.g., 34 ± 2 °C, e.g., 34 ± 1 °C, e.g., 34 ± 0.5 °C) to about 200 ± 20 °C (e.g., 200 ± 10 °C, e.g., 200 ± 5 °C, e.g., 200 ± 4 °C, e.g., 200 ± 3 °C, e.g., 200 ± 2 °C, e.g., 200 ± 1 °C, e.g., 200 ± 0.5 °C))

[0411] In some implementations, form J exhibits a weight loss of about 0.9% at temperatures ranging from about 34°C to about 200°C, as measured by TGA.

[0412] In some implementations, form J is characterized by being substantially similar to Figure 17 Or the TGA spectrum shown in 56.

[0413] In some implementations, the purity of form J is greater than 99.0%, greater than 99.1%, greater than 99.2%, greater than 99.3%, greater than 99.4%, greater than 99.5%, greater than 99.6%, greater than 99.7%, greater than 99.8%, or greater than 99.9%.

[0414] In some implementations, form J experiences water absorption rates of less than 2.0%, less than 1.5%, less than 1.0%, less than 0.75%, or less than 0.5% at 95% RH.

[0415] In some implementations, after being placed in an open container at 25°C / 92.5%RH for one week, the purity of form J is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0416] In some implementations, after being placed in an open container at 40°C / 75% RH for one week, the purity of form J is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0417] In some implementations, after being placed in a closed container at 60°C for one week, the purity of form J is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0418] In some embodiments, form J has a solubility in pH 1.2 HCl solution (0.1 N) of more than 20 μg / mL, more than 40 μg / mL, more than 60 μg / mL, more than 80 μg / mL, more than 100 μg / mL, or more than 110 μg / mL over 2 hours.

[0419] In some embodiments, form J has a solubility of more than 50 μg / mL, more than 60 μg / mL, more than 70 μg / mL, more than 80 μg / mL, or more than 90 μg / mL in a pH 1.2 HCl solution (0.1 N) over 24 hours.

[0420] In some embodiments, form J has a solubility in SGF (pH 2.0) of more than 20 μg / mL, more than 40 μg / mL, more than 60 μg / mL, more than 80 μg / mL, or more than 100 μg / mL within 2 hours.

[0421] In some implementations, form J has a solubility in SGF (pH 2.0) of more than 50 μg / mL, more than 60 μg / mL, more than 70 μg / mL, more than 80 μg / mL, or more than 90 μg / mL over 24 hours.

[0422] In some implementations, form J has a solubility in FeSSIF-v1 (pH 5.0) of more than 20 μg / mL, more than 40 μg / mL, more than 60 μg / mL, more than 80 μg / mL, or more than 100 μg / mL over 2 hours.

[0423] In some implementations, form J has a solubility in FeSSIF-v1 (pH 5.0) of more than 5 μg / mL, more than 10 μg / mL, more than 15 μg / mL, or more than 20 μg / mL over 24 hours.

[0424] In some embodiments, form J has a solubility in water of more than 2 μg / mL, more than 4 μg / mL, more than 8 μg / mL, more than 12 μg / mL, or more than 16 μg / mL within 2 hours.

[0425] In some embodiments, form J has a solubility in water of more than 2 μg / mL, more than 4 μg / mL, more than 8 μg / mL, more than 12 μg / mL, more than 16 μg / mL, or more than 20 μg / mL within 24 hours.

[0426] Form K In some implementations, the crystal form is compound 1, its salt, its solvate, or its hydrate, in the form of K.

[0427] In some embodiments, the crystal form is K, which is a salt of compound 1, its solvate, or its hydrate.

[0428] In some embodiments, the crystal form is the maleate salt of compound 1, its solvate, or its hydrate, in the form K.

[0429] In some implementations, the crystal form is the maleate form K of compound 1.

[0430] In some embodiments, the maleate salt comprises compound 1 and maleic acid in a ratio of about 1:1. In some embodiments, the maleate salt comprises compound 1 and maleic acid in a ratio of about 1:2. In some embodiments, the maleate salt comprises compound 1 and maleic acid in a ratio of about 2:1.

[0431] X-ray powder diffraction (XRPD) characterization In some implementations, form K is characterized by being substantially similar to Figure 58 The XRPD spectrum shown is the XRPD spectrum.

[0432] Differential Scanning Calorimetry (DSC) Characterization In some embodiments, form K is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 57.1 ± 20 °C (e.g., 57.1 ± 10 °C (e.g., 57.1 ± 5 °C (e.g., 57.1 ± 4 °C (e.g., 57.1 ± 3 °C (e.g., 57.1 ± 2 °C (e.g., 57.1 ± 1 °C (e.g., 57.1 ± 0.5 °C))))))))

[0433] In some implementations, form K is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 57.1 °C.

[0434] In some embodiments, form K is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 121 ± 20 °C (e.g., 121 ± 10 °C (e.g., 121 ± 5 °C (e.g., 121 ± 4 °C (e.g., 121 ± 3 °C (e.g., 121 ± 2 °C (e.g., 121 ± 1 °C (e.g., 121 ± 0.5 °C))))))))

[0435] In some implementations, form K is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 121 °C.

[0436] In some embodiments, form K is characterized by having a DSC curve with an endothermic signal (e.g., a peak) associated with an enthalpy of about 12.9 ± 1.5 J / g (e.g., 12.9 ± 1.3 J / g (e.g., 12.9 ± 1.0 J / g (e.g., 12.9 ± 0.8 J / g (e.g., 12.9 ± 0.6 J / g (e.g., 12.9 ± 0.4 J / g (e.g., 12.9 ± 0.2 J / g (e.g., 12.9 ± 0.1 J / g))))))))

[0437] In some implementations, form K is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 12.9 J / g.

[0438] In some embodiments, form K is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of about 91.9 ± 10 J / g (e.g., 91.9 ± 8 J / g (e.g., 91.9 ± 6 J / g (e.g., 91.9 ± 5 J / g (e.g., 91.9 ± 4 J / g (e.g., 91.9 ± 3 J / g (e.g., 91.9 ± 2 J / g (e.g., 91.9 ± 1 J / g)))))))

[0439] In some implementations, form K is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 91.9 J / g.

[0440] In some implementations, form K is characterized by being substantially similar to Figure 59 The DSC spectrum shown is the DSC spectrum.

[0441] Thermogravimetric analysis (TGA) characterization In some embodiments, form K exhibits a weight loss of about 0.1% to about 5% as measured by TGA at temperatures ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C, e.g., 34 ± 5 ​​°C, e.g., 34 ± 4 °C, e.g., 34 ± 3 °C, e.g., 34 ± 2 °C, e.g., 34 ± 1 °C, e.g., 34 ± 0.5 °C) to about 80 ± 20 °C (e.g., 80 ± 10 °C, e.g., 80 ± 5 °C, e.g., 80 ± 4 °C, e.g., 80 ± 3 °C, e.g., 80 ± 2 °C, e.g., 80 ± 1 °C, e.g., 80 ± 0.5 °C)).

[0442] In some implementations, form K exhibits a weight loss of about 2.0% at temperatures ranging from about 34°C to about 80°C, as measured by TGA.

[0443] In some embodiments, form K exhibits a weight loss of about 8% to about 25% in the temperature range of about 80 ± 20 °C (e.g., 80 ± 10 °C, e.g., 80 ± 5 °C, e.g., 80 ± 4 °C, e.g., 80 ± 3 °C, e.g., 80 ± 2 °C, e.g., 80 ± 1 °C, e.g., 80 ± 0.5 °C) to about 250 ± 20 °C (e.g., 250 ± 10 °C, e.g., 250 ± 5 °C, e.g., 250 ± 4 °C, e.g., 250 ± 3 °C, e.g., 250 ± 2 °C, e.g., 250 ± 1 °C, e.g., 250 ± 0.5 °C)))))), as measured by TGA.

[0444] In some implementations, form K exhibits a weight loss of about 15% at temperatures ranging from about 80°C to about 250°C, as measured by TGA.

[0445] In some implementations, form K is characterized by being substantially similar to Figure 60 The TGA spectrum shown is the TGA spectrum.

[0446] Form L In some implementations, the crystal form is compound 1, its salt, its solvate, or its hydrate, in the form of L.

[0447] In some embodiments, the crystal form is a salt of compound 1, its solvate, or its hydrate, in the form of L.

[0448] In some embodiments, the crystal form is the fumarate of compound 1, its solvate, or its hydrate, in the form L.

[0449] In some embodiments, the crystal form is the fumarate form L of compound 1.

[0450] In some embodiments, the fumarate comprises compound 1 and fumaric acid in a ratio of about 1:1. In some embodiments, the fumarate comprises compound 1 and fumaric acid in a ratio of about 1:2. In some embodiments, the fumarate comprises compound 1 and fumaric acid in a ratio of about 2:1.

[0451] X-ray powder diffraction (XRPD) characterization In some embodiments, form L is characterized by an X-ray diffraction (“XRPD”) pattern of a signal (e.g., a peak) contained in Cu Kα radiation at 12.5±0.2, 15.6±0.2, and 27.0±0.2 °2θ (e.g., 12.5±0.1, 15.6±0.1, and 27.0±0.1 °2θ (e.g., 12.5, 15.6, and 27.0 °2θ)).

[0452] In some embodiments, the XRPD plot of form L further includes at least one signal (e.g., a peak) using Cu Kα radiation selected from 12.5±0.2, 15.6±0.2, and 27.0±0.2 °2θ (e.g., 12.5±0.1, 15.6±0.1, and 27.0±0.1 °2θ (e.g., 12.5, 15.6, and 27.0 °2θ)).

[0453] In some embodiments, the XRPD plot of form L further includes at least two signals (e.g., peaks) selected from 12.5±0.2, 15.6±0.2 and 27.0±0.2 °2θ (e.g. 12.5±0.1, 15.6±0.1 and 27.0±0.1 °2θ (e.g. 12.5, 15.6 and 27.0 °2θ)) using Cu Kα radiation.

[0454] In some embodiments, the XRPD plot of form L further includes a signal (e.g., a peak) at 12.5±0.2, 15.6±0.2, and 27.0±0.2 °2θ (e.g., 12.5±0.1, 15.6±0.1, and 27.0±0.1 °2θ (e.g., 12.5, 15.6, and 27.0 °2θ) using Cu Kα radiation.

[0455] In some embodiments, form L is characterized by an X-ray diffraction (“XRPD”) pattern using Cu Kα radiation containing at least three signals (e.g., peaks) selected from 12.0±0.2, 14.5±0.2, 15.6±0.2, 18.7±0.2, 27.0±0.2 and 27.2±0.2 °2θ (e.g. 12.0±0.1, 14.5±0.1, 15.6±0.1, 18.7±0.1, 27.0±0.1 and 27.2±0.1 °2θ (e.g. 12.0, 14.5, 15.6, 18.7, 27.0 and 27.2 °2θ)).

[0456] In some embodiments, the XRPD plot of form L includes at least four signals (e.g., peaks) selected from 12.0±0.2, 14.5±0.2, 15.6±0.2, 18.7±0.2, 27.0±0.2 and 27.2±0.2 °2θ (e.g. 12.0±0.1, 14.5±0.1, 15.6±0.1, 18.7±0.1, 27.0±0.1 and 27.2±0.1 °2θ (e.g. 12.0, 14.5, 15.6, 18.7, 27.0 and 27.2 °2θ)) using Cu Kα radiation.

[0457] In some embodiments, the XRPD plot of form L includes at least five signals (e.g., peaks) selected from 12.0±0.2, 14.5±0.2, 15.6±0.2, 18.7±0.2, 27.0±0.2 and 27.2±0.2 °2θ (e.g. 12.0±0.1, 14.5±0.1, 15.6±0.1, 18.7±0.1, 27.0±0.1 and 27.2±0.1 °2θ (e.g. 12.0, 14.5, 15.6, 18.7, 27.0 and 27.2 °2θ) using Cu Kα radiation.

[0458] In some embodiments, the XRPD plot of form L contains a signal (e.g., a peak) at 12.0±0.2, 14.5±0.2, 15.6±0.2, 18.7±0.2, 27.0±0.2, and 27.2±0.2 °2θ (e.g., 12.0±0.1, 14.5±0.1, 15.6±0.1, 18.7±0.1, 27.0±0.1, and 27.2±0.1 °2θ (e.g., 12.0, 14.5, 15.6, 18.7, 27.0, and 27.2 °2θ) using Cu Kα radiation.

[0459] In some implementations, form L is characterized by being substantially similar to Figure 20 Or the XRPD diagram shown in 62.

[0460] In some implementations, form L is characterized by an XRPD plot containing signals (e.g., peaks) at approximately the locations shown in the table below. It should be understood that the values ​​in the table are approximate and subject to instrument and experimental variations.

[0461] Table 5: List of exemplary XRPD signals of form L Differential Scanning Calorimetry (DSC) Characterization In some embodiments, form L is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 195 ± 20 °C (e.g., 195 ± 10 °C (e.g., 195 ± 5 °C (e.g., 195 ± 4 °C (e.g., 195 ± 3 °C (e.g., 195 ± 2 °C (e.g., 195 ± 1 °C (e.g., 195 ± 0.5 °C))))))))

[0462] In some implementations, form L is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 195 °C.

[0463] In some embodiments, form L is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of about 111 ± 11 J / g (e.g., 111 ± 10 J / g (e.g., 111 ± 8 J / g (e.g., 111 ± 6 J / g (e.g., 111 ± 4 J / g (e.g., 111 ± 3 J / g (e.g., 111 ± 2 J / g (e.g., 111 ± 1 J / g)))))))).

[0464] In some implementations, form L is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 111 J / g.

[0465] In some embodiments, form L is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 196 ± 20 °C (e.g., 196 ± 10 °C (e.g., 196 ± 5 °C (e.g., 196 ± 4 °C (e.g., 196 ± 3 °C (e.g., 196 ± 2 °C (e.g., 196 ± 1 °C (e.g., 196 ± 0.5 °C))))))))

[0466] In some implementations, form L is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 196 °C.

[0467] In some embodiments, form L is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of about 99 ± 10 J / g (e.g., 99 ± 9 J / g (e.g., 99 ± 8 J / g (e.g., 99 ± 6 J / g (e.g., 99 ± 4 J / g (e.g., 99 ± 3 J / g (e.g., 99 ± 2 J / g (e.g., 99 ± 1 J / g)))))))

[0468] In some implementations, form L is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 99 J / g.

[0469] In some implementations, form L is characterized by being substantially similar to Figure 21 Or the DSC spectrum shown in 63.

[0470] Thermogravimetric analysis (TGA) characterization In some embodiments, form L exhibits a weight loss of about 0.1% to about 2% in the temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C, e.g., 34 ± 5 ​​°C, e.g., 34 ± 4 °C, e.g., 34 ± 3 °C, e.g., 34 ± 2 °C, e.g., 34 ± 1 °C, e.g., 34 ± 0.5 °C) to about 180 ± 20 °C (e.g., 180 ± 10 °C, e.g., 180 ± 5 °C, e.g., 180 ± 4 °C, e.g., 180 ± 3 °C, e.g., 180 ± 2 °C, e.g., 180 ± 1 °C, e.g., 180 ± 0.5 °C)))))), as measured by TGA.

[0471] In some implementations, form L exhibits a weight loss of about 0.8% at temperatures ranging from about 34°C to about 180°C, as measured by TGA.

[0472] In some embodiments, form L exhibits a weight loss of about 0.05% to about 2% in the temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C, e.g., 34 ± 5 ​​°C, e.g., 34 ± 4 °C, e.g., 34 ± 3 °C, e.g., 34 ± 2 °C, e.g., 34 ± 1 °C, e.g., 34 ± 0.5 °C) to about 185 ± 20 °C (e.g., 185 ± 10 °C, e.g., 185 ± 5 °C, e.g., 185 ± 4 °C, e.g., 185 ± 3 °C, e.g., 185 ± 2 °C, e.g., 185 ± 1 °C, e.g., 185 ± 0.5 °C))))))), as measured by TGA.

[0473] In some implementations, form L exhibits a weight loss of about 0.5% at temperatures ranging from about 34°C to about 185°C, as measured by TGA.

[0474] In some implementations, form L is characterized by being substantially similar to Figure 22 Or the TGA spectrum shown in 64.

[0475] In some implementations, the purity of form L is greater than 99.0%, greater than 99.1%, greater than 99.2%, greater than 99.3%, greater than 99.4%, greater than 99.5%, greater than 99.6%, greater than 99.7%, greater than 99.8%, or greater than 99.9%.

[0476] In some implementations, form L experiences water absorption rates of less than 1.0%, less than 0.8%, less than 0.6%, less than 0.4%, or less than 0.2% at 95% RH.

[0477] In some implementations, after being placed in an open container at 25°C / 92.5%RH for one week, the purity of form L is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0478] In some implementations, after being placed in an open container at 40°C / 75% RH for one week, the purity of form L is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0479] In some implementations, after being placed in a closed container at 60°C for one week, the purity of form L is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0480] In some embodiments, form L has a solubility in pH 1.2 HCl solution (0.1 N) of more than 20 μg / mL, more than 40 μg / mL, more than 60 μg / mL, more than 80 μg / mL, more than 100 μg / mL, more than 110 μg / mL, or more than 130 μg / mL over 2 hours.

[0481] In some embodiments, form L has a solubility in pH 1.2 HCl solution (0.1 N) of more than 20 μg / mL, more than 40 μg / mL, more than 60 μg / mL, more than 80 μg / mL, more than 100 μg / mL, or more than 110 μg / mL over 24 hours.

[0482] In some implementations, form L has a solubility in SGF (pH 2.0) of more than 40 μg / mL, more than 80 μg / mL, more than 100 μg / mL, more than 120 μg / mL, or more than 140 μg / mL within 2 hours.

[0483] In some implementations, form L has a solubility in SGF (pH 2.0) of more than 20 μg / mL, more than 40 μg / mL, more than 60 μg / mL, more than 80 μg / mL, or more than 100 μg / mL over 24 hours.

[0484] In some implementations, form L has a solubility in FeSSIF-v1 (pH 5.0) of more than 40 μg / mL, more than 80 μg / mL, more than 100 μg / mL, more than 120 μg / mL, more than 140 μg / mL, or more than 160 μg / mL over 2 hours.

[0485] In some implementations, form L has a solubility in FeSSIF-v1 (pH 5.0) of more than 5 μg / mL, more than 10 μg / mL, more than 15 μg / mL, or more than 20 μg / mL over 24 hours.

[0486] Form M In some implementations, the crystal form is compound 1, its salt, its solvate, or its hydrate, in the form of M.

[0487] In some embodiments, the crystal form is a salt of compound 1, its solvate, or its hydrate, in the form M.

[0488] In some embodiments, the crystal form is the fumarate of compound 1, its solvate, or its hydrate, in the form M.

[0489] In some embodiments, the crystal form is the fumarate form M of compound 1.

[0490] In some embodiments, the fumarate comprises compound 1 and fumaric acid in a ratio of about 1:1. In some embodiments, the fumarate comprises compound 1 and fumaric acid in a ratio of about 1:2. In some embodiments, the fumarate comprises compound 1 and fumaric acid in a ratio of about 2:1.

[0491] X-ray powder diffraction (XRPD) characterization In some implementations, form M is characterized by being substantially similar to Figure 66 The XRPD spectrum shown is the XRPD spectrum.

[0492] Differential Scanning Calorimetry (DSC) Characterization In some embodiments, form M is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 54.0 ± 20 °C (e.g., 54.0 ± 10 °C (e.g., 54.0 ± 5 °C (e.g., 54.0 ± 4 °C (e.g., 54.0 ± 3 °C (e.g., 54.0 ± 2 °C (e.g., 54.0 ± 1 °C (e.g., 54.0 ± 0.5 °C))))))))

[0493] In some implementations, form M is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 54.0 °C.

[0494] In some embodiments, form M is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 125 ± 20 °C (e.g., 125 ± 10 °C (e.g., 125 ± 5 °C (e.g., 125 ± 4 °C (e.g., 125 ± 3 °C (e.g., 125 ± 2 °C (e.g., 125 ± 1 °C (e.g., 125 ± 0.5 °C))))))))

[0495] In some implementations, form M is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 125 °C.

[0496] In some embodiments, form M is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of about 26.1 ± 2.5 J / g (e.g., 26.1 ± 2.0 J / g (e.g., 26.1 ± 1.5 J / g (e.g., 26.1 ± 1.0 J / g (e.g., 26.1 ± 0.8 J / g (e.g., 26.1 ± 0.6 J / g (e.g., 26.1 ± 0.4 J / g (e.g., 26.1 ± 0.2 J / g))))))))

[0497] In some implementations, form M is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 26.1 J / g.

[0498] In some embodiments, form M is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of approximately 34.9 ± 3.5 J / g (e.g., 34.9 ± 3.0 J / g (e.g., 34.9 ± 2.5 J / g (e.g., 34.9 ± 2.0 J / g (e.g., 34.9 ± 1.5 J / g (e.g., 34.9 ± 1.0 J / g (e.g., 34.9 ± 0.5 J / g (e.g., 34.9 ± 0.3 J / g)))))))

[0499] In some implementations, form M is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 34.9 J / g.

[0500] In some implementations, form M is characterized by being substantially similar to Figure 67 The DSC spectrum shown is the DSC spectrum.

[0501] Thermogravimetric analysis (TGA) characterization In some embodiments, form M exhibits a weight loss of about 0.1% to about 5% in the temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ...

[0502] In some implementations, form M exhibits a weight loss of about 1.6% at temperatures ranging from about 34°C to about 100°C, as measured by TGA.

[0503] In some implementations, form M is characterized by being substantially similar to Figure 68 The TGA spectrum shown is the TGA spectrum.

[0504] Form N In some implementations, the crystal form is compound 1, its salt, its solvate, or its hydrate, in the form of N.

[0505] In some embodiments, the crystal form is a salt of compound 1, its solvate, or its hydrate, in the form of N.

[0506] In some embodiments, the crystal form is the fumarate of compound 1, its solvate, or its hydrate, in the form N.

[0507] In some implementations, the crystal form is the fumarate form N of compound 1.

[0508] In some embodiments, the fumarate comprises compound 1 and fumaric acid in a ratio of about 1:1. In some embodiments, the fumarate comprises compound 1 and fumaric acid in a ratio of about 1:2. In some embodiments, the fumarate comprises compound 1 and fumaric acid in a ratio of about 2:1.

[0509] X-ray powder diffraction (XRPD) characterization In some implementations, form N is characterized by being substantially similar to Figure 70 The XRPD spectrum shown is the XRPD spectrum.

[0510] Differential Scanning Calorimetry (DSC) Characterization In some embodiments, form N is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 62.0 ± 20 °C (e.g., 62.0 ± 10 °C (e.g., 62.0 ± 5 °C (e.g., 62.0 ± 4 °C (e.g., 62.0 ± 3 °C (e.g., 62.0 ± 2 °C (e.g., 62.0 ± 1 °C (e.g., 62.0 ± 0.5 °C))))))))

[0511] In some implementations, form N is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 62.0 °C.

[0512] In some embodiments, form N is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 107 ± 20 °C (e.g., 107 ± 10 °C (e.g., 107 ± 5 °C (e.g., 107 ± 4 °C (e.g., 107 ± 3 °C (e.g., 107 ± 2 °C (e.g., 107 ± 1 °C (e.g., 107 ± 0.5 °C))))))))

[0513] In some implementations, form N is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 107 °C.

[0514] In some embodiments, form N is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of approximately 37.8 ± 3.8 J / g (e.g., 37.8 ± 3.4 J / g (e.g., 37.8 ± 3.0 J / g (e.g., 37.8 ± 2.5 J / g (e.g., 37.8 ± 2.0 J / g (e.g., 37.8 ± 1.5 J / g (e.g., 37.8 ± 1.0 J / g (e.g., 37.8 ± 0.5 J / g))))))))

[0515] In some implementations, form N is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 37.8 J / g.

[0516] In some embodiments, form N is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of about 22.1 ± 2.5 J / g (e.g., 22.1 ± 2.0 J / g (e.g., 22.1 ± 1.5 J / g (e.g., 22.1 ± 1.0 J / g (e.g., 22.1 ± 0.8 J / g (e.g., 22.1 ± 0.6 J / g (e.g., 22.1 ± 0.4 J / g (e.g., 22.1 ± 0.2 J / g))))))))

[0517] In some implementations, form N is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 22.1 J / g.

[0518] In some implementations, form N is characterized by being substantially similar to Figure 71 The DSC spectrum shown is the DSC spectrum.

[0519] Thermogravimetric analysis (TGA) characterization In some embodiments, form N exhibits a weight loss of about 0.1% to about 5% in the temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C, e.g., 34 ± 5 ​​°C, e.g., 34 ± 4 °C, e.g., 34 ± 3 °C, e.g., 34 ± 2 °C, e.g., 34 ± 1 °C, e.g., 34 ± 0.5 °C) to about 110 ± 20 °C (e.g., 110 ± 10 °C, e.g., 110 ± 5 °C, e.g., 110 ± 4 °C, e.g., 110 ± 3 °C, e.g., 110 ± 2 °C, e.g., 110 ± 1 °C, e.g., 110 ± 0.5 °C)))))), as measured by TGA.

[0520] In some implementations, form N exhibits a weight loss of about 1.8% at temperatures ranging from about 34°C to about 110°C, as measured by TGA.

[0521] In some implementations, form N is characterized by being substantially similar to Figure 72 The TGA spectrum shown is the TGA spectrum.

[0522] Form O In some implementations, the crystal form is compound 1, its salt, its solvate, or its hydrate, in the form of O.

[0523] In some embodiments, the crystal form is a salt of compound 1, its solvate, or its hydrate, in the form of O.

[0524] In some embodiments, the crystal form is the L-tartrate of compound 1, its solvate, or its hydrate, in the form of O.

[0525] In some embodiments, the crystal form is the L-tartrate form O of compound 1.

[0526] In some embodiments, the L-tartrate comprises compound 1 and L-tartaric acid in a ratio of about 1:1. In some embodiments, the L-tartrate comprises compound 1 and L-tartaric acid in a ratio of about 1:2. In some embodiments, the L-tartrate comprises compound 1 and L-tartaric acid in a ratio of about 2:1.

[0527] X-ray powder diffraction (XRPD) characterization In some implementations, form O is characterized by being substantially similar to Figure 74 The XRPD spectrum shown is the XRPD spectrum.

[0528] Differential Scanning Calorimetry (DSC) Characterization In some embodiments, form O is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 52.7 ± 20 °C (e.g., 52.7 ± 10 °C (e.g., 52.7 ± 5 °C (e.g., 52.7 ± 4 °C (e.g., 52.7 ± 3 °C (e.g., 52.7 ± 2 °C (e.g., 52.7 ± 1 °C (e.g., 52.7 ± 0.5 °C))))))))

[0529] In some implementations, form O is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 52.7 °C.

[0530] In some embodiments, form O is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 129 ± 20 °C (e.g., 129 ± 10 °C (e.g., 129 ± 5 °C (e.g., 129 ± 4 °C (e.g., 129 ± 3 °C (e.g., 129 ± 2 °C (e.g., 129 ± 1 °C (e.g., 129 ± 0.5 °C))))))))

[0531] In some implementations, form O is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 129 °C.

[0532] In some embodiments, form O is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of about 24.5 ± 2.5 J / g (e.g., 24.5 ± 2.0 J / g (e.g., 24.5 ± 1.5 J / g (e.g., 24.5 ± 1.0 J / g (e.g., 24.5 ± 0.8 J / g (e.g., 24.5 ± 0.6 J / g (e.g., 24.5 ± 0.4 J / g (e.g., 24.5 ± 0.2 J / g))))))))

[0533] In some implementations, form O is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 24.5 J / g.

[0534] In some embodiments, form O is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of approximately 34.8 ± 3.5 J / g (e.g., 34.8 ± 3.0 J / g (e.g., 34.8 ± 2.5 J / g (e.g., 34.8 ± 2.0 J / g (e.g., 34.8 ± 1.5 J / g (e.g., 34.8 ± 1.0 J / g (e.g., 34.8 ± 0.5 J / g (e.g., 34.8 ± 0.3 J / g))))))))

[0535] In some implementations, form O is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 34.8 J / g.

[0536] In some implementations, form O is characterized by being substantially similar to Figure 75 The DSC spectrum shown is the DSC spectrum.

[0537] Thermogravimetric analysis (TGA) characterization In some embodiments, form O exhibits a weight loss of about 0.1% to about 5% at temperatures ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C, e.g., 34 ± 5 ​​°C, e.g., 34 ± 4 °C, e.g., 34 ± 3 °C, e.g., 34 ± 2 °C, e.g., 34 ± 1 °C, e.g., 34 ± 0.5 °C) to about 100 ± 20 °C (e.g., 100 ± 10 °C, e.g., 100 ± 5 °C, e.g., 100 ± 4 °C, e.g., 100 ± 3 °C, e.g., 100 ± 2 °C, e.g., 100 ± 1 °C, e.g., 100 ± 0.5 °C))

[0538] In some implementations, form O exhibits a weight loss of about 1.6% at temperatures ranging from about 34°C to about 100°C, as measured by TGA.

[0539] In some embodiments, form O exhibits a weight loss of about 0.3% to about 2.5% at temperatures ranging from about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))) to about 140 ± 20 °C (e.g., 140 ± 10 °C (e.g., 140 ± 5 °C (e.g., 140 ± 4 °C (e.g., 140 ± 3 °C (e.g., 140 ± 2 °C (e.g., 140 ± 1 °C (e.g., 140 ± 0.5 °C)))))))) as measured by TGA).

[0540] In some embodiments, form O exhibits a weight loss of about 1.0% at temperatures ranging from about 100°C to about 140°C, as measured by TGA.

[0541] In some implementations, form O is characterized by being substantially similar to Figure 76 The TGA spectrum shown is the TGA spectrum.

[0542] Form P In some implementations, the crystal form is compound 1, its salt, its solvate, or its hydrate, in the form of P.

[0543] In some embodiments, the crystal form is a salt of compound 1, its solvate, or its hydrate, in the form of P.

[0544] In some embodiments, the crystal form is the L-malate of compound 1, its solvate, or its hydrate, in the form P.

[0545] In some embodiments, the crystal form is the L-malate form P of compound 1.

[0546] In some embodiments, the L-malate comprises compound 1 and L-malic acid in a ratio of about 1:1. In some embodiments, the L-malate comprises compound 1 and L-malic acid in a ratio of about 1:2. In some embodiments, the L-malate comprises compound 1 and L-malic acid in a ratio of about 2:1.

[0547] X-ray powder diffraction (XRPD) characterization In some implementations, form P is characterized by being substantially similar to Figure 78 The XRPD spectrum shown is the XRPD spectrum.

[0548] Differential Scanning Calorimetry (DSC) Characterization In some embodiments, form P is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 109 ± 20 °C (e.g., 109 ± 10 °C (e.g., 109 ± 5 °C (e.g., 109 ± 4 °C (e.g., 109 ± 3 °C (e.g., 109 ± 2 °C (e.g., 109 ± 1 °C (e.g., 109 ± 0.5 °C)))))))).

[0549] In some implementations, form P is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 109 °C.

[0550] In some embodiments, form P is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 169 ± 20 °C (e.g., 169 ± 10 °C (e.g., 169 ± 5 °C (e.g., 169 ± 4 °C (e.g., 169 ± 3 °C (e.g., 169 ± 2 °C (e.g., 169 ± 1 °C (e.g., 169 ± 0.5 °C))))))))

[0551] In some implementations, form P is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 169 °C.

[0552] In some embodiments, form P is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of about 57.5 ± 6.0 J / g (e.g., 57.5 ± 5.0 J / g (e.g., 57.5 ± 4.0 J / g (e.g., 57.5 ± 3.0 J / g (e.g., 57.5 ± 2.0 J / g (e.g., 57.5 ± 1.5 J / g (e.g., 57.5 ± 1.0 J / g (e.g., 57.5 ± 0.5 J / g))))))))

[0553] In some implementations, form P is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 57.5 J / g.

[0554] In some embodiments, form P is characterized by having a DSC curve of an endothermic signal (e.g., a peak) associated with an enthalpy of about 21.5 ± 2.5 J / g (e.g., 21.5 ± 2.0 J / g (e.g., 21.5 ± 1.5 J / g (e.g., 21.5 ± 1.0 J / g (e.g., 21.5 ± 0.8 J / g (e.g., 21.5 ± 0.6 J / g (e.g., 21.5 ± 0.4 J / g (e.g., 21.5 ± 0.2 J / g))))))))

[0555] In some implementations, form P is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 21.5 J / g.

[0556] In some implementations, form P is characterized by being substantially similar to Figure 79 The DSC spectrum shown is the DSC spectrum.

[0557] Thermogravimetric analysis (TGA) characterization In some embodiments, form P exhibits a weight loss of about 0.1% to about 5% in the temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C, e.g., 34 ± 5 ​​°C, e.g., 34 ± 4 °C, e.g., 34 ± 3 °C, e.g., 34 ± 2 °C, e.g., 34 ± 1 °C, e.g., 34 ± 0.5 °C) to about 130 ± 20 °C (e.g., 130 ± 10 °C, e.g., 130 ± 5 °C, e.g., 130 ± 4 °C, e.g., 130 ± 3 °C, e.g., 130 ± 2 °C, e.g., 130 ± 1 °C, e.g., 130 ± 0.5 °C)))))), as measured by TGA.

[0558] In some implementations, form P exhibits a weight loss of about 2.1% at temperatures ranging from about 34°C to about 130°C, as measured by TGA.

[0559] In some embodiments, form P exhibits a weight loss of about 15% to about 30% in the temperature range of about 130 ± 20 °C (e.g., 130 ± 10 °C (e.g., 130 ± 5 °C (e.g., 130 ± 4 °C (e.g., 130 ± 3 °C (e.g., 130 ± 2 °C (e.g., 130 ± 0.5 °C) ...

[0560] In some implementations, form P exhibits a weight loss of about 21% at temperatures ranging from about 130°C to about 300°C, as measured by TGA.

[0561] In some implementations, form P is characterized by being substantially similar to Figure 80 The TGA spectrum shown is the TGA spectrum.

[0562] Methods for preparing crystalline forms In some respects, this disclosure is characterized by a method for preparing compound 1 or a pharmaceutically acceptable salt thereof in crystalline form.

[0563] In some aspects, this disclosure provides a method for preparing a crystalline form of compound 1 or a pharmaceutically acceptable salt thereof, the method comprising one or more steps as described herein.

[0564] In some aspects, this disclosure provides a compound that is obtainable, acquired, or directly obtained by a method for preparing compound 1 or a pharmaceutically acceptable salt thereof in crystalline form.

[0565] Compound 1 or a pharmaceutically acceptable salt thereof may be prepared by any suitable technique known in the art or as described in PCT application number PCT / US2022 / 076164 (incorporated herein by reference). Specific processes for preparing these compounds are further described in the appended examples.

[0566] In some embodiments, the crystalline form of compound 1 can be prepared by equilibrating compound 1 at 25°C in an appropriate amount of solvent for 2 weeks using a stirring plate.

[0567] In some embodiments, the crystalline form of compound 1 can be prepared by equilibrating compound 1 at 50°C in an appropriate amount of solvent for 1 week using a stirring plate.

[0568] In some embodiments, the crystalline form of compound 1 can be prepared by equilibrating compound 1 in a suitable solvent at a temperature between 5°C and 50°C for 10 cycles at a heating / cooling rate of 0.1°C / min.

[0569] In some embodiments, the crystalline form of compound 1 can be prepared by dissolving compound 1 in an appropriate amount of solvent, filtering the resulting solution through a 0.45µm syringe nylon membrane filter, and slowly evaporating the filtered solution under ambient conditions.

[0570] In some embodiments, the crystalline form of compound 1 can be prepared by dissolving compound 1 in an appropriate amount of solvent, filtering the resulting solution through a 0.45µm syringe nylon membrane filter, and rapidly evaporating the filtered solution under a nitrogen flow.

[0571] In some embodiments, the crystalline form of compound 1 can be prepared by dissolving compound 1 in a very small amount of solvent at 50°C, filtering the resulting solution through a 0.45µm syringe nylon membrane filter, and cooling the filtered solution to 5°C at a rate of 0.1°C / min.

[0572] In some embodiments, the crystalline form of compound 1 can be prepared by dissolving compound 1 in a very small amount of solvent at 50°C, filtering the resulting solution through a 0.45µm syringe nylon membrane filter, and cooling the filtered solution to -20°C at 0.1°C / min.

[0573] In some embodiments, the crystalline form of compound 1 can be prepared by dissolving compound 1 in a very small amount of solvent at 50°C, filtering the resulting solution through a 0.45µm syringe nylon membrane filter, and stirring the filtered solution in an ice bath at 0°C.

[0574] In some embodiments, the crystalline form of compound 1 can be prepared by dissolving compound 1 in a very small amount of solvent at ambient temperature (approximately 20°C-25°C), filtering the resulting solution through a 0.45µm syringe nylon membrane filter, and slowly adding 1-4 times the amount of antisolvent to the filtered solution until a large amount of solid precipitates out.

[0575] In some embodiments, the crystalline form of compound 1 can be prepared by dissolving compound 1 in a very small amount of solvent at ambient temperature (approximately 20°C-25°C), filtering the resulting solution through a 0.45µm syringe nylon membrane filter, and rapidly adding the filtered solution to 4 times the volume of antisolvent.

[0576] In some embodiments, the crystalline form of compound 1 can be prepared by dissolving compound 1 in a very small amount of solvent at ambient temperature (approximately 20°C-25°C), filtering the resulting solution through a 0.45µm syringe nylon membrane filter, and then subjecting it to vapor diffusion using an antisolvent at ambient temperature for up to 14 days.

[0577] In some embodiments, the crystalline form of compound 1 can be prepared by adding an appropriate amount of solvent to compound 1, stirring the suspension at 50°C for 2 hours, cooling to 25°C and stirring at 25°C for 4 days, filtering the resulting solution by centrifugation at 14,000 rpm through a 0.45µm syringe nylon membrane filter, and vacuum drying the solid at 50°C for 2 hours.

[0578] In some embodiments, the crystalline form of compound 1 can be prepared by adding an appropriate amount of solvent to compound 1, stirring the suspension at 50°C for 2 hours, cooling to 25°C and stirring at 25°C for 4 days, cooling the solution to 5°C, centrifuging the obtained solution through a 0.45µm syringe nylon membrane filter at 14,000 rpm, and vacuum drying the solid at 50°C for 2 hours.

[0579] In some embodiments, the crystalline form of compound 1 can be prepared by adding an appropriate amount of solvent to compound 1, stirring the suspension at 25°C for 4 days, centrifuging the resulting solution through a 0.45µm syringe nylon membrane filter at 14,000 rpm, and then vacuum drying the solid at 50°C for 2 hours.

[0580] In some embodiments, the crystalline form of compound 1 can be prepared by adding an appropriate amount of solvent to compound 1, stirring the suspension at 25°C for 4 days, cooling the solution to 5°C, centrifuging the obtained solution through a 0.45µm syringe nylon membrane filter at 14,000 rpm, and vacuum drying the solid at 50°C for 2 hours.

[0581] Amorphous forms and their combinations In some respects, this disclosure provides an amorphous form of compound 1, its salt, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof.

[0582] In some respects, this disclosure provides an amorphous form of compound 1.

[0583] In some aspects, this disclosure provides an assembly comprising: Compound 1, its salts, its solvates, its hydrates or pharmaceutically acceptable salts in amorphous form; and polymer.

[0584] In some aspects, this disclosure provides a composition (e.g., a pharmaceutical composition) that includes the combinations disclosed herein.

[0585] In some implementations, the polymer is polyvinylpyrrolidone (PVP).

[0586] In some embodiments, the polymer comprises a copolymer of N-vinylpyrrolidone and vinyl acetate.

[0587] In some embodiments, the polymer comprises a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

[0588] In some implementations, the polymer is PVP VA64, Soluplus, Kollidon 12 PF, HPMC ASMG, HPMC E3, Eudragit E100, or Eudragit L100-55.

[0589] In some implementations, the polymer is used as Eudragit ® sell.

[0590] In some implementations, the polymer is used as Soluplus.® sell.

[0591] In some implementations, the polymer is Kollidon ® sell.

[0592] In some implementations, the polymer is Kollidon ® 12 PF for sale.

[0593] In some implementations, the polymer is sold as PVP VA64.

[0594] In some implementations, the polymer is sold as HPMC ASMG.

[0595] In some implementations, the polymer is sold as HPMC E3.

[0596] In some implementations, the polymer is used as Eudragit ® E100 for sale.

[0597] In some implementations, the polymer is used as Eudragit ® L100-55 for sale.

[0598] In some implementations, the polymer is hydroxypropyl methylcellulose (HPMC).

[0599] In some implementations, the polymer is a copolymer based on polymethacrylate.

[0600] In some implementations, the polymer is PVP VA64.

[0601] In some implementations, the polymer is HPMC ASMG.

[0602] In some implementations, the polymer is HPMC E3.

[0603] In some implementations, the polymer is Eudragit. ® E100.

[0604] In some implementations, the polymer is Eudragit. ® L100-55.

[0605] In some embodiments, the amorphous form is combined with the polymer in a ratio of about 1:0.5 (w / w), about 1:1 (w / w), about 1:2 (w / w), about 1:3 (w / w), about 1:4 (w / w), or about 1:5 (w / w).

[0606] In some implementations, the amorphous form is combined with the polymer at a ratio of about 1:1 (w / w).

[0607] In some implementations, the amorphous form is combined with the polymer at a ratio of about 1:4 (w / w).

[0608] In some embodiments, the composition is a solid dispersion.

[0609] In some respects, the composition is a solid dispersion prepared by spray drying.

[0610] In some respects, the composition is a solid dispersion prepared by hot melt extrusion (HME).

[0611] In some embodiments, the composition is prepared from form A of compound 1.

[0612] Thermogravimetric analysis (TGA) characterization In some embodiments, the combination (e.g., the composition) exhibits a weight loss of about 2.5% to about 10% as measured by TGA at temperatures ranging from about 33 ± 20 °C (e.g., 33 ± 10 °C (e.g., 33 ± 5 °C (e.g., 33 ± 4 °C (e.g., 33 ± 3 °C (e.g., 33 ± 2 °C (e.g., 33 ± 1 °C (e.g., 33 ± 0.5 °C) ...

[0613] In some embodiments, the combination (e.g., the composition) exhibits a weight loss of about 5.2% at temperatures ranging from about 33°C to about 100°C, as measured by TGA.

[0614] In some embodiments, the combination (e.g., the composition) is characterized by being substantially similar to Figure 86 The TGA spectrum shown is the TGA spectrum.

[0615] In some embodiments, the combination (e.g., the composition) exhibits a weight loss of about 0.5% to about 5% in temperatures ranging from about 32 ± 20 °C (e.g., 32 ± 10 °C (e.g., 32 ± 5 °C (e.g., 32 ± 4 °C (e.g., 32 ± 3 °C (e.g., 32 ± 2 °C (e.g., 32 ± 1 °C (e.g., 32 ± 0.5 °C))))))) at temperatures ranging from about 32 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA.

[0616] In some embodiments, the combination (e.g., the composition) exhibits a weight loss of about 1.7% at temperatures ranging from about 32°C to about 100°C, as measured by TGA.

[0617] In some embodiments, the combination (e.g., the composition) is characterized by being substantially similar to Figure 87 The TGA spectrum shown is the TGA spectrum.

[0618] In some embodiments, the combination (e.g., the composition) exhibits a weight loss of about 0.5% to about 5% as measured by TGA at temperatures ranging from about 33 ± 20 °C (e.g., 33 ± 10 °C (e.g., 33 ± 5 °C (e.g., 33 ± 4 °C (e.g., 33 ± 3 °C (e.g., 33 ± 2 °C (e.g., 33 ± 1 °C (e.g., 33 ± 0.5 °C) ...

[0619] In some embodiments, the combination (e.g., the composition) exhibits a weight loss of about 2.8% at temperatures ranging from about 33°C to about 100°C, as measured by TGA.

[0620] In some embodiments, the combination (e.g., the composition) is characterized by being substantially similar to Figure 88 The TGA spectrum shown is the TGA spectrum.

[0621] In some embodiments, the combination (e.g., the composition) exhibits a weight loss of about 0.1% to about 5% as measured by TGA at temperatures ranging from about 33 ± 20 °C (e.g., 33 ± 10 °C (e.g., 33 ± 5 °C (e.g., 33 ± 4 °C (e.g., 33 ± 3 °C (e.g., 33 ± 2 °C (e.g., 33 ± 1 °C (e.g., 33 ± 0.5 °C) ...

[0622] In some embodiments, the combination (e.g., the composition) exhibits a weight loss of about 1.0% at temperatures ranging from about 33°C to about 100°C, as measured by TGA.

[0623] In some embodiments, the combination (e.g., the composition) is characterized by being substantially similar to Figure 89 The TGA spectrum shown is the TGA spectrum.

[0624] In some embodiments, the combination (e.g., the composition) exhibits a weight loss of about 0.5% to about 10% as measured by TGA at temperatures ranging from about 32 ± 20 °C (e.g., 32 ± 10 °C (e.g., 32 ± 5 °C (e.g., 32 ± 4 °C (e.g., 32 ± 3 °C (e.g., 32 ± 2 °C (e.g., 32 ± 1 °C (e.g., 32 ± 0.5 °C) ...

[0625] In some embodiments, the combination (e.g., the composition) exhibits a weight loss of about 3.2% at temperatures ranging from about 32°C to about 100°C, as measured by TGA.

[0626] In some embodiments, the combination (e.g., the composition) is characterized by being substantially similar to Figure 90 The TGA spectrum shown is the TGA spectrum.

[0627] Modulated differential scanning calorimetry (mDSC) characterization In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) measured by mDSC at 106 ± 20 °C (e.g., 106 ± 10 °C (e.g., 106 ± 5 °C (e.g., 106 ± 4 °C (e.g., 106 ± 3 °C (e.g., 106 ± 2 °C (e.g., 106 ± 1 °C (e.g., 106 ± 0.5 °C)). g ).

[0628] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) of about 106 °C as measured by mDSC. g ).

[0629] In some embodiments, the combination (e.g., the composition) is characterized by being substantially similar to Figure 91 The mDSC spectrum shown is the mDSC spectrum.

[0630] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0631] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 99.0%, greater than 99.1%, greater than 99.2%, greater than 99.3%, greater than 99.4%, greater than 99.5%, greater than 99.6%, greater than 99.7%, greater than 99.8%, or greater than 99.9%.

[0632] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) measured by mDSC at 102 ± 20°C (e.g., 102 ± 10°C (e.g., 102 ± 5°C (e.g., 102 ± 4°C (e.g., 102 ± 3°C (e.g., 102 ± 2°C (e.g., 102 ± 1°C (e.g., 102 ± 0.5°C)). g ).

[0633] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) of about 102 °C as measured by mDSC. g ).

[0634] In some embodiments, the combination (e.g., the composition) is characterized by being substantially similar to Figure 92 The mDSC spectrum shown is the mDSC spectrum.

[0635] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0636] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 99.0%, greater than 99.1%, greater than 99.2%, greater than 99.3%, greater than 99.4%, greater than 99.5%, greater than 99.6%, greater than 99.7%, greater than 99.8%, or greater than 99.9%.

[0637] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) measured by mDSC at 104 ± 20 °C (e.g., 104 ± 10 °C, 104 ± 5 ​​°C, 104 ± 4 °C, 104 ± 3 °C, 104 ± 2 °C, 104 ± 1 °C, 104 ± 0.5 °C). g ).

[0638] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) of about 104 °C as measured by mDSC. g ).

[0639] In some embodiments, the combination (e.g., the composition) is characterized by being substantially similar to Figure 93 The mDSC spectrum shown is the mDSC spectrum.

[0640] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0641] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 99.0%, greater than 99.1%, greater than 99.2%, greater than 99.3%, greater than 99.4%, greater than 99.5%, greater than 99.6%, greater than 99.7%, greater than 99.8%, or greater than 99.9%.

[0642] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) measured by mDSC at 48 ± 20 °C (e.g., 48 ± 10 °C, 48 ± 5 °C, 48 ± 4 °C, 48 ± 3 °C, 48 ± 2 °C, 48 ± 1 °C, 48 ± 0.5 °C). g ).

[0643] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) at about 48°C, as measured by mDSC. g ).

[0644] In some embodiments, the combination (e.g., the composition) is characterized by being substantially similar to Figure 94 The mDSC spectrum shown is the mDSC spectrum.

[0645] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0646] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 99.0%, greater than 99.1%, greater than 99.2%, greater than 99.3%, greater than 99.4%, greater than 99.5%, greater than 99.6%, greater than 99.7%, greater than 99.8%, or greater than 99.9%.

[0647] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) measured by mDSC at 181 ± 20 °C (e.g., 181 ± 10 °C, 181 ± 5 °C, 181 ± 4 °C, 181 ± 3 °C, 181 ± 2 °C, 181 ± 1 °C, 181 ± 0.5 °C). g ).

[0648] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) of about 181°C as measured by mDSC. g ).

[0649] In some embodiments, the combination (e.g., the composition) is characterized by being substantially similar to Figure 95 The mDSC spectrum shown is the mDSC spectrum.

[0650] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0651] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 99.0%, greater than 99.1%, greater than 99.2%, greater than 99.3%, greater than 99.4%, greater than 99.5%, greater than 99.6%, greater than 99.7%, greater than 99.8%, or greater than 99.9%.

[0652] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) measured by mDSC at 107 ± 20°C (e.g., 107 ± 10°C (e.g., 107 ± 5°C (e.g., 107 ± 4°C (e.g., 107 ± 3°C (e.g., 107 ± 2°C (e.g., 107 ± 1°C (e.g., 107 ± 0.5°C)). g ).

[0653] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) of about 107 °C, as measured by mDSC. g ).

[0654] In some embodiments, the combination (e.g., the composition) is characterized by being substantially similar to Figure 96 The mDSC spectrum shown is the mDSC spectrum.

[0655] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0656] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 99.0%, greater than 99.1%, greater than 99.2%, greater than 99.3%, greater than 99.4%, greater than 99.5%, greater than 99.6%, greater than 99.7%, greater than 99.8%, or greater than 99.9%.

[0657] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) measured by mDSC at 72 ± 20 °C (e.g., 72 ± 10 °C, 72 ± 5 °C, 72 ± 4 °C, 72 ± 3 °C, 72 ± 2 °C, 72 ± 1 °C, 72 ± 0.5 °C). g ).

[0658] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) at about 72°C, as measured by mDSC. g ).

[0659] In some embodiments, the combination (e.g., the composition) is characterized by being substantially similar to Figure 97 The mDSC spectrum shown is the mDSC spectrum.

[0660] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0661] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 99.0%, greater than 99.1%, greater than 99.2%, greater than 99.3%, greater than 99.4%, greater than 99.5%, greater than 99.6%, greater than 99.7%, greater than 99.8%, or greater than 99.9%.

[0662] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) measured by mDSC at 107 ± 20°C (e.g., 107 ± 10°C (e.g., 107 ± 5°C (e.g., 107 ± 4°C (e.g., 107 ± 3°C (e.g., 107 ± 2°C (e.g., 107 ± 1°C (e.g., 107 ± 0.5°C)). g ).

[0663] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) of about 107 °C, as measured by mDSC. g ).

[0664] In some embodiments, the combination (e.g., the composition) is characterized by being substantially similar to Figure 98 The mDSC spectrum shown is the mDSC spectrum.

[0665] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0666] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 99.0%, greater than 99.1%, greater than 99.2%, greater than 99.3%, greater than 99.4%, greater than 99.5%, greater than 99.6%, greater than 99.7%, greater than 99.8%, or greater than 99.9%.

[0667] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) measured by mDSC at 91 ± 20 °C (e.g., 91 ± 10 °C, 91 ± 5 °C, 91 ± 4 °C, 91 ± 3 °C, 91 ± 2 °C, 91 ± 1 °C, 91 ± 0.5 °C). g ).

[0668] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (T0) of about 91°C as measured by mDSC. g ).

[0669] In some embodiments, the combination (e.g., the composition) is characterized by being substantially similar to Figure 99 The mDSC spectrum shown is the mDSC spectrum.

[0670] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.

[0671] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is greater than 99.0%, greater than 99.1%, greater than 99.2%, greater than 99.3%, greater than 99.4%, greater than 99.5%, greater than 99.6%, greater than 99.7%, greater than 99.8%, or greater than 99.9%.

[0672] Pharmaceutical Composition In some respects, this disclosure is characterized by pharmaceutical compositions comprising the crystal form of compound 1 described herein, its solvate, its hydrate or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients.

[0673] Pharmaceutical compositions comprising the active compounds of this disclosure can be prepared in a manner commonly known. For example It is manufactured using conventional processes such as mixing, dissolving, granulation, forming into sugar-coated pellets, grinding, emulsification, encapsulation, entrapping, or lyophilization. Pharmaceutical compositions can be formulated in a conventional manner using one or more pharmaceutically acceptable carriers, which contain excipients and / or adjuvants that facilitate the processing of the active compound into a pharmaceutically usable formulation. Of course, the appropriate formulation depends on the chosen route of administration.

[0674] Suitable pharmaceutical compositions for injectable applications include sterile aqueous solutions (in the water-soluble case) or dispersions, as well as sterile powders for the ad hoc preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, antibacterial water, and polyoxyethylene castor oil (Cremophor EL). (BASF, Parsippany, NJ) or phosphate-buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to facilitate injection. The composition must be stable under the conditions of preparation and storage and must be preserved against contamination by microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.) and suitable mixtures thereof. Appropriate flowability can be maintained, for example, by using coatings such as lecithin, by maintaining the desired particle size in the case of a dispersion, and by using surfactants. Antimicrobial action can be achieved by various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc.). In many cases, including isotonic agents such as sugars, polyols (such as mannitol and sorbitol), and sodium chloride in the composition is preferred. Extended absorption of the injectable composition can be achieved by including agents that delay absorption, such as aluminum monostearate and gelatin, in the composition.

[0675] Sterile injectable solutions can be prepared by incorporating the desired amount of the active compound with one or a combination of the ingredients listed above (as needed) into a suitable solvent, followed by filtration and sterilization. Typically, dispersions are prepared by incorporating the active compound into a sterile medium containing a basic dispersion medium and any other desired ingredients from the ingredients listed above. In the case of sterile powders used to prepare sterile injectable solutions, the preparation method involves vacuum drying and freeze-drying of a powder containing the active ingredient plus any other desired ingredients from its previously sterile filtered solution.

[0676] Oral compositions typically include an inert diluent or an edible, pharmaceutically acceptable carrier. They may be encapsulated in gelatin capsules or compressed into tablets. For oral therapeutic administration, the active compound may be incorporated with excipients and used in tablet, lozenge, or capsule form. Oral compositions may also be prepared using a fluid carrier used as a mouthwash, wherein the compound in the fluid carrier is administered orally and rinsed and spat out or swallowed. Pharmaceutically compatible binders and / or adjuvant materials may be included as part of the composition. Tablets, pills, capsules, lozenges, etc., may contain any of the following components or compounds with similar properties: binders, such as microcrystalline cellulose, tragacanth gum, or gelatin; excipients, such as starch or lactose; disintegrants, such as alginate, primordial gluten, or corn starch; lubricants, such as magnesium stearate or strobilurin; gliding agents, such as colloidal silica; sweeteners, such as sucrose or saccharin; or flavoring agents, such as peppermint, methyl salicylate, or orange flavoring.

[0677] For administration by inhalation, the compound is delivered as an aerosol spray from a source containing a suitable propellant ( For example Gases (such as carbon dioxide) are delivered via pressurized containers or dispensers or atomizers.

[0678] Systemic application can also be performed transmucosal or transdermal. For transmucosal or transdermal application, a penetrant suitable for the target barrier can be used in the formulation. Such penetrants are generally known in the art and, for example, for transmucosal application, include cleansers, bile salts, and clostridial acid derivatives. Transmucosal application can be achieved by using nasal sprays or suppositories. For transdermal application, as is generally known in the art, the active compound is formulated as an ointment, cream, gel, or lotion.

[0679] The active compound can be prepared with a pharmaceutically acceptable carrier that protects the compound from rapid elimination from the body, such as controlled-release formulations, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydride, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Methods for preparing such formulations will be apparent to those skilled in the art.

[0680] For ease of administration and uniform dosage, it may be particularly advantageous to formulate oral or parenteral compositions in dose-unit form. As used herein, dose-unit form refers to a physically discrete unit suitable as a unit dose to a subject to be treated; each unit contains a predetermined amount of active compound calculated to bind with the desired drug carrier to produce the desired therapeutic effect. The specifications of the dose-unit form of this disclosure are determined by and directly dependent on the unique properties of the active compound and the specific therapeutic effect to be achieved.

[0681] In therapeutic applications, the dosage of the pharmaceutical composition used according to this disclosure varies depending on the pharmaceutical agent, the age, weight, and clinical condition of the receiving patient, the experience and judgment of the clinician or practitioner administering the therapy, and other factors affecting the selected dosage. Generally, the dosage should be sufficient to alleviate, and preferably eliminate, the symptoms of the disease, and even more preferably to induce complete remission of the disease.

[0682] It should be understood that the pharmaceutical composition may be included in a container, package or dispenser along with the instructions for use.

[0683] How to use In some aspects, this disclosure provides a method for treating or preventing cancer in a subject, the method comprising administering to the subject a pharmaceutically effective amount of compound 1, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[0684] In some aspects, this disclosure provides a method for treating or preventing cancer in a subject, the method comprising administering to the subject a pharmaceutically effective amount of compound 1 (e.g., form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K, form L, form M, form N, form O, or form P), its solvate, its hydrate, or a pharmaceutically acceptable salt thereof.

[0685] In some aspects, this disclosure provides a compound 1, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof for treating or preventing cancer in a subject.

[0686] In some aspects, this disclosure provides a compound 1 (e.g., form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K, form L, form M, form N, form O, or form P) for treating or preventing cancer in a subject, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof.

[0687] In some respects, this disclosure provides for the use of compound 1, its solvates, its hydrates or pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prevention of cancer in a subject.

[0688] In some respects, this disclosure provides the use of compound 1 (e.g., form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K, form L, form M, form N, form O, or form P), its solvates, its hydrates, or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for treating or preventing cancer in a subject.

[0689] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form A are applied.

[0690] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form B are applied.

[0691] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form C are applied.

[0692] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form D are applied.

[0693] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form E are applied.

[0694] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form F are applied.

[0695] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form G are applied.

[0696] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form H are applied.

[0697] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form I are applied.

[0698] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form J are applied.

[0699] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form K are applied.

[0700] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form L are applied.

[0701] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form M are applied.

[0702] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form N are applied.

[0703] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form O are applied.

[0704] In some implementations, compound 1, its solvate, its hydrate, or its pharmaceutically acceptable salt form P are applied.

[0705] Suitable subjects and diseases In some implementations, the subjects are mammals.

[0706] In some implementations, the subjects are humans.

[0707] In some implementations, the subjects are mice.

[0708] In some implementations, the subjects are rats.

[0709] In some implementations, the subjects are dogs.

[0710] In some implementations, the subjects are monkeys.

[0711] In some implementation schemes, cancer is characterized by BRAF At least one oncogenic mutation in a gene.

[0712] It should be understood that the characteristic is BRAF Cancers caused by at least one oncogenic mutation in a gene are usually associated with BRAF Cancers associated with at least one oncogenic mutation in a gene, including but not limited to those whose primary oncogenic activity is believed to be caused by... BRAF Cancer driven by at least one oncogenic mutation in a gene.

[0713] In some implementations, the cancer is characterized by at least one oncogenic variant of B-Raf.

[0714] It should be understood that cancers characterized by at least one carcinogenic variant of B-Raf are cancers that are generally associated with at least one carcinogenic variant of B-Raf, including but not limited to cancers whose primary carcinogenic activity is believed to be driven by at least one carcinogenic variant of B-Raf.

[0715] It should be understood that oncogenic variants of B-Raf are those containing at least one oncogenic mutation and expressed as containing at least one oncogenic mutation. BRAF The B-Raf protein is produced as a result of the gene.

[0716] In some implementation schemes, the subject has BRAF At least one oncogenic mutation in a gene.

[0717] In some implementations, the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of B-Raf.

[0718] As technicians will understand, in genes (e.g.) BRAF In the context of genes, oncogenic mutations may include, but are not limited to, mutations that cause one amino acid to replace another amino acid at a specific position within B-Raf, mutations that cause one or more amino acids to replace one or more amino acids between two specific positions within B-Raf, mutations that cause one or more amino acids to be inserted between two positions within B-Raf, mutations that cause one or more amino acids to be deleted between two positions within B-Raf, and mutations that cause B-Raf or a portion thereof to fuse with another protein or a portion thereof, or any combination thereof. As those skilled in the art will understand, in the context of genes, oncogenic mutations may include, but are not limited to, missense mutations, nonsynonymous mutations, insertions of one or more nucleotides, deletions of one or more nucleotides, inversions, and deletion-insertion. As those skilled in the art will understand, in the context of genes (e.g., BRAF In the context of ), a gene may have one or more of the oncogenic mutations of the types mentioned above, including combinations of different types of oncogenic mutations.

[0719] As those skilled in the art will understand, in the context of a gene (e.g., B-Raf), oncogenic mutations may include, but are not limited to, substitution of one amino acid for another at a specific position within B-Raf, substitution of one or more amino acids for one or more amino acids between two specific positions within B-Raf, insertion of one or more amino acids between two positions within B-Raf, deletion of one or more amino acids between two positions within B-Raf, and fusion of B-Raf or a portion thereof with another protein or a portion thereof, or any combination thereof. As those skilled in the art will understand, in the context of a protein (e.g., B-Raf), a protein may have one or more of the types of oncogenic mutations described above, including combinations of different types of oncogenic mutations.

[0720] In some implementations, the oncogenic mutation of B-Raf can be any B-Raf mutation listed in Table 6. Oncogenic variants of B-Raf can contain any combination of oncogenic mutations listed in Table 6. In a non-limiting example, an oncogenic variant of B-Raf can contain the oncogenic mutations K601E and S363F.

[0721] Table 6. B-Raf mutations (numbered according to SEQ ID NO: 1) As will be understood by those skilled in the art, L485-P490>Y and L485-P490Y refer to the substitution of residues L485 to P490 of B-Raf (SEQ ID NO: 1) with tyrosine (Y) residues.

[0722] In some embodiments, the oncogenic mutation of B-Raf may comprise the deletion of any combination of one or more amino acids between L485 and P490 of B-Raf (SEQ ID NO: 1). In some embodiments, the oncogenic mutation of B-Raf may comprise the deletion of any combination of one or more amino acids between L485 and Q494 of B-Raf (SEQ ID NO: 1). In some embodiments, the oncogenic mutation of B-Raf may comprise the deletion of any combination of one or more amino acids between A481 and Q494 of B-Raf (SEQ ID NO: 1). In some embodiments, the oncogenic mutation of B-Raf may comprise the deletion of any combination of one or more amino acids between K475 and N500 of B-Raf (SEQ ID NO: 1). In some embodiments, any of the foregoing deletions may further comprise any combination of one or more substitutions and / or insertions within the indicated residue range.

[0723] The wild-type B-Raf sequence disclosed herein may contain the following amino acid sequence, consist essentially of the following amino acid sequence, or consist of the following amino acid sequence: 1 MAALSGGGGGG GAEPGQALFN GDMEPEAGAG AGAAASSAAD PAIPEEVWNI 51 KQMIKLTQEH IEALLDKFGG EHNPPSIYLE AYEEYTSKLD ALQQREQQLL 101 ESLGNGTDFS VSSSASMDTV TSSSSSSLSV LPSSLSVFQN PTDVARSNPK 151 SPQKPIVRVF LPNKQRTVVP ARCGVTVRDS LKKALMMRGL IPECCAVYRI 201 QDGEKKPIGW DTDISWLTGE ELHVEVLENV PLTTHNFVRK TFFTLAFCDF 251 CRKLLFQGFR CQTCGYKFHQ RCSTEVPLMC VNYDQLDLLF VSKFFEHHPI 301 PQEEASLAET ALTSGSSPSA PASDSIGPQI LTSPSPSKSI PIPQPFRPAD 351 EDHRNQFGQR DRSSSAPNVH INTIEPVNID DLIRDQGFRG DGGSTTGLSA 401 TPPASLPGSL TNVKALQKSP GPQRERKSSS SSEDRNRMKT LGRRDSSDDW 451 EIPDGQITVG QRIGSGSFGT VYKGKWHGDV AVKMLNVTAP TPQQLQAFKN 501 EVGVLRKTRH VNILLFMGYS TKPQLAIVTQ WCEGSSLYHH LHIIETKFEM 551 IKLIDIARQT AQGMDYLHAK SIIHRDLKSN NIFLHEDLTV KIGDFGLATV 601 KSRWSGSHQF EQLSGSILWM APEVIRMQDK NPYSFQSDVY AFGIVLYELM 651 TGQLPYSNIN NRDQIIFMVG RGYLSPDLSK VRSNCPKAMK RLMAECLKKK 701 RDERPLFPQI LASIELLARS LPKIHRSASE PSLNRAGFQT EDFSLYACAS 751 PKTPIQAGGY GAFPVH (SEQ ID NO: 1) In some implementations, the oncogenic mutation is a type I mutation. Therefore, in some implementations, the oncogenic variant of B-Raf contains a type I mutation.

[0724] In some implementations, the oncogenic mutation is a type II mutation. Therefore, in some implementations, the oncogenic variant of B-Raf contains a type II mutation.

[0725] In some implementations, the oncogenic mutation is a Class III mutation. Therefore, in some implementations, the oncogenic variant of B-Raf contains a Class III mutation.

[0726] In some implementations, the carcinogenic variant of B-Raf can be any of the B-Raf variants listed in Table 7.

[0727] Table 7. Carcinogenic variants of B-Raf (numbered according to SEQ ID NO: 1) In some embodiments, the oncogenic variant of B-Raf may comprise a deletion of any combination of one or more amino acids between L485 and P490 of B-Raf (SEQ ID NO: 1). In some embodiments, the oncogenic variant of B-Raf may comprise a deletion of any combination of one or more amino acids between L485 and Q494 of B-Raf (SEQ ID NO: 1). In some embodiments, the oncogenic variant of B-Raf may comprise a deletion of any combination of one or more amino acids between A481 and Q494 of B-Raf (SEQ ID NO: 1). In some embodiments, the oncogenic variant of B-Raf may comprise a deletion of any combination of one or more amino acids between K475 and N500 of B-Raf (SEQ ID NO: 1). In some embodiments, any of the foregoing deletions may further comprise any combination of one or more substitutions and / or insertions within the indicated residue range.

[0728] In some embodiments, the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of B-Raf and containing at least one additional protein in the RAF and / or MAPK / ERK signaling pathway with at least one mutation. In some embodiments, the at least one additional protein may be selected from N-Ras, K-Ras, and neurofibromatosis protein 1 (NF1). In some embodiments, at least one mutation in the at least one additional protein may be an oncogenic mutation.

[0729] In some embodiments, the subject has at least one tumor and / or cancer cell expressing an oncogenic variant of B-Raf and containing at least one mutated N-Ras protein. In some embodiments, the N-Ras protein containing at least one mutated protein may be N-Ras-G12D, N-Ras-Q61K, and / or N-Ras-Q61R. In some embodiments, the N-Ras protein containing at least one mutated protein may be N-Ras-Q61L and / or N-Ras-G13D. In a non-limiting example, the subject may have at least one tumor and / or cancer cell expressing both B-Raf-D594G and N-Ras-G12D.

[0730] In some embodiments, the subject has at least one tumor and / or cancer cell expressing an oncogenic variant of B-Raf and containing at least one mutated K-Ras protein. In some embodiments, the K-Ras protein containing at least one mutated protein may be K-Ras-G12V, K-Ras-G12D, K-Ras-G12A, K-Ras-G12S, K-Ras-G12C, K-Ras-Q61H, K-Ras-Q61L, K-Ras-G13C, and / or K-Ras-G13D.

[0731] In some implementations, the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of B-Raf and containing at least one mutation in the NF1 protein. Exemplary mutations within the NF1 protein include, but are not limited to, missense mutations, nonsense mutations, frameshift mutations and splice site mutations, insertions, deletions, and translocations.

[0732] In some embodiments, the cancer is characterized by at least one oncogenic mutation in at least one protein in the RAF and / or MAPK / ERK signaling pathway. In some embodiments, at least one protein in the RAF and / or MAPK / ERK signaling pathway may be selected from N-Ras, K-Ras, and NF1.

[0733] In some implementation schemes, cancer is characterized by KRAS At least one oncogenic mutation in a gene.

[0734] It should be understood that the characteristic is KRAS Cancers caused by at least one oncogenic mutation in a gene are usually associated with KRAS Cancers associated with at least one oncogenic mutation in a gene, including but not limited to those whose primary oncogenic activity is believed to be caused by... KRAS Cancer driven by at least one oncogenic mutation in a gene.

[0735] In some implementations, the cancer is characterized by at least one oncogenic variant of K-Ras.

[0736] It should be understood that cancers characterized by at least one oncogenic variant of K-Ras are cancers that are generally associated with at least one oncogenic variant of K-Ras, including but not limited to cancers whose primary oncogenic activity is believed to be driven by at least one oncogenic variant of K-Ras.

[0737] It should be understood that oncogenic variants of K-Ras are those containing at least one oncogenic mutation and expressed as containing at least one oncogenic mutation. KRAS The result of the gene is the production of the K-Ras protein.

[0738] In some implementation schemes, the subject has KRAS At least one oncogenic mutation in a gene.

[0739] In some implementations, the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of K-Ras.

[0740] In some embodiments, the oncogenic mutation of K-Ras may be selected from K-Ras-G12V, K-Ras-G12D, K-Ras-G12A, K-Ras-G12S, K-Ras-G12C, K-Ras-Q61H, K-Ras-Q61L, K-Ras-G13C, and K-Ras-G13D. In some embodiments, the oncogenic mutation of K-Ras may be a mutation that induces constitutive RAF dimer activation. In some embodiments, the oncogenic mutation of K-Ras is not a K-Ras-G12C mutation. In some embodiments, the oncogenic mutation of K-Ras may be K-Ras-G12D. In some embodiments, the oncogenic mutation of K-Ras may be K-Ras-G12V.

[0741] In some implementation schemes, cancer is characterized by NRAS At least one oncogenic mutation in a gene.

[0742] It should be understood that the characteristic is NRAS Cancers caused by at least one oncogenic mutation in a gene are usually associated with NRAS Cancers associated with at least one oncogenic mutation in a gene, including but not limited to those whose primary oncogenic activity is believed to be caused by... NRAS Cancer driven by at least one oncogenic mutation in a gene.

[0743] In some implementations, the cancer is characterized by at least one oncogenic variant of N-Ras.

[0744] It should be understood that cancer characterized by at least one carcinogenic variant of N-Ras is cancer that is generally associated with at least one carcinogenic variant of N-Ras, including but not limited to cancers whose primary carcinogenic activity is believed to be driven by at least one carcinogenic variant of N-Ras.

[0745] It should be understood that oncogenic variants of N-Ras are those containing at least one oncogenic mutation and expressed as containing at least one oncogenic mutation. NRAS The N-Ras protein produced as a result of the gene.

[0746] In some implementation schemes, the subject has NRAS At least one oncogenic mutation in a gene.

[0747] In some implementations, the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of N-Ras.

[0748] In some embodiments, the oncogenic mutation of N-Ras may be selected from N-Ras-G12D, N-Ras-Q61K, N-Ras-Q61R, N-Ras-Q61L, and N-Ras-G13D. In some embodiments, the oncogenic mutation of N-Ras may be a mutation that induces constitutive RAF dimer activation.

[0749] In some implementation schemes, cancer is characterized by NF1 At least one oncogenic mutation in the gene. In some implementations, NF1 Oncogenic mutations in genes can be loss-of-function mutations.

[0750] It should be understood that the characteristic is NF1 Cancers caused by at least one oncogenic mutation in a gene are usually associated with NF1 Cancers associated with at least one oncogenic mutation in a gene, including but not limited to those whose primary oncogenic activity is believed to be caused by... NF1 Cancer driven by at least one oncogenic mutation in a gene.

[0751] In some implementations, the cancer is characterized by at least one oncogenic variant of NF1.

[0752] It should be understood that cancers characterized by at least one carcinogenic variant of NF1 are cancers that are generally associated with at least one carcinogenic variant of NF1, including but not limited to cancers whose primary carcinogenic activity is believed to be driven by at least one carcinogenic variant of N-Ras.

[0753] It should be understood that oncogenic variants of NF1 are those containing at least one oncogenic mutation and expressed as containing at least one oncogenic mutation. NF1 The NF1 protein is produced as a result of genetic factors. In some respects, oncogenic mutations in the NF1 protein can be loss-of-function mutations in the NF1 protein.

[0754] In some implementation schemes, the subject has NF1 At least one oncogenic mutation in a gene.

[0755] In some implementations, the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of NF1.

[0756] In some implementation schemes, cancer is characterized by any combination of the following: NRAS At least one oncogenic mutation in a gene KRAS At least one oncogenic mutation in the gene and NF1 At least one oncogenic mutation in a gene. An oncogenic mutation can be any of the oncogenic mutations described herein.

[0757] Therefore, in some embodiments, the cancer is characterized by any combination of the following: at least one oncogenic variant of K-Ras, at least one oncogenic variant of N-Ras, and at least one oncogenic variant of NF1.

[0758] In some implementations, the cancer is characterized by at least one oncogenic mutation in the gene encoding the RAS GTPase.

[0759] It should be understood that cancer characterized by at least one oncogenic mutation in the gene encoding RAS GTPase is cancer that is generally associated with at least one oncogenic mutation in the gene encoding RAS GTPase, including but not limited to cancers whose primary oncogenic activity is believed to be driven by at least one oncogenic mutation in the gene encoding RAS GTPase.

[0760] In some implementations, the cancer is characterized by at least one oncogenic variant of the RAS GTPase.

[0761] It should be understood that cancers characterized by at least one oncogenic variant of RAS GTPase are cancers that are generally associated with at least one oncogenic variant of RAS GTPase, including but not limited to cancers whose primary oncogenic activity is believed to be driven by at least one oncogenic variant of RAS GTPase.

[0762] It should be understood that oncogenic variants of RAS GTPases are RAS GTPase proteins that contain at least one oncogenic mutation and are produced as a result of expressing a gene encoding a RAS GTPase containing at least one oncogenic mutation.

[0763] In some implementations, the subject has at least one oncogenic mutation in a gene encoding the RAS GTPase.

[0764] In some implementations, the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of the RAS GTPase.

[0765] In some implementations, the RAS GTPase can be NRAS, KRAS, or HRAS.

[0766] In some implementation schemes, cancer is characterized by HRAS At least one oncogenic mutation in a gene.

[0767] It should be understood that the characteristic is HRAS Cancers caused by at least one oncogenic mutation in a gene are usually associated with HRAS Cancers associated with at least one oncogenic mutation in a gene, including but not limited to those whose primary oncogenic activity is believed to be caused by... HRAS Cancer driven by at least one oncogenic mutation in a gene.

[0768] In some implementations, the cancer is characterized by at least one carcinogenic variant of H-Ras.

[0769] It should be understood that cancers characterized by at least one carcinogenic variant of H-Ras are cancers that are generally associated with at least one carcinogenic variant of H-Ras, including but not limited to cancers whose primary carcinogenic activity is believed to be driven by at least one carcinogenic variant of H-Ras.

[0770] It should be understood that oncogenic variants of H-Ras are those containing at least one oncogenic mutation and expressed as containing at least one oncogenic mutation. HRAS The H-Ras protein is produced as a result of the gene.

[0771] In some implementation schemes, the subject has HRAS At least one oncogenic mutation in a gene.

[0772] In some implementations, the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of H-Ras.

[0773] In some implementation schemes, cancer includes carcinoma, lymphoma, blastoma, sarcoma, leukemia, brain cancer, breast cancer, blood cancer, bone cancer, lung cancer, skin cancer, liver cancer, ovarian cancer, bladder cancer, renal cancer, kidney cancer, gastric cancer, thyroid cancer, pancreatic cancer, esophageal cancer, prostate cancer, cervical cancer, uterine cancer, stomach cancer, soft tissue cancer, laryngeal cancer, small intestine cancer, testicular cancer, anal cancer, vulvar cancer, joint cancer, oral cancer, pharyngeal cancer, or colorectal cancer.

[0774] In some implementations, the cancer is adrenocortical carcinoma, bladder urothelial carcinoma, invasive breast cancer, cervical squamous cell carcinoma, cervical adenocarcinoma, bile duct carcinoma, colon adenocarcinoma, lymphoma (diffuse large B-cell lymphoma), esophageal cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, renal chromophobe cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, acute myeloid leukemia, low-grade glioma of the brain, hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, mesothelioma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma, paraganglioma, prostate adenocarcinoma, rectal adenocarcinoma, sarcoma, cutaneous melanoma, gastric adenocarcinoma, testicular germ cell tumor, thyroid cancer, thymoma, uterine carcinosarcoma, and uveal melanoma. Other examples include breast cancer, lung cancer, lymphoma, melanoma, liver cancer, colorectal cancer, ovarian cancer, bladder cancer, kidney cancer, or stomach cancer. Other examples of cancer include neuroendocrine carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer, thyroid cancer, endometrial cancer, bile duct cancer, esophageal cancer, anal cancer, salivary cancer, vulvar cancer, cervical cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenal tumors, anal cancer, bile duct cancer, bladder cancer, bone cancer, colorectal cancer, brain tumors, breast cancer, cancer of unknown primary origin (CUP), cancer spread to bone, cancer spread to brain, cancer spread to liver, cancer spread to lung, carcinoid tumors, cervical cancer, childhood cancer, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), colorectal cancer, ear cancer, endometrial cancer, eye cancer, follicular dendritic cell sarcoma, gallbladder cancer, and gastric cancer. Cancer, gastroesophageal junction cancer, germ cell tumors, gestational trophoblastic disease (GIT), hairy cell leukemia, head and neck cancer, Hodgkin lymphoma, Kaposi's sarcoma, kidney cancer, laryngeal cancer, leukemia, leukoderma, liver cancer, lung cancer, lymphoma, malignant schwannoma, mediastinal germ cell tumor, melanoma, skin cancer, male cancer, Merkel cell skin cancer, mesothelioma, hydatidiform mole, oropharyngeal cancer, myeloma, nasal and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, neuroendocrine tumors, non-Hodgkin lymphoma (NHL), esophageal cancer, ovarian cancer, pancreatic cancer, penile cancer, persistent trophoblastic disease and choriocarcinoma, pheochromocytoma, prostate cancer, pseudomyxoma peritonei, rectal cancer, retinoblastoma, salivary gland cancer, secondary cancers, signet cell carcinoma. Cancer, skin cancer, small intestine cancer, soft tissue sarcoma, stomach cancer, T-cell childhood non-Hodgkin lymphoma (NHL), testicular cancer, thymic cancer, thyroid cancer, tongue cancer, tonsil cancer, adrenal tumors, uterine cancer, vaginal cancer, vulvar cancer, Wilms' tumor, uterine cancer, and gynecological cancers.Examples of cancers include, but are not limited to: hematologic malignancies, lymphoma, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, chronic myeloid leukemia, acute myeloid leukemia, myelodysplastic syndrome, myelofibrosis, biliary tract cancer, hepatocellular carcinoma, colorectal cancer, breast cancer, lung cancer, non-small cell lung cancer, ovarian cancer, thyroid cancer, renal cell carcinoma, pancreatic cancer, bladder cancer, skin cancer, malignant melanoma, Merkel cell carcinoma, uveal melanoma, or glioblastoma multiforme.

[0775] In some implementations, the cancer is a hematologic cancer.

[0776] In some implementations, the cancer is solid cancer (also known as solid malignancy or solid tumor).

[0777] In some implementation schemes, cancer includes melanoma, breast cancer, head and neck cancer, esophageal and gastric cancer, stomach and small intestine cancer, lung cancer, mesothelioma, cholangiocarcinoma, pancreatic cancer, kidney cancer, colorectal cancer, endometrial cancer, cervical cancer, ovarian cancer, bladder cancer, prostate cancer, soft tissue sarcoma, CNS and brain cancer, or thyroid cancer.

[0778] In some implementation schemes, the cancer is non-small cell lung cancer (NSCLC), colorectal cancer, melanoma, thyroid cancer, histiocytosis, small bowel cancer, gastrointestinal neuroendocrine carcinoma, unknown primary cancer, non-melanoma skin cancer, prostate cancer, gastric cancer, non-Hodgkin's lymphoma, papillary thyroid carcinoma, or glioblastoma.

[0779] In some implementations, the cancer is NSCLC. In some implementations, the NSCLC has not yet undergone small cell lung cancer transformation.

[0780] In some implementations, the cancer is a histiocytic tumor. In some implementations, the histiocytic tumor is Langerhans cell histiocytosis (LCH). In some implementations, the histiocytic tumor is Erdheim Chester disease (ECD).

[0781] In some implementations, the cancer is melanoma.

[0782] In some implementation schemes, the cancer is thyroid cancer.

[0783] In some implementation schemes, the cancer is colorectal cancer.

[0784] In some implementations, the cancer is glioma.

[0785] In some implementations, the cancer is an astrocytoma, brainstem glioma, ependymoma, oligoastrocytoma, oligodendroglioma, or optic pathway glioma.

[0786] In some implementations, the cancer is a low-grade glioma (e.g., a glioma caused by astrocytes and / or oligodendrocytes).

[0787] In some implementations, the cancer is a glioma (e.g., a low-grade glioma) in a subject who is 18 years of age or older.

[0788] In some implementations, the cancer is a glioma (e.g., a low-grade glioma) in a subject under the age of 18.

[0789] In some implementations, the cancer is glioblastoma.

[0790] In some implementations, any cancer described herein may be a recurrent cancer.

[0791] In some implementations, any cancer described herein can be an advanced cancer.

[0792] In some implementations, any cancer described herein may be a metastatic cancer.

[0793] In some implementations, any tumor described herein may be a recurrent tumor.

[0794] In some implementations, any tumor described herein may be an advanced tumor.

[0795] In some implementations, any tumor described herein may be a metastatic tumor.

[0796] In some embodiments, the cancer is NSCLC, and the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of B-Raf. In some aspects, the oncogenic variant of B-Raf is a B-Raf protein containing at least one type I mutation. In some aspects, the oncogenic variant of B-Raf is a B-Raf protein containing at least one type II mutation. In some aspects, the oncogenic variant of B-Raf is a B-Raf protein containing at least one type III mutation. In some embodiments, the oncogenic variant is B-Raf-V600E. In some embodiments, the NSCLC can be recurrent, advanced, metastatic, or any combination thereof.

[0797] In some embodiments, the cancer is NSCLC, and the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of K-Ras. In some embodiments, the oncogenic variant of K-Ras is a K-Ras protein containing an oncogenic mutation that is not K-Ras-G12C. In some embodiments, the NSCLC can be recurrent, advanced, metastatic, or any combination thereof.

[0798] In some embodiments, the cancer is a histiocytic tumor, and the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of B-Raf. In some aspects, the oncogenic variant of B-Raf is a B-Raf protein comprising at least one class I mutation, at least one class II mutation, at least one class III mutation, or any combination thereof. In some embodiments, the cancer is a histiocytic tumor, and the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of N-Ras. In some embodiments, the histiocytic tumor may be recurrent.

[0799] In some embodiments, the cancer is melanoma, and the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of B-Raf. In some aspects, the oncogenic variant of B-Raf is a B-Raf protein comprising at least one class I mutation, at least one class II mutation, at least one class III mutation, or any combination thereof. In some embodiments, the oncogenic variant is B-Raf-V600E. In some embodiments, the melanoma can be recurrent, advanced, metastatic, or any combination thereof.

[0800] In some embodiments, the cancer is melanoma, and the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of N-Ras. In some embodiments, the melanoma can be recurrent, advanced, metastatic, or any combination thereof.

[0801] In some implementations, the cancer is thyroid cancer, and the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of B-Raf. In some aspects, the oncogenic variant of B-Raf is a B-Raf protein containing at least one type I mutation, at least one type II mutation, at least one type III mutation, or any combination thereof.

[0802] In some implementations, the cancer is colorectal cancer, and the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of B-Raf. In some aspects, the oncogenic variant of B-Raf is a B-Raf protein containing at least one type II mutation, at least one type III mutation, or any combination thereof.

[0803] In some embodiments, application of the compounds disclosed herein does not induce paradoxical activation of wild-type B-Raf.

[0804] In some embodiments, administration of the compounds disclosed herein does not substantially increase the amount of p-ERK in the subject.

[0805] In some embodiments, administration of the compounds of this disclosure results in a p-ERK level in the subject that is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% lower than that of comparable subjects who have been administered vemurafenib or encorafenib.

[0806] In some embodiments, administration of the compounds of this disclosure results in a p-ERK level in the subject being at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% lower than that in a comparable subject who has not received the compound.

[0807] In some embodiments, administration of the compounds disclosed herein reduces tumor volume in a subject by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, or at least about 99%.

[0808] In some implementations, the cancer is insensitive to or resistant to treatment with one or more MAPK pathway inhibitors.

[0809] In some implementations, the cancer is insensitive to or resistant to treatment with BRAF inhibitors, MEK inhibitors, or combinations thereof.

[0810] In some implementations, the cancer is insensitive to or resistant to treatment using a combination of BRAF inhibitors and MEK inhibitors.

[0811] In some implementations, the cancer is insensitive to treatment with a combination of BRAF inhibitors and MEK inhibitors.

[0812] In some implementations, the cancer is resistant to treatment using a combination of BRAF inhibitors and MEK inhibitors.

[0813] In some implementations, the subject has an adverse response to treatment with one or more MAPK pathway inhibitors.

[0814] In some implementations, the subject has an adverse reaction to treatment with BRAF inhibitors, MEK inhibitors, or combinations thereof.

[0815] In some implementations, the subject experienced an adverse reaction to treatment with a combination of BRAF inhibitors and MEK inhibitors.

[0816] In some implementations, adverse reactions are new cancers (e.g., skin cancer), bleeding, gastrointestinal effects, effects on the kidneys and / or liver, eye problems, lung problems, fever, or any combination thereof.

[0817] In some implementations, the subject has previously been administered one or more MAPK pathway inhibitors, and despite prior administration, the subject has experienced disease progression.

[0818] In some implementations, the subject has previously been given a BRAF inhibitor, a MEK inhibitor, or a combination thereof, and despite prior administration, the subject has experienced disease progression.

[0819] In some implementations, the subject has previously been administered a combination of BRAF inhibitors and MEK inhibitors, and despite prior administration, the subject has experienced disease progression.

[0820] In some implementations, the subject has at least one brain metastasis.

[0821] In some implementation schemes, the subjects did not have brain metastases.

[0822] MAPK pathway inhibitors In some implementations, one or more MAPK pathway inhibitors comprise BRAF inhibitors, MEK inhibitors, or any combination thereof.

[0823] In some implementations, one or more MAPK pathway inhibitors comprise a combination of a BRAF inhibitor and a MEK inhibitor.

[0824] In some implementations, the BRAF inhibitor is vemurafenib, dabrafenib, or encofinib.

[0825] In some implementations, the BRAF inhibitor is vemurafenib.

[0826] In some implementations, the BRAF inhibitor is dabrafenib.

[0827] In some implementations, the BRAF inhibitor is entrobinib.

[0828] In some implementations, the MEK inhibitor is trametinib, cobimetinib, or bimetinib.

[0829] In some implementations, the MEK inhibitor is trametinib.

[0830] In some implementations, the MEK inhibitor is cobimetinib.

[0831] In some implementations, the MEK inhibitor is bimetinib.

[0832] definition It should be understood that the compounds described herein include the compounds themselves, as well as their salts and their solvates, if applicable. For example, salts can be formed between an anion and a positively charged group (e.g., amino) on a substituted benzene compound. Suitable anions include chlorides, bromides, iodides, sulfates, hydrogen sulfates, aminosulfonates, nitrates, phosphates, citrates, methanesulfonates, trifluoroacetates, glutamates, glucurons, glutarates, malates, maleates, succinates, fumarates, tartrates, toluenesulfonates, salicylates, lactates, naphthalenesulfonates, and acetates (e.g., trifluoroacetates).

[0833] Unless otherwise expressly stated, the terms "about" and "about" are synonymous. In some embodiments, "about" and "about" refer to the amount, value, dose, or duration ±20%, ±15%, ±10%, ±8%, ±6%, ±5%, ±4%, ±2%, ±1%, or ±0.5%. In some embodiments, "about" and "about" refer to the listed amount or duration ±10%, ±8%, ±6%, ±5%, ±4%, or ±2%. In some embodiments, "about" and "about" refer to the listed amount, value, dose, or duration ±5%. In some embodiments, "about" and "about" refer to the listed amount, value, dose, or duration ±2%. In some embodiments, "about" and "about" refer to the listed amount, value, dose, or duration ±1%.

[0834] As used herein, the term "pharmaceutically acceptable anion" refers to an anion suitable for forming a pharmaceutically acceptable salt. Similarly, salts can also be formed between a cation and a negatively charged group (e.g., a carboxyl group) on a substituted benzene compound. Suitable cations include sodium, potassium, magnesium, calcium, and ammonium cations such as tetramethylammonium ions. Substituted benzene compounds also include those containing a quaternary nitrogen atom.

[0835] It should be understood that the compounds of this disclosure (e.g., salts of the compounds) may exist in hydrated or unhydrated (anhydrous) form or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates and dihydrates. Non-limiting examples of solvates include ethanol solvates and acetone solvates.

[0836] As used herein, unless otherwise specified, the expressions “one or more of A, B or C”, “one or more of A, B or C”, “one or more of A, B and C”, “one or more of A, B and C”, “selected from the group consisting of A, B and C”, “selected from A, B and C”, etc., are used interchangeably and all refer to the group consisting of A, B and / or C, that is, one or more A, one or more B, one or more C or any combination thereof.

[0837] It should be understood that throughout the specification, when a composition is described as having, including, or comprising a specific component, it is anticipated that the composition is substantially composed of, or composed of, said component. Similarly, when a method or process is described as having, including, or comprising specific process steps, these processes are also substantially composed of, or composed of, said processing steps. Furthermore, it should be understood that the order of steps or the sequence of certain actions is irrelevant as long as the invention remains operable. Moreover, two or more steps or actions may be performed simultaneously.

[0838] It should be understood that the compounds disclosed herein can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or readily prepared intermediates, employing standard synthetic methods and procedures known to those skilled in the art or obvious to those skilled in the art based on the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules and for the transformation and manipulation of functional groups are available from relevant scientific literature or from standard textbooks in the field. While not limited to any one or more sources, classic texts incorporated herein by reference, such as Smith, MB, March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure , 5th ed., John Wiley&Sons: New York, 2001; Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis , 3rd ed., John Wiley&Sons: New York, 1999; R. Larock, Comprehensive Organic Transformations , VCH Publishers (1989); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis John Wiley and Sons (1994); and L. Paquette (eds.), Encyclopedia of Reagents for Organic Synthesis John Wiley and Sons (1995) is a useful and well-regarded reference textbook for organic synthesis known to those skilled in the art.

[0839] It should be understood that, unless otherwise stated, any description of a treatment or prevention method includes the use of Compound 1 or a pharmaceutically acceptable salt thereof in a crystalline form to provide the treatment or prevention as described herein. It should be further understood that, unless otherwise stated, any description of a treatment or prevention method includes the use of Compound 1 or a pharmaceutically acceptable salt thereof in a crystalline form to prepare a medicament for the treatment or prevention of such condition. Treatment or prevention includes the treatment or prevention of human or non-human animals, including rodents and other disease models.

[0840] It should be understood that, unless otherwise stated, any description of a treatment method includes the use of compound 1 or a pharmaceutically acceptable salt thereof in a crystalline form to provide the treatment as described herein. It should be further understood that, unless otherwise stated, any description of a treatment method includes the use of compound 1 or a pharmaceutically acceptable salt thereof in a crystalline form to prepare a medicament for treating this condition. Treatment includes treatment of humans or non-human animals, including rodents and other disease models.

[0841] As used herein, the term "subject" refers to a subject who has a disease or has an increased risk of developing the disease. "Subject" includes mammals. Mammals can be... For example Humans or suitable non-human mammals, such as primates, mice, rats, dogs, cats, cattle, horses, goats, camels, sheep, or pigs. Subjects may also be birds or poultry. In one implementation, the mammal is a human.

[0842] In some embodiments, the term "subject in need" can refer to a subject who has been previously diagnosed or identified as having a disease or condition disclosed herein. A subject in need can also be a subject suffering from a disease or condition disclosed herein. Alternatively, a subject in need can be a subject with an increased risk of developing such a disease or condition relative to the general population (i.e., a subject who is more susceptible to developing such a condition relative to the general population). A subject in need can suffer from a treatment-resistant or drug-resistant disease or condition disclosed herein (i.e., a disease or condition disclosed herein that is unresponsive to treatment or has not yet responded). A subject in need may be drug-resistant at the start of treatment or may become drug-resistant during treatment. In some embodiments, a subject in need has received all known effective therapies for the disease or condition disclosed herein but treatment has failed. In some embodiments, a subject in need has received at least one prior therapy.

[0843] As used herein, the terms "treating" or "treatment" describe the management and care of a patient in order to combat a disease, symptom, or condition, and include the administration of the compounds of this disclosure or their pharmaceutically acceptable salts, polymorphs, or solvates to alleviate or eliminate the symptoms or complications of the disease, symptom, or condition. The term "treatment" may also include... in vitro Treatment of cell or animal models.

[0844] It should be understood that the crystalline form of compound 1 or its pharmaceutically acceptable salt may or may be used to prevent related diseases, symptoms or conditions or to identify suitable candidates for such purposes.

[0845] As used herein, the terms “preventing,” “prevent,” or “protecting against” describe reducing or eliminating the onset of symptoms or complications of such diseases, conditions, or ailments.

[0846] It should be understood that "solubility" or "solubility grade" refers to the property of the polymorphs disclosed herein (e.g., forms A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, or P) to dissolve in a liquid solvent and form a homogeneous solution. In some embodiments, solubility is expressed as concentration by the mass of solute per unit volume of solvent (e.g., g solute / kg solvent, g / dL (100 mL), mg / ml, etc.), molar concentration, weight molality, mole fraction, or other similar concentration descriptions. Those skilled in the art will understand that the maximum equilibrium amount of solute that can be dissolved per volume of solvent is the solubility of that solute in that solvent under specified conditions (including temperature, pressure, pH, and the properties of the solvent).

[0847] As used herein, "stable" means a polymorph that maintains its purity, appearance, and / or analytical parameters within a defined time and temperature range compared to the separated polymorph. In some embodiments, the "stable" polymorph exhibits less than about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1 month, about 2 months, about 3 months, or about 4 months of impurities.

[0848] As used herein, the term "pharmaceutical composition" refers to a formulation comprising a compound of the present disclosure in a form suitable for administration to a subject. In one embodiment, the pharmaceutical composition is in bulk or unit dosage form. Unit dosage form is any of a variety of forms, including, for example, capsules, IV bags, tablets, single pumps on an aerosol inhaler, or vials. The active ingredient in a unit dose of the composition ( For example The amount of the disclosed compound (or a formulation thereof, including its salts, hydrates, solvates, or isomers) is an effective amount and varies depending on the specific treatment involved. Those skilled in the art will understand that it is sometimes necessary to routinely adjust the dosage according to the patient's age and condition. The dosage will also depend on the route of administration. Various routes are considered, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalation, oral, sublingual, intrapleural, intrathecal, intranasal, etc. Dosage forms for topical or transdermal application of the disclosed compounds include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalers. In one embodiment, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any desired preservatives, buffers, or propellants.

[0849] As used herein, the term “pharmaceutically acceptable” means those compounds, anionic, cationic, materials, compositions, carriers, and / or dosage forms that are suitable for use in human and animal tissues to the extent of correct medical judgment without causing excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.

[0850] As used herein, the term "pharmaceuticalally acceptable excipient" refers to an excipient that can be used to prepare a pharmaceutical composition which is generally safe and non-toxic and is biologically or otherwise desirable and includes excipients acceptable for veterinary and human pharmaceutical use. "Pharmaceuticalally acceptable excipient" as used in the specification and claims includes one or more such excipients.

[0851] As used herein, the term "therapeutic effective amount" refers to the amount of a drug agent used to treat, improve, or prevent an identified disease or symptom, or to exhibit a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend on the subject's weight, body type, and health status; the nature and severity of the symptom; and the choice of treatment or combination of treatments to be administered. The therapeutic effective amount for a given situation can be determined through routine laboratory testing within the skill and judgment of a clinician.

[0852] It should be understood that all these forms are also contemplated within the scope of the claimed disclosure for compounds of this disclosure that are capable of further forming salts.

[0853] As used herein, the term "pharmaceutically acceptable salt" refers to a derivative of the compounds disclosed herein, wherein the parent compound is modified by preparing an acid or its basic salt. In some embodiments, the pharmaceutically acceptable salt of the compound is also a prodrug of the compound. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, and basic or organic salts of acidic residues such as carboxylic acids. Pharmaceutically acceptable salts include, for example, conventional non-toxic salts or quaternary ammonium salts of parent compounds formed from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include, but are not limited to, non-toxic salts derived from inorganic and organic acids selected from: 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetate, ethanedisulfonic acid, 1,2-ethanesulfonic acid, fumaric acid, glucoheponic acid, gluconic acid, glutamic acid, glycolic acid, glycolamide arsenoic acid, hexylresorcinol acid, and hydrabamic acid. Hydrobromic acid, hydrochloric acid, hydroiodic acid, hydroxymaleic acid, hydroxynaphthyl carboxylic acid, hydroxyethanesulfonic acid, lactic acid, lactobionic acid, lauryl sulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, naphthalenesulfonic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, acetic acid, succinic acid, aminosulfonic acid, p-aminobenzenesulfonic acid, sulfuric acid, tannic acid, tartaric acid, toluenesulfonic acid; and common amino acids. For example Glycine, alanine, phenylalanine, arginine, etc.

[0854] Other examples of pharmaceutically acceptable salts include hexanoic acid, cyclopentanepropionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-en-1-carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, mucoconic acid, etc. This disclosure also covers the situation where acidic protons present in the parent compound are reacted with metal ions (… For example Salts are formed when an alkali metal ion, alkaline earth ion, or aluminum ion is substituted for or coordinated with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, or N-methylglucosamine. In the salt form, it should be understood that the ratio of the compound to the cation or anion of the salt can be 1:1, or any quantitative ratio other than 1:1, such as 3:1, 2:1, 1:2, or 1:3.

[0855] It should be understood that all references to pharmaceutically acceptable salts include the same salt in its solvation form (solvent) or crystalline form (polymorph) as defined herein.

[0856] The compound or a pharmaceutically acceptable salt thereof may be administered orally, nasally, dermally, pulmonaryly, by inhalation, sublingually, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally, and parenterally. In one embodiment, the compound is administered orally. Those skilled in the art will recognize the advantages of certain routes of administration.

[0857] The dosing regimen for a compound is selected based on a number of factors, including the patient's type, species, age, weight, sex, and medical condition; the severity of the condition to be treated; the route of administration; the patient's renal and hepatic function; and the specific compound or its salt used. A generally skilled physician or veterinarian can readily determine and prescribe the effective amount of drug required to prevent, counteract, or halt the progression of the condition.

[0858] Techniques for preparing and applying the disclosed compounds can be found in [the following text is missing from the original] Remington: the Science and Practice of Pharmacy , 19th edition, Mack Publishing Co., Easton, PA (1995). In one embodiment, the compounds described herein and their pharmaceutically acceptable salts are used in combination with pharmaceutically acceptable carriers or diluents in a pharmaceutical formulation. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The compounds will be present in such pharmaceutical compositions in an amount sufficient to provide the desired dose within the range described herein.

[0859] Unless otherwise specified, all percentages and ratios used herein are by weight. Other features and advantages of this disclosure will become apparent from various examples. The examples provided illustrate different components and methods useful in practicing this disclosure. The examples do not limit the scope of the claimed disclosure. Based on this disclosure, those skilled in the art can identify and employ other components and methods that can be used in practicing this disclosure.

[0860] All publications and patent documents cited herein are incorporated herein by reference as if each such publication or document were specifically and individually indicated to be incorporated herein by reference. The citation of publications and patent documents does not constitute an admission of any applicable prior art, nor does it constitute any admission of the content or dates of such publications and patent documents. The invention has now been described in writing, and those skilled in the art will recognize that the invention can be practiced in various embodiments, and that the foregoing description and examples are for illustrative purposes and not for limiting the scope of the following claims.

[0861] Exemplary Implementation Exemplary Implementation Scheme 1. A compound 1: The crystal form of its solvate, its hydrate, or its pharmaceutically acceptable salt.

[0862] Exemplary Implementation 2. The crystal form as described in Exemplary Implementation 1, wherein the crystal form is a crystalline form.

[0863] Exemplary Implementation 3. The crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is form A, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[0864] Exemplary Embodiment 4. The crystal form as described in any of the foregoing exemplary embodiments, wherein form A is characterized by an X-ray powder diffraction (“XRPD”) pattern using Cu Kα radiation containing signals (e.g., peaks) at 13.2±0.2, 22.3±0.2, and 25.3±0.2 °2θ (e.g., 13.2±0.1, 22.3±0.1, and 25.3±0.1 °2θ (e.g., 13.2, 22.3, and 25.3 °2θ)).

[0865] Exemplary Implementation 5. The crystal form as described in any of the foregoing exemplary implementations, wherein the XRPD pattern of Form A further comprises at least one signal (e.g., a peak) selected from 18.5±0.2, 19.4±0.2, and 24.8±0.2 °2θ (e.g., 18.5±0.1, 19.4±0.1, and 24.8±0.1 °2θ (e.g., 18.5, 19.4, and 24.8 °2θ)) using Cu Kα radiation. Optionally, the XRPD plot of form A further includes at least two signals (e.g., peaks) selected from 18.5±0.2, 19.4±0.2 and 24.8±0.2 °2θ (e.g. 18.5±0.1, 19.4±0.1 and 24.8±0.1 °2θ (e.g. 18.5, 19.4 and 24.8 °2θ)) using Cu Kα radiation. Optionally, the XRPD plot of form A further includes a signal (e.g., a peak) at 18.5±0.2, 19.4±0.2, and 24.8±0.2 °2θ (e.g., 18.5±0.1, 19.4±0.1, and 24.8±0.1 °2θ (e.g., 18.5, 19.4, and 24.8 °2θ) using Cu Kα radiation.

[0866] Exemplary Embodiment 6. The crystal form as described in any of the foregoing exemplary embodiments, wherein form A is characterized by an X-ray powder diffraction (“XRPD”) pattern using Cu Kα radiation containing at least three signals (e.g., peaks) selected from 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2 and 25.3±0.2 °2θ (e.g. 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1 and 25.3±0.1 °2θ (e.g. 13.2, 18.5, 19.4, 22.3, 24.8 and 25.3 °2θ)); Optionally, the XRPD plot of form A includes at least four signals (e.g., peaks) selected from 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2 and 25.3±0.2 °2θ (e.g. 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1 and 25.3±0.1 °2θ (e.g. 13.2, 18.5, 19.4, 22.3, 24.8 and 25.3 °2θ) using Cu Kα radiation. Optionally, the XRPD plot of form A includes at least five signals (e.g., peaks) selected from 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2 and 25.3±0.2 °2θ (e.g. 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1 and 25.3±0.1 °2θ (e.g. 13.2, 18.5, 19.4, 22.3, 24.8 and 25.3 °2θ) using Cu Kα radiation. Optionally, the XRPD plot of form A includes a signal (e.g., a peak) at 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2 and 25.3±0.2 °2θ (e.g. 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1 and 25.3±0.1 °2θ (e.g. 13.2, 18.5, 19.4, 22.3, 24.8 and 25.3 °2θ) using Cu Kα radiation.

[0867] Exemplary Embodiment 7. The crystal form as described in any of the foregoing exemplary embodiments, wherein form A is characterized by being substantially similar to Figure 1 The XRPD spectrum shown is the XRPD spectrum.

[0868] Exemplary Implementation 8. The crystal form as described in any of the foregoing exemplary implementations, wherein form A is characterized by an XRPD plot containing signals (e.g., peaks) at approximately the locations shown in Table 1 below.

[0869] Exemplary Embodiment 9. The crystal form as described in any of the foregoing exemplary embodiments, wherein form A is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 208 ± 20 °C (e.g., 208 ± 10 °C (e.g., 208 ± 5 °C (e.g., 208 ± 4 °C (e.g., 208 ± 3 °C (e.g., 208 ± 2 °C (e.g., 208 ± 1 °C (e.g., 208 ± 0.5 °C)))))))); Optionally, form A is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 208 °C.

[0870] Exemplary Embodiment 10. The crystal form as described in any of the foregoing exemplary embodiments, wherein form A is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 93 ± 9 J / g (e.g., 93 ± 8 J / g (e.g., 93 ± 7 J / g (e.g., 93 ± 6 J / g (e.g., 93 ± 5 J / g (e.g., 93 ± 4 J / g (e.g., 93 ± 3 J / g (e.g., 93 ± 2 J / g)))))))); Optionally, form A is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 93 J / g; Alternatively, form A is characterized by being substantially similar to Figure 2 The DSC spectrum shown is the DSC spectrum.

[0871] Exemplary Embodiment 11. The crystal form as described in any of the foregoing exemplary embodiments, wherein form A exhibits a weight loss of about 0.05% to about 0.5%, as measured by TGA, in a temperature range of about 35 ± 20 °C (e.g., 35 ± 10 °C (e.g., 35 ± 5 °C (e.g., 35 ± 4 °C (e.g., 35 ± 3 °C (e.g., 35 ± 2 °C (e.g., 35 ± 1 °C (e.g., 35 ± 0.5 °C) ... Optionally, form A exhibits a weight loss of about 0.28% at temperatures ranging from about 35°C to about 200°C, as measured by TGA. Alternatively, form A is characterized by being substantially similar to Figure 3 The TGA spectrum shown is the TGA spectrum.

[0872] Exemplary Implementation 12. A crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is form B, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[0873] Exemplary Embodiment 13. The crystal form as described in any of the foregoing exemplary embodiments, wherein form B is characterized by being substantially similar to Figure 82 The XRPD spectrum shown is the XRPD spectrum.

[0874] Exemplary Embodiment 14. The crystal form as described in any of the foregoing exemplary embodiments, wherein form B is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 208 ± 20 °C (e.g., 208 ± 10 °C (e.g., 208 ± 5 °C (e.g., 208 ± 4 °C (e.g., 208 ± 3 °C (e.g., 208 ± 2 °C (e.g., 208 ± 1 °C (e.g., 208 ± 0.5 °C)))))))); Optionally, form B is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 208 °C.

[0875] Exemplary Embodiment 15. The crystal form as described in any of the foregoing exemplary embodiments, wherein form B is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 86 ± 9 J / g (e.g., 86 ± 8 J / g (e.g., 86 ± 7 J / g (e.g., 86 ± 6 J / g (e.g., 86 ± 5 J / g (e.g., 86 ± 4 J / g (e.g., 86 ± 3 J / g (e.g., 86 ± 2 J / g)))))))); Optionally, form B is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 86 J / g; Alternatively, form B is characterized by being substantially similar to Figure 83 The DSC spectrum shown is the DSC spectrum.

[0876] Exemplary Embodiment 16. The crystal form as described in any of the foregoing exemplary embodiments, wherein form B exhibits a weight loss of about 0.5% to about 4.0% as measured by TGA in a temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ... Optionally, form B exhibits a weight loss of about 2.3% at temperatures ranging from about 34°C to about 180°C, as measured by TGA. Alternatively, form B is characterized by being substantially similar to Figure 84 The TGA spectrum shown is the TGA spectrum.

[0877] Exemplary Implementation 17. A crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is form C, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[0878] Exemplary Embodiment 18. The crystal form as described in any of the foregoing exemplary embodiments, wherein the crystal form is the hydrochloride salt of compound 1, its solvate, or its hydrate, in the form C.

[0879] Exemplary Implementation 19. The crystal form as described in any of the foregoing exemplary implementations, wherein the crystal form is the form C of the hydrochloride salt of compound 1.

[0880] Exemplary Embodiment 20. The crystal form as described in any of the foregoing exemplary embodiments, wherein the hydrochloride comprises compound 1 and hydrochloric acid present in a ratio of about 1:1.

[0881] Exemplary Embodiment 21. The crystal form as described in any of the foregoing exemplary embodiments, wherein the hydrochloride comprises compound 1 and hydrochloric acid present in a ratio of about 1:2.

[0882] Exemplary Embodiment 22. The crystal form as described in any of the foregoing exemplary embodiments, wherein the hydrochloride comprises compound 1 and hydrochloric acid present in a ratio of about 2:1.

[0883] Exemplary Implementation 23. The crystal form as described in any of the foregoing exemplary implementations, wherein form C is characterized by being substantially similar to Figure 25The XRPD spectrum shown is the XRPD spectrum.

[0884] Exemplary Implementation 24. The crystal form as described in any of the foregoing exemplary implementations, wherein form C is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 56.6 ± 20 °C (e.g., 56.6 ± 10 °C (e.g., 56.6 ± 5 °C (e.g., 56.6 ± 4 °C (e.g., 56.6 ± 3 °C (e.g., 56.6 ± 2 °C (e.g., 56.6 ± 1 °C (e.g., 56.6 ± 0.5 °C)))))))); Optionally, form C is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 56.6 °C.

[0885] Exemplary Embodiment 25. The crystal form as described in any of the foregoing exemplary embodiments, wherein form C is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 188 ± 20 °C (e.g., 188 ± 10 °C (e.g., 188 ± 5 °C (e.g., 188 ± 4 °C (e.g., 188 ± 3 °C (e.g., 188 ± 2 °C (e.g., 188 ± 1 °C (e.g., 188 ± 0.5 °C)))))))); Optionally, form C is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 188 °C.

[0886] Exemplary Implementation 26. The crystal form as described in any of the foregoing exemplary implementations, wherein form C is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 4.09 ± 0.4 J / g (e.g., 4.09 ± 0.3 J / g (e.g., 4.09 ± 0.2 J / g (e.g., 4.09 ± 0.1 J / g (e.g., 4.09 ± 0.08 J / g (e.g., 4.09 ± 0.06 J / g (e.g., 4.09 ± 0.04 J / g (e.g., 4.09 ± 0.02 J / g)). Optionally, form C is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 4.09 J / g.

[0887] Exemplary Embodiment 27. The crystal form as described in any of the foregoing exemplary embodiments, wherein form C is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 111 ± 12 J / g (e.g., 111 ± 10 J / g (e.g., 111 ± 8 J / g (e.g., 111 ± 6 J / g (e.g., 111 ± 4 J / g (e.g., 111 ± 3 J / g (e.g., 111 ± 2 J / g (e.g., 111 ± 1 J / g)))))))); Optionally, form C is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 111 J / g; Alternatively, the form C is characterized by being substantially similar to Figure 26 The DSC spectrum shown is the DSC spectrum.

[0888] Exemplary Embodiment 28. The crystal form as described in any of the foregoing exemplary embodiments, wherein form C exhibits a weight loss of about 0.05% to about 2.5% as measured by TGA in a temperature range of about 33 ± 20 °C (e.g., 33 ± 10 °C (e.g., 33 ± 5 °C (e.g., 33 ± 4 °C (e.g., 33 ± 3 °C (e.g., 33 ± 2 °C (e.g., 33 ± 1 °C (e.g., 33 ± 0.5 °C) ... Optionally, form C exhibits a weight loss of about 0.9% at temperatures ranging from about 33°C to about 100°C, as measured by TGA.

[0889] Exemplary Embodiment 29. The crystal form as described in any of the foregoing exemplary embodiments, wherein form C exhibits a weight loss of about 1% to about 7% as measured by TGA in a temperature range of about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C) ... Optionally, form C exhibits a weight loss of about 4.4% at temperatures ranging from about 100°C to about 200°C, as measured by TGA. Alternatively, the form C is characterized by being substantially similar to Figure 27 The TGA spectrum shown is the TGA spectrum.

[0890] Exemplary Implementation 30. A crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is form D, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[0891] Exemplary Implementation 31. The crystal form as described in any of the foregoing exemplary implementations, wherein the crystal form is the hydrochloride salt of compound 1, its solvate, or its hydrate in form D.

[0892] Exemplary Implementation 32. The crystal form as described in any of the foregoing exemplary implementations, wherein the crystal form is in the form D of the hydrochloride salt of compound 1.

[0893] Exemplary Embodiment 33. The crystal form as described in any of the foregoing exemplary embodiments, wherein the hydrochloride comprises compound 1 and hydrochloric acid present in a ratio of about 1:1.

[0894] Exemplary Implementation 34. The crystal form as described in any of the foregoing exemplary implementations, wherein the hydrochloride comprises compound 1 and hydrochloric acid present in a ratio of about 1:2.

[0895] Exemplary Implementation 35. The crystal form as described in any of the foregoing exemplary implementations, wherein the hydrochloride comprises compound 1 and hydrochloric acid present in a ratio of about 1:3.

[0896] Exemplary Implementation 36. The crystal form as described in any of the foregoing exemplary implementations, wherein the hydrochloride comprises compound 1 and hydrochloric acid present in a ratio of about 2:1.

[0897] Exemplary Embodiment 37. The crystal form as described in any of the foregoing exemplary embodiments, wherein form D is characterized by an X-ray powder diffraction (“XRPD”) pattern using Cu Kα radiation containing signals (e.g., peaks) at 7.7±0.2, 21.2±0.2, and 26.3±0.2 °2θ (e.g., 7.7±0.1, 21.2±0.1, and 26.3±0.1 °2θ (e.g., 7.7, 21.2, and 26.3 °2θ)); Optionally, the XRPD plot of form D further includes at least one signal (e.g., a peak) selected from 27.8±0.2, 28.7±0.2 and 30.2±0.2 °2θ (e.g. 27.8±0.1, 28.7±0.1 and 30.2±0.1 °2θ (e.g. 27.8, 28.7 and 30.2 °2θ)) using Cu Kα radiation. Optionally, the XRPD plot of form D further includes at least two signals (e.g., peaks) selected from 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2θ (e.g., 27.8±0.1, 28.7±0.1, and 30.2±0.1 °2θ (e.g., 27.8, 28.7, and 30.2 °2θ)) using Cu Kα radiation. Optionally, the XRPD plot of form D further includes a signal (e.g., a peak) at 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2θ (e.g., 27.8±0.1, 28.7±0.1, and 30.2±0.1 °2θ (e.g., 27.8, 28.7, and 30.2 °2θ) using Cu Kα radiation.

[0898] Exemplary Embodiment 38. The crystal form as described in any of the foregoing exemplary embodiments, wherein form D is characterized by an X-ray powder diffraction (“XRPD”) pattern using Cu Kα radiation containing at least three signals (e.g., peaks) selected from 7.7±0.2, 21.2±0.2, 26.3±0.2, 27.8±0.2, 28.7±0.2 and 30.2±0.2 °2θ (e.g. 7.7±0.1, 21.2±0.1, 26.3±0.1, 27.8±0.1, 28.7±0.1 and 30.2±0.1 °2θ (e.g. 7.7, 21.2, 26.3, 27.8, 28.7 and 30.2 °2θ)); Optionally, the XRPD plot of form D includes at least four signals (e.g., peaks) selected from 7.7±0.2, 21.2±0.2, 26.3±0.2, 27.8±0.2, 28.7±0.2 and 30.2±0.2 °2θ (e.g. 7.7±0.1, 21.2±0.1, 26.3±0.1, 27.8±0.1, 28.7±0.1 and 30.2±0.1 °2θ (e.g. 7.7, 21.2, 26.3, 27.8, 28.7 and 30.2 °2θ)) using Cu Kα radiation. Optionally, the XRPD plot of form D includes at least five signals (e.g., peaks) selected from 7.7±0.2, 21.2±0.2, 26.3±0.2, 27.8±0.2, 28.7±0.2 and 30.2±0.2 °2θ (e.g. 7.7±0.1, 21.2±0.1, 26.3±0.1, 27.8±0.1, 28.7±0.1 and 30.2±0.1 °2θ (e.g. 7.7, 21.2, 26.3, 27.8, 28.7 and 30.2 °2θ)) using Cu Kα radiation. Optionally, the XRPD plot of form D includes a signal (e.g., a peak) at 7.7±0.2, 21.2±0.2, 26.3±0.2, 27.8±0.2, 28.7±0.2 and 30.2±0.2 °2θ (e.g. 7.7±0.1, 21.2±0.1, 26.3±0.1, 27.8±0.1, 28.7±0.1 and 30.2±0.1 °2θ (e.g. 7.7, 21.2, 26.3, 27.8, 28.7 and 30.2 °2θ) using Cu Kα radiation.

[0899] Exemplary Embodiment 39. The crystal form as described in any of the foregoing exemplary embodiments, wherein form D is characterized by being substantially similar to Figure 6 or Figure 29 The XRPD diagram shown is an XRPD diagram.

[0900] Exemplary Implementation 40. The crystal form as described in any of the foregoing exemplary implementations, wherein form D is characterized by an XRPD plot containing signals (e.g., peaks) at approximately the locations shown in Table 2 below.

[0901] Exemplary Implementation 41. The crystal form as described in any of the foregoing exemplary implementations, wherein form D is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 61.5 ± 20 °C (e.g., 61.5 ± 10 °C (e.g., 61.5 ± 5 °C (e.g., 61.5 ± 4 °C (e.g., 61.5 ± 3 °C (e.g., 61.5 ± 2 °C (e.g., 61.5 ± 1 °C (e.g., 61.5 ± 0.5 °C)))))))); Optionally, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 61.5 °C.

[0902] Exemplary Embodiment 42. The crystal form as described in any of the foregoing exemplary embodiments, wherein form D is characterized by having a DSC curve with an endothermic signal (e.g., a peak) at 141 ± 20 °C (e.g., 141 ± 10 °C (e.g., 141 ± 5 °C (e.g., 141 ± 4 °C (e.g., 141 ± 3 °C (e.g., 141 ± 2 °C (e.g., 141 ± 1 °C (e.g., 141 ± 0.5 °C))))))); Optionally, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 141 °C.

[0903] Exemplary Embodiment 43. The crystal form as described in any of the foregoing exemplary embodiments, wherein form D is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 67 ± 20 °C (e.g., 67 ± 10 °C (e.g., 67 ± 5 °C (e.g., 67 ± 4 °C (e.g., 67 ± 3 °C (e.g., 67 ± 2 °C (e.g., 67 ± 1 °C (e.g., 67 ± 0.5 °C)))))))); Optionally, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 67 °C.

[0904] Exemplary Embodiment 44. The crystal form as described in any of the foregoing exemplary embodiments, wherein form D is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 145 ± 20 °C (e.g., 145 ± 10 °C (e.g., 145 ± 5 °C (e.g., 145 ± 4 °C (e.g., 145 ± 3 °C (e.g., 145 ± 2 °C (e.g., 145 ± 1 °C (e.g., 145 ± 0.5 °C)))))))); Optionally, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 145 °C.

[0905] Exemplary Embodiment 45. The crystal form as described in any of the foregoing exemplary embodiments, wherein form D is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 8.48 ± 0.8 J / g (e.g., 8.48 ± 0.7 J / g (e.g., 8.48 ± 0.6 J / g (e.g., 8.48 ± 0.5 J / g (e.g., 8.48 ± 0.4 J / g (e.g., 8.48 ± 0.3 J / g (e.g., 8.48 ± 0.2 J / g (e.g., 8.48 ± 0.1 J / g)). Optionally, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 8.48 J / g.

[0906] Exemplary Embodiment 46. The crystal form as described in any of the foregoing exemplary embodiments, wherein form D is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 354 ± 35 J / g (e.g., 354 ± 30 J / g (e.g., 354 ± 25 J / g (e.g., 354 ± 20 J / g (e.g., 354 ± 15 J / g (e.g., 354 ± 10 J / g (e.g., 354 ± 5 ​​J / g (e.g., 354 ± 3 J / g)))))))); Optionally, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 354 J / g.

[0907] Exemplary Embodiment 47. The crystal form as described in any of the foregoing exemplary embodiments, wherein form D is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 16.2 ± 2 J / g (e.g., 16.2 ± 1.5 J / g (e.g., 16.2 ± 1 J / g (e.g., 16.2 ± 0.8 J / g (e.g., 16.2 ± 0.6 J / g (e.g., 16.2 ± 0.4 J / g (e.g., 16.2 ± 0.2 J / g (e.g., 16.2 ± 0.1 J / g))))))) Optionally, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 16.2 J / g.

[0908] Exemplary Embodiment 48. The crystal form as described in any of the foregoing exemplary embodiments, wherein form D is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 255 ± 25 J / g (e.g., 255 ± 20 J / g (e.g., 255 ± 15 J / g (e.g., 255 ± 10 J / g (e.g., 255 ± 5 J / g (e.g., 255 ± 4 J / g (e.g., 255 ± 2 J / g (e.g., 255 ± 1 J / g)))))))); Optionally, form D is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 255 J / g; Alternatively, the form D is characterized by being substantially similar to Figure 7 or Figure 30 The DSC spectrum shown is the DSC spectrum.

[0909] Exemplary Embodiment 49. The crystal form as described in any of the foregoing exemplary embodiments, wherein form D exhibits a weight loss of about 0.1% to about 5% as measured by TGA in a temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ... Optionally, form D exhibits a weight loss of about 1.8% at temperatures ranging from about 34°C to about 90°C, as measured by TGA.

[0910] Exemplary Embodiment 50. The crystal form as described in any of the foregoing exemplary embodiments, wherein form D exhibits a weight loss of about 10% to about 25% in the temperature range of about 90 ± 20 °C (e.g., 90 ± 10 °C (e.g., 90 ± 5 °C (e.g., 90 ± 4 °C (e.g., 90 ± 3 °C (e.g., 90 ± 2 °C (e.g., 90 ± 1 °C (e.g., 90 ± 0.5 °C)))))))) from about 90 ± 20 °C (e.g., 170 ± 10 °C (e.g., 170 ± 5 °C (e.g., 170 ± 4 °C (e.g., 170 ± 3 °C (e.g., 170 ± 2 °C (e.g., 170 ± 1 °C (e.g., 170 ± 0.5 °C)))))))), as measured by TGA; Optionally, form D exhibits a weight loss of about 17% at temperatures ranging from about 90°C to about 170°C, as measured by TGA.

[0911] Exemplary Embodiment 51. The crystal form as described in any of the foregoing exemplary embodiments, wherein form D exhibits a weight loss of about 0.1% to about 5% as measured by TGA in a temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ... Optionally, form D exhibits a weight loss of about 2.6% at temperatures ranging from about 34°C to about 100°C, as measured by TGA.

[0912] Exemplary Embodiment 52. The crystal form as described in any of the foregoing exemplary embodiments, wherein form D exhibits a weight loss of about 8% to about 25% in the temperature range of about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))) from about 100 ± 20 °C (e.g., 200 ± 10 °C (e.g., 200 ± 5 °C (e.g., 200 ± 4 °C (e.g., 200 ± 3 °C (e.g., 200 ± 2 °C (e.g., 200 ± 1 °C (e.g., 200 ± 0.5 °C))))))) as measured by TGA; Optionally, form D exhibits a weight loss of about 15% at temperatures ranging from about 100°C to about 200°C, as measured by TGA. Alternatively, the form D is characterized by being substantially similar to Figure 8 or Figure 31 The TGA spectrum shown is the TGA spectrum.

[0913] Exemplary Implementation 53. A crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is form E, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[0914] Exemplary Embodiment 54. The crystal form as described in any of the foregoing exemplary embodiments, wherein the crystal form is the sulfate form E of compound 1.

[0915] Exemplary Embodiment 55. The crystal form as described in any of the foregoing exemplary embodiments, wherein the sulfate comprises compound 1 and sulfuric acid present in a ratio of about 1:1.

[0916] Exemplary Embodiment 56. The crystal form as described in any of the foregoing exemplary embodiments, wherein the sulfate comprises compound 1 and sulfuric acid present in a ratio of about 1:2.

[0917] Exemplary Embodiment 57. The crystal form as described in any of the foregoing exemplary embodiments, wherein the sulfate comprises compound 1 and sulfuric acid present in a ratio of about 2:1.

[0918] Exemplary Embodiment 58. The crystal form as described in any of the foregoing exemplary embodiments, wherein form E is characterized by being substantially similar to Figure 33 The XRPD spectrum shown is the XRPD spectrum.

[0919] Exemplary Embodiment 59. The crystal form as described in any of the foregoing exemplary embodiments, wherein form E is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 65.9 ± 20 °C (e.g., 65.9 ± 10 °C (e.g., 65.9 ± 5 °C (e.g., 65.9 ± 4 °C (e.g., 65.9 ± 3 °C (e.g., 65.9 ± 2 °C (e.g., 65.9 ± 1 °C (e.g., 65.9 ± 0.5 °C)))))))); Optionally, form E is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 65.9 °C.

[0920] Exemplary Embodiment 60. The crystal form as described in any of the foregoing exemplary embodiments, wherein form E is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 200 ± 20 °C (e.g., 200 ± 10 °C (e.g., 200 ± 5 °C (e.g., 200 ± 4 °C (e.g., 200 ± 3 °C (e.g., 200 ± 2 °C (e.g., 200 ± 1 °C (e.g., 200 ± 0.5 °C)))))))); Optionally, form E is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 200 °C.

[0921] Exemplary Embodiment 61. The crystal form as described in any of the foregoing exemplary embodiments, wherein form E is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 19.3 ± 2.0 J / g (e.g., 19.3 ± 1.5 J / g (e.g., 19.3 ± 1.0 J / g (e.g., 19.3 ± 0.8 J / g (e.g., 19.3 ± 0.6 J / g (e.g., 19.3 ± 0.4 J / g (e.g., 19.3 ± 0.2 J / g (e.g., 19.3 ± 0.1 J / g)). Optionally, form E is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 19.3 J / g.

[0922] Exemplary Implementation 62. The crystal form as described in any of the foregoing exemplary implementations, wherein form E is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 64.3 ± 6.5 J / g (e.g., 64.3 ± 4.0 J / g (e.g., 64.3 ± 2.0 J / g (e.g., 64.3 ± 1.0 J / g (e.g., 64.3 ± 0.8 J / g (e.g., 64.3 ± 0.6 J / g (e.g., 64.3 ± 0.4 J / g (e.g., 64.3 ± 0.2 J / g)). Optionally, form E is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 64.3 J / g; Alternatively, the form E is characterized by being substantially similar to Figure 34 The DSC spectrum shown is the DSC spectrum.

[0923] Exemplary Embodiment 63. The crystal form as described in any of the foregoing exemplary embodiments, wherein form E exhibits a weight loss of about 0.05% to about 4.5% as measured by TGA in a temperature range of about 33 ± 20 °C (e.g., 33 ± 10 °C (e.g., 33 ± 5 °C (e.g., 33 ± 4 °C (e.g., 33 ± 3 °C (e.g., 33 ± 2 °C (e.g., 33 ± 1 °C (e.g., 33 ± 0.5 °C) ... Optionally, form E exhibits a weight loss of about 1.3% at temperatures ranging from about 33°C to about 100°C, as measured by TGA. Alternatively, the form E is characterized by being substantially similar to Figure 35 The TGA spectrum shown is the TGA spectrum.

[0924] Exemplary Implementation 64. A crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is form F, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[0925] Exemplary Implementation 65. The crystal form as described in any of the foregoing exemplary implementations, wherein the crystal form is in the form F of a phosphate of compound 1.

[0926] Exemplary Implementation 66. The crystal form as described in any of the foregoing exemplary implementations, wherein the phosphate comprises compound 1 and phosphoric acid present in a ratio of about 1:1.

[0927] Exemplary Implementation 67. The crystal form as described in any of the foregoing exemplary implementations, wherein the phosphate comprises compound 1 and phosphoric acid present in a ratio of about 1:2.

[0928] Exemplary Implementation 68. The crystal form as described in any of the foregoing exemplary implementations, wherein the phosphate comprises compound 1 and phosphoric acid present in a ratio of about 2:1.

[0929] Exemplary Implementation 69. The crystal form as described in any of the foregoing exemplary implementations, wherein form F is characterized by being substantially similar to Figure 37 The XRPD spectrum shown is the XRPD spectrum.

[0930] Exemplary Embodiment 70. The crystal form as described in any of the foregoing exemplary embodiments, wherein form F is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 72.2 ± 20 °C (e.g., 72.2 ± 10 °C (e.g., 72.2 ± 5 °C (e.g., 72.2 ± 4 °C (e.g., 72.2 ± 3 °C (e.g., 72.2 ± 2 °C (e.g., 72.2 ± 1 °C (e.g., 72.2 ± 0.5 °C)))))))); Optionally, form F is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 72.2 °C.

[0931] Exemplary Embodiment 71. The crystal form as described in any of the foregoing exemplary embodiments, wherein form F is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 159 ± 20 °C (e.g., 159 ± 10 °C (e.g., 159 ± 5 °C (e.g., 159 ± 4 °C (e.g., 159 ± 3 °C (e.g., 159 ± 2 °C (e.g., 159 ± 1 °C (e.g., 159 ± 0.5 °C)))))))); Optionally, form F is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 159 °C.

[0932] Exemplary Implementation 72. The crystal form as described in any of the foregoing exemplary implementations, wherein form F is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 64.4 ± 6.5 J / g (e.g., 64.4 ± 5.0 J / g (e.g., 64.4 ± 4.0 J / g (e.g., 64.4 ± 3.0 J / g (e.g., 64.4 ± 2.0 J / g (e.g., 64.4 ± 1.0 J / g (e.g., 64.4 ± 0.8 J / g (e.g., 64.4 ± 0.5 J / g)). Optionally, form F is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 64.4 J / g.

[0933] Exemplary Implementation 73. The crystal form as described in any of the foregoing exemplary implementations, wherein form F is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 33.6 ± 3.5 J / g (e.g., 33.6 ± 3.0 J / g (e.g., 33.6 ± 2.5 J / g (e.g., 33.6 ± 2.0 J / g (e.g., 33.6 ± 1.5 J / g (e.g., 33.6 ± 1.0 J / g (e.g., 33.6 ± 0.5 J / g (e.g., 33.6 ± 0.3 J / g)). Optionally, form F is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 33.6 J / g; Alternatively, the form F is characterized by being substantially similar to Figure 38 The DSC spectrum shown is the DSC spectrum.

[0934] Exemplary Embodiment 74. The crystal form as described in any of the foregoing exemplary embodiments, wherein form F exhibits a weight loss of about 0.5% to about 7.5% in the temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C)))))))) from about 34 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C)))))))) as measured by TGA; Optionally, form F exhibits a weight loss of about 3.6% at temperatures ranging from about 34°C to about 100°C, as measured by TGA. Alternatively, the form F is characterized by being substantially similar to Figure 39 The TGA spectrum shown is the TGA spectrum.

[0935] Exemplary Implementation 75. A crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is form G, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[0936] Exemplary Implementation 76. The crystal form as described in any of the foregoing exemplary implementations, wherein the crystal form is in the form G of compound 1, its salt, its solvate or its hydrate.

[0937] Exemplary Implementation 77. The crystal form as described in any of the foregoing exemplary implementations, wherein the crystal form is a salt of compound 1, its solvate, or its hydrate in the form of G.

[0938] Exemplary Implementation 78. The crystal form as described in any of the foregoing exemplary implementations, wherein the crystal form is in the form G of a phosphate, solvate, or hydrate of compound 1.

[0939] Exemplary Implementation 79. The crystal form as described in any of the foregoing exemplary implementations, wherein the crystal form is in the form G of the phosphate of compound 1.

[0940] Exemplary Implementation 80. The crystal form as described in any of the foregoing exemplary implementations, wherein the phosphate comprises compound 1 and phosphoric acid present in a ratio of about 1:1.

[0941] Exemplary Embodiment 81. The crystal form as described in any of the foregoing exemplary embodiments, wherein the phosphate comprises compound 1 and phosphoric acid present in a ratio of about 1:2.

[0942] Exemplary Embodiment 82. The crystal form as described in any of the foregoing exemplary embodiments, wherein the phosphate comprises compound 1 and phosphoric acid present in a ratio of about 2:1.

[0943] Exemplary Implementation 83. The crystal form as described in any of the foregoing exemplary implementations, wherein form G is characterized by being substantially similar to Figure 41 The XRPD spectrum shown is the XRPD spectrum.

[0944] Exemplary Embodiment 84. The crystal form as described in any of the foregoing exemplary embodiments, wherein form G is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 75.1 ± 20 °C (e.g., 75.1 ± 10 °C (e.g., 75.1 ± 5 °C (e.g., 75.1 ± 4 °C (e.g., 75.1 ± 3 °C (e.g., 75.1 ± 2 °C (e.g., 75.1 ± 1 °C (e.g., 75.1 ± 0.5 °C)))))))); Optionally, form G is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 75.1 °C.

[0945] Exemplary Embodiment 85. The crystal form as described in any of the foregoing exemplary embodiments, wherein form G is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 58.4 ± 6.0 J / g (e.g., 58.4 ± 5.0 J / g (e.g., 58.4 ± 4.0 J / g (e.g., 58.4 ± 3.0 J / g (e.g., 58.4 ± 2.0 J / g (e.g., 58.4 ± 1.5 J / g (e.g., 58.4 ± 1.0 J / g (e.g., 58.4 ± 0.5 J / g)). Optionally, form G is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 58.4 J / g; Alternatively, the form G is characterized by being substantially similar to Figure 42 The DSC spectrum shown is the DSC spectrum.

[0946] Exemplary Embodiment 86. The crystal form as described in any of the foregoing exemplary embodiments, wherein form G exhibits a weight loss of about 2.0% to about 7.5% as measured by TGA in a temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ... Optionally, form G exhibits a weight loss of about 4.1% at temperatures ranging from about 34°C to about 100°C, as measured by TGA. Alternatively, the form G is characterized by being substantially similar to Figure 43 The TGA spectrum shown is the TGA spectrum.

[0947] Exemplary Implementation 87. A crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is form H, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[0948] Exemplary Embodiment 88. The crystal form as described in any of the foregoing exemplary embodiments, wherein the crystal form is the methanesulfonate form H of Compound 1.

[0949] Exemplary Embodiment 89. The crystal form as described in any of the foregoing exemplary embodiments, wherein the methanesulfonate comprises compound 1 and methanesulfonic acid present in a ratio of about 1:1.

[0950] Exemplary Embodiment 90. The crystal form as described in any of the foregoing exemplary embodiments, wherein the methanesulfonate comprises compound 1 and methanesulfonic acid present in a ratio of about 1:2.

[0951] Exemplary Embodiment 91. The crystal form as described in any of the foregoing exemplary embodiments, wherein the methanesulfonate comprises compound 1 and methanesulfonic acid present in a ratio of about 2:1.

[0952] Exemplary Embodiment 92. The crystal form as described in any of the foregoing exemplary embodiments, wherein form H is characterized by being substantially similar to Figure 45 The XRPD spectrum shown is the XRPD spectrum.

[0953] Exemplary Embodiment 93. The crystal form as described in any of the foregoing exemplary embodiments, wherein form H is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 72.4 ± 20 °C (e.g., 72.4 ± 10 °C (e.g., 72.4 ± 5 ​​°C (e.g., 72.4 ± 4 °C (e.g., 72.4 ± 3 °C (e.g., 72.4 ± 2 °C (e.g., 72.4 ± 1 °C (e.g., 72.4 ± 0.5 °C)))))))); Optionally, form H is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 72.4 °C.

[0954] Exemplary Embodiment 94. The crystal form as described in any of the foregoing exemplary embodiments, wherein form H is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 163 ± 20 °C (e.g., 163 ± 10 °C (e.g., 163 ± 5 °C (e.g., 163 ± 4 °C (e.g., 163 ± 3 °C (e.g., 163 ± 2 °C (e.g., 163 ± 1 °C (e.g., 163 ± 0.5 °C))))))); Optionally, form H is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 163 °C.

[0955] Exemplary Implementation 95. The crystal form as described in any of the foregoing exemplary implementations, wherein form H is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 49.3 ± 5.0 J / g (e.g., 49.3 ± 4.5 J / g (e.g., 49.3 ± 4.0 J / g (e.g., 49.3 ± 3.5 J / g (e.g., 49.3 ± 3.0 J / g (e.g., 49.3 ± 2.5 J / g (e.g., 49.3 ± 2.0 J / g (e.g., 49.3 ± 1.0 J / g)). Optionally, form H is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 49.3 J / g.

[0956] Exemplary Implementation 96. The crystal form as described in any of the foregoing exemplary embodiments, wherein form H is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 59.1 ± 6.0 J / g (e.g., 59.1 ± 4.0 J / g (e.g., 59.1 ± 3.0 J / g (e.g., 59.1 ± 2.0 J / g (e.g., 59.1 ± 1.5 J / g (e.g., 59.1 ± 1.0 J / g (e.g., 59.1 ± 0.5 J / g (e.g., 59.1 ± 0.3 J / g)). Optionally, form H is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 59.1 J / g; Alternatively, the form H is characterized by being substantially similar to Figure 46 The DSC spectrum shown is the DSC spectrum.

[0957] Exemplary Embodiment 97. The crystal form as described in any of the foregoing exemplary embodiments, wherein form H exhibits a weight loss of about 0.1% to about 5% as measured by TGA in a temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ... Optionally, form H exhibits a weight loss of about 2.4% at temperatures ranging from about 34°C to about 100°C, as measured by TGA. Alternatively, the form H is characterized by being substantially similar to Figure 47 The TGA spectrum shown is the TGA spectrum.

[0958] Exemplary Implementation 98. A crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is Form I, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[0959] Exemplary Implementation 99. The crystal form as described in any of the foregoing exemplary implementations, wherein the crystal form is form I of compound 1, its salt, its solvate or its hydrate.

[0960] Exemplary Implementation 100. The crystal form as described in any of the foregoing exemplary implementations, wherein the crystal form is a salt of compound 1, its solvate, or its hydrate in form I.

[0961] Exemplary Implementation 101. The crystal form as described in any of the foregoing exemplary implementations, wherein the crystal form is a benzenesulfonate of compound 1, its solvate, or its hydrate in form I.

[0962] Exemplary Implementation 102. The crystal form as described in any of the foregoing exemplary implementations, wherein the crystal form is form I of the benzenesulfonate of compound 1.

[0963] Exemplary Embodiment 103. The crystal form as described in any of the foregoing exemplary embodiments, wherein the benzenesulfonate comprises compound 1 and benzenesulfonic acid present in a ratio of about 1:1.

[0964] Exemplary Embodiment 104. The crystal form as described in any of the foregoing exemplary embodiments, wherein the benzenesulfonate comprises compound 1 and benzenesulfonic acid present in a ratio of about 1:2.

[0965] Exemplary Embodiment 105. The crystal form as described in any of the foregoing exemplary embodiments, wherein the benzenesulfonate comprises compound 1 and benzenesulfonic acid present in a ratio of about 2:1.

[0966] Exemplary Implementation 106. The crystal form as described in any of the foregoing exemplary implementations, wherein Form I is characterized by an X-ray powder diffraction (“XRPD”) pattern using Cu Kα radiation containing signals (e.g., peaks) at 12.4±0.2, 16.6±0.2, and 23.4±0.2 °2θ (e.g., 12.4±0.1, 16.6±0.1, and 23.4±0.1 °2θ (e.g., 12.4, 16.6, and 23.4 °2θ)); Optionally, the XRPD plot of form I further includes at least one signal (e.g., a peak) selected from 19.3±0.2, 26.3±0.2 and 27.2±0.2 °2θ (e.g. 19.3±0.1, 26.3±0.1 and 27.2±0.1 °2θ (e.g. 19.3, 26.3 and 27.2 °2θ)) using Cu Kα radiation. Optionally, the XRPD plot of form I further includes at least two signals (e.g., peaks) selected from 19.3±0.2, 26.3±0.2 and 27.2±0.2 °2θ (e.g. 19.3±0.1, 26.3±0.1 and 27.2±0.1 °2θ (e.g. 19.3, 26.3 and 27.2 °2θ)) using Cu Kα radiation. Optionally, the XRPD plot of form I further includes a signal (e.g., a peak) at 19.3±0.2, 26.3±0.2, and 27.2±0.2 °2θ (e.g., 19.3±0.1, 26.3±0.1, and 27.2±0.1 °2θ (e.g., 19.3, 26.3, and 27.2 °2θ)) using Cu Kα radiation.

[0967] Exemplary Embodiment 107. A crystal form as described in any of the foregoing exemplary embodiments, wherein Form I is characterized by using Cu Kα radiation to generate an X-ray powder diffraction (“XRPD”) pattern containing at least three signals (e.g., peaks) selected from 12.4±0.2, 16.6±0.2, 19.3±0.2, 23.4±0.2, 26.3±0.2 and 27.2±0.2 °2θ (e.g. 12.4±0.1, 16.6±0.1, 19.3±0.1, 23.4±0.1, 26.3±0.1 and 27.2±0.1 °2θ (e.g. 6.7, 12.1, 15.1, 17.5, 24.2 and 24.6 °2θ)); Optionally, the XRPD plot of Form I includes at least four signals (e.g., peaks) selected from 12.4±0.2, 16.6±0.2, 19.3±0.2, 23.4±0.2, 26.3±0.2 and 27.2±0.2 °2θ (e.g. 12.4±0.1, 16.6±0.1, 19.3±0.1, 23.4±0.1, 26.3±0.1 and 27.2±0.1 °2θ (e.g. 6.7, 12.1, 15.1, 17.5, 24.2 and 24.6 °2θ) using Cu Kα radiation. Optionally, the XRPD plot of Form I includes at least five signals (e.g., peaks) selected from 12.4±0.2, 16.6±0.2, 19.3±0.2, 23.4±0.2, 26.3±0.2 and 27.2±0.2 °2θ (e.g. 12.4±0.1, 16.6±0.1, 19.3±0.1, 23.4±0.1, 26.3±0.1 and 27.2±0.1 °2θ (e.g. 6.7, 12.1, 15.1, 17.5, 24.2 and 24.6 °2θ) using Cu Kα radiation. Optionally, the XRPD plot of form I includes a signal (e.g., a peak) at 12.4±0.2, 16.6±0.2, 19.3±0.2, 23.4±0.2, 26.3±0.2 and 27.2±0.2 °2θ (e.g. 12.4±0.1, 16.6±0.1, 19.3±0.1, 23.4±0.1, 26.3±0.1 and 27.2±0.1 °2θ (e.g. 6.7, 12.1, 15.1, 17.5, 24.2 and 24.6 °2θ) using Cu Kα radiation.

[0968] Exemplary Implementation 108. The crystal form as described in any of the foregoing exemplary implementations, wherein form I is characterized by being substantially similar to Figure 11 or Figure 49 The XRPD diagram shown is an XRPD diagram.

[0969] Exemplary Implementation 109. The crystal form as described in any of the foregoing exemplary implementations, wherein Form I is characterized by an XRPD plot containing signals (e.g., peaks) at approximately the locations shown in Table 3 below.

[0970] Exemplary Embodiment 110. The crystal form as described in any of the foregoing exemplary embodiments, wherein Form I is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 233 ± 20 °C (e.g., 233 ± 10 °C (e.g., 233 ± 5 °C (e.g., 233 ± 4 °C (e.g., 233 ± 3 °C (e.g., 233 ± 2 °C (e.g., 233 ± 1 °C (e.g., 233 ± 0.5 °C))))))); Optionally, Form I is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 233 °C.

[0971] Exemplary Embodiment 111. The crystal form as described in any of the foregoing exemplary embodiments, wherein Form I is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 128 ± 20 °C (e.g., 128 ± 10 °C (e.g., 128 ± 5 °C (e.g., 128 ± 4 °C (e.g., 128 ± 3 °C (e.g., 128 ± 2 °C (e.g., 128 ± 1 °C (e.g., 128 ± 0.5 °C)))))))); Optionally, Form I is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 128 °C.

[0972] Exemplary Embodiment 112. The crystal form as described in any of the foregoing exemplary embodiments, wherein Form I is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 235 ± 20 °C (e.g., 235 ± 10 °C (e.g., 235 ± 5 °C (e.g., 235 ± 4 °C (e.g., 235 ± 3 °C (e.g., 235 ± 2 °C (e.g., 235 ± 1 °C (e.g., 235 ± 0.5 °C))))))); Optionally, Form I is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 235 °C.

[0973] Exemplary Embodiment 113. The crystal form as described in any of the foregoing exemplary embodiments, wherein Form I is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 96 ± 9 J / g (e.g., 96 ± 8 J / g (e.g., 96 ± 7 J / g (e.g., 96 ± 6 J / g (e.g., 96 ± 5 J / g (e.g., 96 ± 4 J / g (e.g., 96 ± 2 J / g (e.g., 96 ± 1 J / g)))))))); Optionally, form I is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 96 J / g.

[0974] Exemplary Embodiment 114. The crystal form as described in any of the foregoing exemplary embodiments, wherein Form I is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 40 ± 4 J / g (e.g., 40 ± 3 J / g (e.g., 40 ± 2 J / g (e.g., 40 ± 1 J / g (e.g., 40 ± 0.75 J / g (e.g., 40 ± 0.5 J / g (e.g., 40 ± 0.2 J / g (e.g., 40 ± 0.1 J / g)))))))); Optionally, form I is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 40 J / g.

[0975] Exemplary Embodiment 115. The crystal form as described in any of the foregoing exemplary embodiments, wherein Form I is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 88 ± 9 J / g (e.g., 88 ± 8 J / g (e.g., 88 ± 7 J / g (e.g., 88 ± 6 J / g (e.g., 88 ± 5 J / g (e.g., 88 ± 4 J / g (e.g., 88 ± 2 J / g (e.g., 88 ± 1 J / g)))))))); Optionally, form I is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 88 J / g; Optionally, form I is characterized by being substantially similar to Figure 12 Or the DSC spectrum shown in 50.

[0976] Exemplary Embodiment 116. The crystal form as described in any of the foregoing exemplary embodiments, wherein Form I exhibits a weight loss of about 0.1% to about 2% as measured by TGA in a temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ... Optionally, Form I exhibits a weight loss of about 0.5% at temperatures ranging from about 34°C to about 230°C, as measured by TGA; Optionally, form I is characterized by being substantially similar to Figure 13 or Figure 51 The TGA spectrum shown is the TGA spectrum.

[0977] Exemplary Implementation 117. A crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is form J, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[0978] Exemplary embodiment 118. The crystal form as described in any of the foregoing exemplary embodiments, wherein the crystal form is the toluenesulfonate form J of compound 1.

[0979] Exemplary Embodiment 119. The crystal form as described in any of the foregoing exemplary embodiments, wherein the toluenesulfonate comprises compound 1 and p-toluenesulfonic acid present in a ratio of about 1:1.

[0980] Exemplary Embodiment 120. The crystal form as described in any of the foregoing exemplary embodiments, wherein the toluenesulfonate comprises compound 1 and p-toluenesulfonic acid present in a ratio of about 1:2.

[0981] Exemplary Embodiment 121. The crystal form as described in any of the foregoing exemplary embodiments, wherein the toluenesulfonate comprises compound 1 and p-toluenesulfonic acid present in a ratio of about 2:1.

[0982] Exemplary Embodiment 122. The crystal form as described in any of the foregoing exemplary embodiments, wherein form J is characterized by an X-ray powder diffraction (“XRPD”) pattern using Cu Kα radiation containing signals (e.g., peaks) at 6.7±0.2, 12.1±0.2, and 15.1±0.2 °2θ (e.g., 6.7±0.1, 12.1±0.1, and 15.1±0.1 °2θ (e.g., 6.7, 12.1, and 15.1 °2θ)); Optionally, the XRPD plot of form J further includes at least one signal (e.g., a peak) selected from 17.5±0.2, 24.2±0.2 and 24.6±0.2 °2θ (e.g. 17.5±0.1, 24.2±0.1 and 24.6±0.1 °2θ (e.g. 17.5, 24.2 and 24.6 °2θ)) using Cu Kα radiation. Optionally, the XRPD plot of form J further includes at least two signals (e.g., peaks) selected from 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2θ (e.g., 17.5±0.1, 24.2±0.1, and 24.6±0.1 °2θ (e.g., 17.5, 24.2, and 24.6 °2θ)) using Cu Kα radiation. Optionally, the XRPD plot of form J further includes a signal (e.g., a peak) at 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2θ (e.g., 17.5±0.1, 24.2±0.1, and 24.6±0.1 °2θ (e.g., 17.5, 24.2, and 24.6 °2θ) using Cu Kα radiation.

[0983] Exemplary Embodiment 123. The crystal form as described in any of the foregoing exemplary embodiments, wherein form J is characterized by an X-ray powder diffraction (“XRPD”) pattern using Cu Kα radiation containing at least three signals (e.g., peaks) selected from 6.7±0.2, 12.1±0.2, 15.1±0.2, 17.5±0.2, 24.2±0.2 and 24.6±0.2 °2θ (e.g. 6.7±0.1, 12.1±0.1, 15.1±0.1, 17.5±0.1, 24.2±0.1 and 24.6±0.1 °2θ (e.g. 6.7, 12.1, 15.1, 17.5, 24.2 and 24.6 °2θ)); Optionally, the XRPD plot of form J includes at least four signals (e.g., peaks) selected from 6.7±0.2, 12.1±0.2, 15.1±0.2, 17.5±0.2, 24.2±0.2 and 24.6±0.2 °2θ (e.g. 6.7±0.1, 12.1±0.1, 15.1±0.1, 17.5±0.1, 24.2±0.1 and 24.6±0.1 °2θ (e.g. 6.7, 12.1, 15.1, 17.5, 24.2 and 24.6 °2θ) using Cu Kα radiation. Optionally, the XRPD plot of form J includes at least five signals (e.g., peaks) selected from 6.7±0.2, 12.1±0.2, 15.1±0.2, 17.5±0.2, 24.2±0.2 and 24.6±0.2 °2θ (e.g. 6.7±0.1, 12.1±0.1, 15.1±0.1, 17.5±0.1, 24.2±0.1 and 24.6±0.1 °2θ (e.g. 6.7, 12.1, 15.1, 17.5, 24.2 and 24.6 °2θ) using Cu Kα radiation. Optionally, the XRPD plot of form J includes a signal (e.g., a peak) at 6.7±0.2, 12.1±0.2, 15.1±0.2, 17.5±0.2, 24.2±0.2 and 24.6±0.2 °2θ (e.g. 6.7±0.1, 12.1±0.1, 15.1±0.1, 17.5±0.1, 24.2±0.1 and 24.6±0.1 °2θ (e.g. 6.7, 12.1, 15.1, 17.5, 24.2 and 24.6 °2θ) using Cu Kα radiation.

[0984] Exemplary Embodiment 124. The crystal form as described in any of the foregoing exemplary embodiments, wherein form J is characterized by being substantially similar to Figure 15 or Figure 54 The XRPD diagram shown is an XRPD diagram.

[0985] Exemplary Implementation 125. The crystal form as described in any of the foregoing exemplary implementations, wherein form J is characterized by an XRPD plot containing signals (e.g., peaks) at approximately the locations shown in Table 4 below.

[0986] Exemplary Embodiment 126. The crystal form as described in any of the foregoing exemplary embodiments, wherein form J is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 204 ± 20 °C (e.g., 204 ± 10 °C (e.g., 204 ± 5 ​​°C (e.g., 204 ± 4 °C (e.g., 204 ± 3 °C (e.g., 204 ± 2 °C (e.g., 204 ± 1 °C (e.g., 204 ± 0.5 °C)))))))); Optionally, form J is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 204 °C.

[0987] Exemplary Embodiment 127. The crystal form as described in any of the foregoing exemplary embodiments, wherein form J is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 76 ± 8 J / g (e.g., 76 ± 7 J / g (e.g., 76 ± 6 J / g (e.g., 76 ± 5 J / g (e.g., 76 ± 4 J / g (e.g., 76 ± 3 J / g (e.g., 76 ± 2 J / g (e.g., 76 ± 1 J / g)))))))); Optionally, form J is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 76 J / g.

[0988] Exemplary Embodiment 128. The crystal form as described in any of the foregoing exemplary embodiments, wherein form J is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 205 ± 20 °C (e.g., 205 ± 10 °C (e.g., 205 ± 5 °C (e.g., 205 ± 4 °C (e.g., 205 ± 3 °C (e.g., 205 ± 2 °C (e.g., 205 ± 1 °C (e.g., 205 ± 0.5 °C)))))))); Optionally, form J is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 205 °C.

[0989] Exemplary Embodiment 129. The crystal form as described in any of the foregoing exemplary embodiments, wherein form J is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 62 ± 6 J / g (e.g., 62 ± 5 J / g (e.g., 62 ± 4 J / g (e.g., 62 ± 3 J / g (e.g., 62 ± 2 J / g (e.g., 62 ± 1 J / g (e.g., 62 ± 0.75 J / g (e.g., 62 ± 0.5 J / g)))))))); Optionally, form J is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 62 J / g; Alternatively, the form J is characterized by being substantially similar to Figure 16 or Figure 55 The DSC spectrum shown is the DSC spectrum.

[0990] Exemplary Embodiment 130. The crystal form as described in any of the foregoing exemplary embodiments, wherein form J exhibits a weight loss of about 0.1% to about 2% as measured by TGA in a temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ... Optionally, form J exhibits a weight loss of about 0.7% at temperatures ranging from about 34°C to about 200°C, as measured by TGA.

[0991] Exemplary Embodiment 131. The crystal form as described in any of the foregoing exemplary embodiments, wherein form J exhibits a weight loss of about 0.1% to about 2.5% as measured by TGA in a temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ... Optionally, form J exhibits a weight loss of about 0.9% at temperatures ranging from about 34°C to about 200°C, as measured by TGA; Alternatively, the form J is characterized by being substantially similar to Figure 17 or Figure 56 The TGA spectrum shown is the TGA spectrum.

[0992] Exemplary Implementation 132. The crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is form K, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[0993] Exemplary Implementation 133. The crystal form as described in any of the foregoing exemplary implementations, wherein the crystal form is the maleate form K of compound 1.

[0994] Exemplary Embodiment 134. The crystal form as described in any of the foregoing exemplary embodiments, wherein the maleate comprises compound 1 and maleic acid present in a ratio of about 1:1.

[0995] Exemplary Embodiment 135. The crystal form as described in any of the foregoing exemplary embodiments, wherein the maleate comprises compound 1 and maleic acid present in a ratio of about 1:2.

[0996] Exemplary Embodiment 136. The crystal form as described in any of the foregoing exemplary embodiments, wherein the maleate comprises compound 1 and maleic acid present in a ratio of about 2:1.

[0997] Exemplary Implementation 137. The crystal form as described in any of the foregoing exemplary embodiments, wherein form K is characterized by being substantially similar to Figure 58 The XRPD spectrum shown is the XRPD spectrum.

[0998] Exemplary Embodiment 138. The crystal form as described in any of the foregoing exemplary embodiments, wherein form K is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 57.1 ± 20 °C (e.g., 57.1 ± 10 °C (e.g., 57.1 ± 5 °C (e.g., 57.1 ± 4 °C (e.g., 57.1 ± 3 °C (e.g., 57.1 ± 2 °C (e.g., 57.1 ± 1 °C (e.g., 57.1 ± 0.5 °C)))))))); Optionally, form K is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 57.1 °C.

[0999] Exemplary Embodiment 139. The crystal form as described in any of the foregoing exemplary embodiments, wherein form K is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 121 ± 20 °C (e.g., 121 ± 10 °C (e.g., 121 ± 5 °C (e.g., 121 ± 4 °C (e.g., 121 ± 3 °C (e.g., 121 ± 2 °C (e.g., 121 ± 1 °C (e.g., 121 ± 0.5 °C))))))); Optionally, form K is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 121 °C.

[1000] Exemplary Embodiment 140. The crystal form as described in any of the foregoing exemplary embodiments, wherein form K is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 12.9 ± 1.5 J / g (e.g., 12.9 ± 1.3 J / g (e.g., 12.9 ± 1.0 J / g (e.g., 12.9 ± 0.8 J / g (e.g., 12.9 ± 0.6 J / g (e.g., 12.9 ± 0.4 J / g (e.g., 12.9 ± 0.2 J / g (e.g., 12.9 ± 0.1 J / g)). Optionally, form K is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 12.9 J / g.

[1001] Exemplary Implementation 141. The crystal form as described in any of the foregoing exemplary implementations, wherein form K is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 91.9 ± 10 J / g (e.g., 91.9 ± 8 J / g (e.g., 91.9 ± 6 J / g (e.g., 91.9 ± 5 J / g (e.g., 91.9 ± 4 J / g (e.g., 91.9 ± 3 J / g (e.g., 91.9 ± 2 J / g (e.g., 91.9 ± 1 J / g)))))))); Optionally, form K is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 91.9 J / g; Alternatively, the form K is characterized by being substantially similar to Figure 59 The DSC spectrum shown is the DSC spectrum.

[1002] Exemplary Embodiment 142. The crystal form as described in any of the foregoing exemplary embodiments, wherein form K exhibits a weight loss of about 0.1% to about 5% as measured by TGA at temperatures ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ... Optionally, form K exhibits a weight loss of about 2.0% at temperatures ranging from about 34°C to about 80°C, as measured by TGA.

[1003] Exemplary Embodiment 143. The crystal form as described in any of the foregoing exemplary embodiments, wherein form K exhibits a weight loss of about 8% to about 25% in the temperature range of about 80 ± 20 °C (e.g., 80 ± 10 °C (e.g., 80 ± 5 °C (e.g., 80 ± 4 °C (e.g., 80 ± 3 °C (e.g., 80 ± 1 °C (e.g., 80 ± 0.5 °C) ... Optionally, form K exhibits a weight loss of about 15% at temperatures ranging from about 80°C to about 250°C, as measured by TGA. Alternatively, the form K is characterized by being substantially similar to Figure 60 The TGA spectrum shown is the TGA spectrum.

[1004] Exemplary Implementation 144. A crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is form L, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[1005] Exemplary Implementation 145. The crystal form as described in any of the foregoing exemplary implementations, wherein the crystal form is the fumarate form L of compound 1.

[1006] Exemplary Embodiment 146. The crystal form as described in any of the foregoing exemplary embodiments, wherein the fumarate comprises compound 1 and fumaric acid present in a ratio of about 1:1.

[1007] Exemplary Embodiment 147. The crystal form as described in any of the foregoing exemplary embodiments, wherein the fumarate comprises compound 1 and fumaric acid present in a ratio of about 1:2.

[1008] Exemplary Embodiment 148. The crystal form as described in any of the foregoing exemplary embodiments, wherein the fumarate comprises compound 1 and fumaric acid present in a ratio of about 2:1.

[1009] Exemplary Embodiment 149. The crystal form as described in any of the foregoing exemplary embodiments, wherein form L is characterized by an X-ray powder diffraction (“XRPD”) pattern using Cu Kα radiation containing signals (e.g., peaks) at 12.5±0.2, 15.6±0.2, and 27.0±0.2 °2θ (e.g., 12.5±0.1, 15.6±0.1, and 27.0±0.1 °2θ (e.g., 12.5, 15.6, and 27.0 °2θ)); Optionally, the XRPD plot of form L further includes at least one signal (e.g., a peak) selected from 12.5±0.2, 15.6±0.2 and 27.0±0.2 °2θ (e.g. 12.5±0.1, 15.6±0.1 and 27.0±0.1 °2θ (e.g. 12.5, 15.6 and 27.0 °2θ)) using Cu Kα radiation. Optionally, the XRPD plot of form L further includes at least two signals (e.g., peaks) selected from 12.5±0.2, 15.6±0.2 and 27.0±0.2 °2θ (e.g. 12.5±0.1, 15.6±0.1 and 27.0±0.1 °2θ (e.g. 12.5, 15.6 and 27.0 °2θ)) using Cu Kα radiation. Optionally, the XRPD plot of form L further includes a signal (e.g., a peak) at 12.5±0.2, 15.6±0.2, and 27.0±0.2 °2θ (e.g., 12.5±0.1, 15.6±0.1, and 27.0±0.1 °2θ (e.g., 12.5, 15.6, and 27.0 °2θ) using Cu Kα radiation.

[1010] Exemplary Embodiment 150. A crystal form as described in any of the foregoing exemplary embodiments, wherein form L is characterized by an X-ray powder diffraction (“XRPD”) pattern using Cu Kα radiation containing at least three signals (e.g., peaks) selected from 12.0±0.2, 14.5±0.2, 15.6±0.2, 18.7±0.2, 27.0±0.2 and 27.2±0.2 °2θ (e.g. 12.0±0.1, 14.5±0.1, 15.6±0.1, 18.7±0.1, 27.0±0.1 and 27.2±0.1 °2θ (e.g. 12.0, 14.5, 15.6, 18.7, 27.0 and 27.2 °2θ)); Optionally, the XRPD plot of form L includes at least four signals (e.g., peaks) selected from 12.0±0.2, 14.5±0.2, 15.6±0.2, 18.7±0.2, 27.0±0.2 and 27.2±0.2 °2θ (e.g. 12.0±0.1, 14.5±0.1, 15.6±0.1, 18.7±0.1, 27.0±0.1 and 27.2±0.1 °2θ (e.g. 12.0, 14.5, 15.6, 18.7, 27.0 and 27.2 °2θ) using Cu Kα radiation. Optionally, the XRPD plot of form L includes at least five signals (e.g., peaks) selected from 12.0±0.2, 14.5±0.2, 15.6±0.2, 18.7±0.2, 27.0±0.2 and 27.2±0.2 °2θ (e.g. 12.0±0.1, 14.5±0.1, 15.6±0.1, 18.7±0.1, 27.0±0.1 and 27.2±0.1 °2θ (e.g. 12.0, 14.5, 15.6, 18.7, 27.0 and 27.2 °2θ) using Cu Kα radiation. Optionally, the XRPD plot of form L includes a signal (e.g., a peak) at 12.0±0.2, 14.5±0.2, 15.6±0.2, 18.7±0.2, 27.0±0.2 and 27.2±0.2 °2θ (e.g. 12.0±0.1, 14.5±0.1, 15.6±0.1, 18.7±0.1, 27.0±0.1 and 27.2±0.1 °2θ (e.g. 12.0, 14.5, 15.6, 18.7, 27.0 and 27.2 °2θ) using Cu Kα radiation.

[1011] Exemplary Implementation 151. The crystal form as described in any of the foregoing exemplary embodiments, wherein form L is characterized by being substantially similar to Figure 20 or Figure 62 The XRPD diagram shown is an XRPD diagram.

[1012] Exemplary Implementation 152. The crystal form as described in any of the foregoing exemplary implementations, wherein the form L is characterized by an XRPD plot containing signals (e.g., peaks) at approximately the locations shown in Table 5 below.

[1013] Exemplary Embodiment 153. The crystal form as described in any of the foregoing exemplary embodiments, wherein form L is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 195 ± 20 °C (e.g., 195 ± 10 °C (e.g., 195 ± 5 °C (e.g., 195 ± 4 °C (e.g., 195 ± 3 °C (e.g., 195 ± 2 °C (e.g., 195 ± 1 °C (e.g., 195 ± 0.5 °C))))))); Optionally, the form L is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 195 °C.

[1014] Exemplary Embodiment 154. The crystal form as described in any of the foregoing exemplary embodiments, wherein form L is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 111 ± 11 J / g (e.g., 111 ± 10 J / g (e.g., 111 ± 8 J / g (e.g., 111 ± 6 J / g (e.g., 111 ± 4 J / g (e.g., 111 ± 3 J / g (e.g., 111 ± 2 J / g (e.g., 111 ± 1 J / g)))))))); Optionally, the form L is characterized by a DSC curve having an endothermic signal (e.g., a peak) related to enthalpy of 111 J / g.

[1015] Exemplary Implementation 155. The crystal form as described in any of the foregoing exemplary implementations, wherein form L is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 196 ± 20 °C (e.g., 196 ± 10 °C (e.g., 196 ± 5 °C (e.g., 196 ± 4 °C (e.g., 196 ± 3 °C (e.g., 196 ± 2 °C (e.g., 196 ± 1 °C (e.g., 196 ± 0.5 °C)))))))); Optionally, the form L is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 196 °C.

[1016] Exemplary Embodiment 156. The crystal form as described in any of the foregoing exemplary embodiments, wherein form L is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 99 ± 10 J / g (e.g., 99 ± 9 J / g (e.g., 99 ± 8 J / g (e.g., 99 ± 6 J / g (e.g., 99 ± 4 J / g (e.g., 99 ± 3 J / g (e.g., 99 ± 2 J / g (e.g., 99 ± 1 J / g)))))))); Optionally, the form L is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 99 J / g; Alternatively, the form L is characterized by being substantially similar to Figure 21 or Figure 63 The DSC spectrum shown is the DSC spectrum.

[1017] Exemplary Embodiment 157. The crystal form as described in any of the foregoing exemplary embodiments, wherein form L exhibits a weight loss of about 0.1% to about 2% as measured by TGA in a temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ... Optionally, form L exhibits a weight loss of about 0.8% at temperatures ranging from about 34°C to about 180°C, as measured by TGA.

[1018] Exemplary Embodiment 158. The crystal form as described in any of the foregoing exemplary embodiments, wherein form L exhibits a weight loss of about 0.05% to about 2% as measured by TGA at temperatures ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ... Optionally, form L exhibits a weight loss of about 0.5% at temperatures ranging from about 34°C to about 185°C, as measured by TGA. Alternatively, the form L is characterized by being substantially similar to Figure 22 or Figure 64 The TGA spectrum shown is the TGA spectrum.

[1019] Exemplary Implementation 159. A crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is form M, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[1020] Exemplary embodiment 160. The crystal form as described in any of the foregoing exemplary embodiments, wherein the crystal form is the fumarate form M of compound 1.

[1021] Exemplary Embodiment 161. The crystal form as described in any of the foregoing exemplary embodiments, wherein the fumarate comprises compound 1 and fumaric acid present in a ratio of about 1:1.

[1022] Exemplary Embodiment 162. The crystal form as described in any of the foregoing exemplary embodiments, wherein the fumarate comprises compound 1 and fumaric acid present in a ratio of about 1:2.

[1023] Exemplary Embodiment 163. The crystal form as described in any of the foregoing exemplary embodiments, wherein the fumarate comprises compound 1 and fumaric acid present in a ratio of about 2:1.

[1024] Exemplary Implementation 164. The crystal form as described in any of the foregoing exemplary implementations, wherein form M is characterized by being substantially similar to Figure 66 The XRPD spectrum shown is the XRPD spectrum.

[1025] Exemplary Embodiment 165. The crystal form as described in any of the foregoing exemplary embodiments, wherein form M is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 54.0 ± 20 °C (e.g., 54.0 ± 10 °C (e.g., 54.0 ± 5 °C (e.g., 54.0 ± 4 °C (e.g., 54.0 ± 3 °C (e.g., 54.0 ± 2 °C (e.g., 54.0 ± 1 °C (e.g., 54.0 ± 0.5 °C)))))))); Optionally, the form M is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 54.0 °C.

[1026] Exemplary Embodiment 166. The crystal form as described in any of the foregoing exemplary embodiments, wherein form M is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 125 ± 20 °C (e.g., 125 ± 10 °C (e.g., 125 ± 5 °C (e.g., 125 ± 4 °C (e.g., 125 ± 3 °C (e.g., 125 ± 2 °C (e.g., 125 ± 1 °C (e.g., 125 ± 0.5 °C))))))); Optionally, the form M is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 125 °C.

[1027] Exemplary Implementation 167. The crystal form as described in any of the foregoing exemplary implementations, wherein form M is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 26.1 ± 2.5 J / g (e.g., 26.1 ± 2.0 J / g (e.g., 26.1 ± 1.5 J / g (e.g., 26.1 ± 1.0 J / g (e.g., 26.1 ± 0.8 J / g (e.g., 26.1 ± 0.6 J / g (e.g., 26.1 ± 0.4 J / g (e.g., 26.1 ± 0.2 J / g)). Optionally, the form M is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 26.1 J / g.

[1028] Exemplary Implementation 168. The crystal form as described in any of the foregoing exemplary implementations, wherein form M is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 34.9 ± 3.5 J / g (e.g., 34.9 ± 3.0 J / g (e.g., 34.9 ± 2.5 J / g (e.g., 34.9 ± 2.0 J / g (e.g., 34.9 ± 1.5 J / g (e.g., 34.9 ± 1.0 J / g (e.g., 34.9 ± 0.5 J / g (e.g., 34.9 ± 0.3 J / g)). Optionally, the form M is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 34.9 J / g; Alternatively, the form M is characterized by being substantially similar to Figure 67 The DSC spectrum shown is the DSC spectrum.

[1029] Exemplary Embodiment 169. The crystal form as described in any of the foregoing exemplary embodiments, wherein form M exhibits a weight loss of about 0.1% to about 5% as measured by TGA in a temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ... Optionally, form M exhibits a weight loss of about 1.6% at temperatures ranging from about 34°C to about 100°C, as measured by TGA. Alternatively, the form M is characterized by being substantially similar to Figure 68 The TGA spectrum shown is the TGA spectrum.

[1030] Exemplary Implementation 170. A crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is form N, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[1031] Exemplary Embodiment 171. The crystal form as described in any of the foregoing exemplary embodiments, wherein the crystal form is the fumarate form N of compound 1.

[1032] Exemplary Embodiment 172. The crystal form as described in any of the foregoing exemplary embodiments, wherein the fumarate comprises compound 1 and fumaric acid present in a ratio of about 1:1.

[1033] Exemplary Embodiment 173. The crystal form as described in any of the foregoing exemplary embodiments, wherein the fumarate comprises compound 1 and fumaric acid present in a ratio of about 1:2.

[1034] Exemplary Embodiment 174. The crystal form as described in any of the foregoing exemplary embodiments, wherein the fumarate comprises compound 1 and fumaric acid present in a ratio of about 2:1.

[1035] Exemplary Embodiment 175. The crystal form as described in any of the foregoing exemplary embodiments, wherein form N is characterized by being substantially similar to Figure 70 The XRPD spectrum shown is the XRPD spectrum.

[1036] Exemplary Embodiment 176. The crystal form as described in any of the foregoing exemplary embodiments, wherein form N is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 62.0 ± 20 °C (e.g., 62.0 ± 10 °C (e.g., 62.0 ± 5 °C (e.g., 62.0 ± 4 °C (e.g., 62.0 ± 3 °C (e.g., 62.0 ± 2 °C (e.g., 62.0 ± 1 °C (e.g., 62.0 ± 0.5 °C)))))))); Optionally, the form N is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 62.0 °C.

[1037] Exemplary Embodiment 177. The crystal form as described in any of the foregoing exemplary embodiments, wherein form N is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 107 ± 20 °C (e.g., 107 ± 10 °C (e.g., 107 ± 5 °C (e.g., 107 ± 4 °C (e.g., 107 ± 3 °C (e.g., 107 ± 2 °C (e.g., 107 ± 1 °C (e.g., 107 ± 0.5 °C))))))); Optionally, the form N is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 107 °C.

[1038] Exemplary Embodiment 178. The crystal form as described in any of the foregoing exemplary embodiments, wherein form N is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 37.8 ± 3.8 J / g (e.g., 37.8 ± 3.4 J / g (e.g., 37.8 ± 3.0 J / g (e.g., 37.8 ± 2.5 J / g (e.g., 37.8 ± 2.0 J / g (e.g., 37.8 ± 1.5 J / g (e.g., 37.8 ± 1.0 J / g (e.g., 37.8 ± 0.5 J / g)). Optionally, the form N is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 37.8 J / g.

[1039] Exemplary Embodiment 179. The crystal form as described in any of the foregoing exemplary embodiments, wherein form N is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 22.1 ± 2.5 J / g (e.g., 22.1 ± 2.0 J / g (e.g., 22.1 ± 1.5 J / g (e.g., 22.1 ± 1.0 J / g (e.g., 22.1 ± 0.8 J / g (e.g., 22.1 ± 0.6 J / g (e.g., 22.1 ± 0.4 J / g (e.g., 22.1 ± 0.2 J / g)). Optionally, the form N is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 22.1 J / g; Alternatively, the form N is characterized by being substantially similar to Figure 71 The DSC spectrum shown is the DSC spectrum.

[1040] Exemplary Embodiment 180. The crystal form as described in any of the foregoing exemplary embodiments, wherein form N exhibits a weight loss of about 0.1% to about 5% as measured by TGA in a temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ... Optionally, form N exhibits a weight loss of about 1.8% at temperatures ranging from about 34°C to about 110°C, as measured by TGA. Alternatively, the form N is characterized by being substantially similar to Figure 72 The TGA spectrum shown is the TGA spectrum.

[1041] Exemplary Implementation 181. A crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is form O, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[1042] Exemplary Embodiment 182. The crystal form as described in any of the foregoing exemplary embodiments, wherein the crystal form is the L-tartrate form O of Compound 1.

[1043] Exemplary Embodiment 183. The crystal form as described in any of the foregoing exemplary embodiments, wherein the L-tartrate comprises compound 1 and L-tartaric acid present in a ratio of about 1:1.

[1044] Exemplary Embodiment 184. The crystal form as described in any of the foregoing exemplary embodiments, wherein the L-tartrate comprises compound 1 and L-tartaric acid present in a ratio of about 1:2.

[1045] Exemplary Embodiment 185. The crystal form as described in any of the foregoing exemplary embodiments, wherein the L-tartrate comprises compound 1 and L-tartaric acid present in a ratio of about 2:1.

[1046] Exemplary Implementation 186. The crystal form as described in any of the foregoing exemplary implementations, wherein form O is characterized by being substantially similar to Figure 74 The XRPD spectrum shown is the XRPD spectrum.

[1047] Exemplary Embodiment 187. The crystal form as described in any of the foregoing exemplary embodiments, wherein form O is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 52.7 ± 20 °C (e.g., 52.7 ± 10 °C (e.g., 52.7 ± 5 °C (e.g., 52.7 ± 4 °C (e.g., 52.7 ± 3 °C (e.g., 52.7 ± 2 °C (e.g., 52.7 ± 1 °C (e.g., 52.7 ± 0.5 °C)))))))); Optionally, form O is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 52.7 °C.

[1048] Exemplary Embodiment 188. The crystal form as described in any of the foregoing exemplary embodiments, wherein form O is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 129 ± 20 °C (e.g., 129 ± 10 °C (e.g., 129 ± 5 °C (e.g., 129 ± 4 °C (e.g., 129 ± 3 °C (e.g., 129 ± 2 °C (e.g., 129 ± 1 °C (e.g., 129 ± 0.5 °C))))))); Optionally, form O is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 129 °C.

[1049] Exemplary Embodiment 189. The crystal form as described in any of the foregoing exemplary embodiments, wherein form O is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 24.5 ± 2.5 J / g (e.g., 24.5 ± 2.0 J / g (e.g., 24.5 ± 1.5 J / g (e.g., 24.5 ± 1.0 J / g (e.g., 24.5 ± 0.8 J / g (e.g., 24.5 ± 0.6 J / g (e.g., 24.5 ± 0.4 J / g (e.g., 24.5 ± 0.2 J / g)). Optionally, form O is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 24.5 J / g.

[1050] Exemplary Embodiment 190. The crystal form as described in any of the foregoing exemplary embodiments, wherein form O is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 34.8 ± 3.5 J / g (e.g., 34.8 ± 3.0 J / g (e.g., 34.8 ± 2.5 J / g (e.g., 34.8 ± 2.0 J / g (e.g., 34.8 ± 1.5 J / g (e.g., 34.8 ± 1.0 J / g (e.g., 34.8 ± 0.5 J / g (e.g., 34.8 ± 0.3 J / g)). Optionally, form O is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 34.8 J / g; Alternatively, the form O is characterized by being substantially similar to Figure 75 The DSC spectrum shown is the DSC spectrum.

[1051] Exemplary Embodiment 191. The crystal form as described in any of the foregoing exemplary embodiments, wherein form O exhibits a weight loss of about 0.1% to about 5% as measured by TGA in a temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ... Optionally, form O exhibits a weight loss of about 1.6% at temperatures ranging from about 34°C to about 100°C, as measured by TGA.

[1052] Exemplary Embodiment 192. The crystal form as described in any of the foregoing exemplary embodiments, wherein form O exhibits a weight loss of about 0.3% to about 2.5% in the temperature range of about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))) from about 140 ± 20 °C (e.g., 140 ± 10 °C (e.g., 140 ± 5 °C (e.g., 140 ± 4 °C (e.g., 140 ± 3 °C (e.g., 140 ± 2 °C (e.g., 140 ± 1 °C (e.g., 140 ± 0.5 °C))))))), as measured by TGA; Optionally, form O exhibits a weight loss of about 1.0% at temperatures ranging from about 100°C to about 140°C, as measured by TGA. Alternatively, the form O is characterized by being substantially similar to Figure 76 The TGA spectrum shown is the TGA spectrum.

[1053] Exemplary Implementation 193. A crystal form as described in Exemplary Implementation 1 or 2, wherein the crystal form is form P, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

[1054] Exemplary Embodiment 194. The crystal form as described in any of the foregoing exemplary embodiments, wherein the crystal form is the L-malate form P of compound 1.

[1055] Exemplary Embodiment 195. The crystal form as described in any of the foregoing exemplary embodiments, wherein the L-malate comprises compound 1 and L-malic acid present in a ratio of about 1:1.

[1056] Exemplary Embodiment 196. The crystal form as described in any of the foregoing exemplary embodiments, wherein the L-malate comprises compound 1 and L-malic acid present in a ratio of about 1:2.

[1057] Exemplary Embodiment 197. The crystal form as described in any of the foregoing exemplary embodiments, wherein the L-malate comprises compound 1 and L-malic acid present in a ratio of about 2:1.

[1058] Exemplary Embodiment 198. The crystal form as described in any of the foregoing exemplary embodiments, wherein form P is characterized by being substantially similar to Figure 78 The XRPD spectrum shown is the XRPD spectrum.

[1059] Exemplary Embodiment 199. The crystal form as described in any of the foregoing exemplary embodiments, wherein form P is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 109 ± 20 °C (e.g., 109 ± 10 °C (e.g., 109 ± 5 °C (e.g., 109 ± 4 °C (e.g., 109 ± 3 °C (e.g., 109 ± 2 °C (e.g., 109 ± 1 °C (e.g., 109 ± 0.5 °C)))))))); Optionally, the form P is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 109 °C.

[1060] Exemplary Implementation 200. A crystal form as described in any of the foregoing exemplary implementations, wherein form P is characterized by having a DSC curve of an endothermic signal (e.g., a peak) at 169 ± 20 °C (e.g., 169 ± 10 °C (e.g., 169 ± 5 °C (e.g., 169 ± 4 °C (e.g., 169 ± 3 °C (e.g., 169 ± 2 °C (e.g., 169 ± 1 °C (e.g., 169 ± 0.5 °C)))))))); Optionally, the form P is characterized by a DSC curve having an endothermic signal (e.g., a peak) at 169 °C.

[1061] Exemplary Implementation 201. The crystal form as described in any of the foregoing exemplary embodiments, wherein form P is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 57.5 ± 6.0 J / g (e.g., 57.5 ± 5.0 J / g (e.g., 57.5 ± 4.0 J / g (e.g., 57.5 ± 3.0 J / g (e.g., 57.5 ± 2.0 J / g (e.g., 57.5 ± 1.5 J / g (e.g., 57.5 ± 1.0 J / g (e.g., 57.5 ± 0.5 J / g)). Optionally, the form P is characterized by a DSC curve having an endothermic signal (e.g., a peak) associated with enthalpy of 57.5 J / g.

[1062] Exemplary Embodiment 202. The crystal form as described in any of the foregoing exemplary embodiments, wherein form P is characterized by having a DSC curve of an endothermic signal (e.g., a peak) related to an enthalpy of about 21.5 ± 2.5 J / g (e.g., 21.5 ± 2.0 J / g (e.g., 21.5 ± 1.5 J / g (e.g., 21.5 ± 1.0 J / g (e.g., 21.5 ± 0.8 J / g (e.g., 21.5 ± 0.6 J / g (e.g., 21.5 ± 0.4 J / g (e.g., 21.5 ± 0.2 J / g)). Optionally, the form P is characterized by a DSC curve having an endothermic signal (e.g., a peak) related to enthalpy of 21.5 J / g; Alternatively, the form P is characterized by being substantially similar to Figure 79 The DSC spectrum shown is the DSC spectrum.

[1063] Exemplary Embodiment 203. The crystal form as described in any of the foregoing exemplary embodiments, wherein form P exhibits a weight loss of about 0.1% to about 5% as measured by TGA in a temperature range of about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 ​​°C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C) ... Optionally, form P exhibits a weight loss of about 2.1% at temperatures ranging from about 34°C to about 130°C, as measured by TGA.

[1064] Exemplary Embodiment 204. The crystal form as described in any of the foregoing exemplary embodiments, wherein form P exhibits a weight loss of about 15% to about 30% in the temperature range of about 130 ± 20 °C (e.g., 130 ± 10 °C (e.g., 130 ± 5 °C (e.g., 130 ± 4 °C (e.g., 130 ± 3 °C (e.g., 130 ± 2 °C (e.g., 130 ± 1 °C (e.g., 130 ± 0.5 °C))))))) from about 130 ± 20 °C (e.g., 300 ± 10 °C (e.g., 300 ± 5 °C (e.g., 300 ± 4 °C (e.g., 300 ± 3 °C (e.g., 300 ± 2 °C (e.g., 300 ± 1 °C (e.g., 300 ± 0.5 °C))))))) as measured by TGA; Optionally, form P exhibits a weight loss of about 21% at temperatures ranging from about 130°C to about 300°C, as measured by TGA. Alternatively, the form P is characterized by being substantially similar to Figure 80 The TGA spectrum shown is the TGA spectrum.

[1065] Exemplary Implementation 205. The crystal form as described in any of the foregoing exemplary implementations has a purity of at least 90%, 95%, 96%, 97%, 98%, or 99%.

[1066] Exemplary Implementation 206. A combination comprising: Compound 1, its salts, its solvates, its hydrates or pharmaceutically acceptable salts in amorphous form; and polymer.

[1067] Exemplary embodiment 207. A composition comprising the combination as described in Exemplary embodiment 206.

[1068] Exemplary embodiment 208. The composition of exemplary embodiment 207, wherein the polymer comprises a copolymer of N-vinylpyrrolidone and vinyl acetate.

[1069] Exemplary Embodiment 209. The composition as described in any of the foregoing exemplary embodiments, wherein the polymer is sold as PVP VA64.

[1070] Exemplary Embodiment 210. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by a Tg at about 106°C as measured by mDSC.

[1071] Exemplary Embodiment 211. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by being substantially similar to Figure 91 The mDSC spectrum shown is the mDSC spectrum.

[1072] Exemplary Embodiment 212. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by a Tg at about 107°C as measured by mDSC.

[1073] Exemplary Embodiment 213. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by being substantially similar to Figure 96 The mDSC spectrum shown is the mDSC spectrum.

[1074] Exemplary Embodiment 214. The composition as described in any of the foregoing exemplary embodiments, wherein the composition exhibits a weight loss of about 2.5% to about 10% at temperatures ranging from about 33±20°C to about 100±20°C, as measured by TGA.

[1075] Exemplary embodiment 215. A composition comprising the combination as described in Exemplary embodiment 207, wherein the polymer comprises hydroxypropyl methylcellulose.

[1076] Exemplary Embodiment 216. The composition as described in any of the foregoing exemplary embodiments, wherein the polymer is sold as HPMC ASMG.

[1077] Exemplary Embodiment 217. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by a Tg at about 102°C as measured by mDSC.

[1078] Exemplary Embodiment 218. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by being substantially similar to Figure 92 The mDSC spectrum shown is the mDSC spectrum.

[1079] Exemplary Embodiment 219. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by a Tg at about 91°C as measured by mDSC.

[1080] Exemplary Embodiment 220. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by being substantially similar to Figure 99 The mDSC spectrum shown is the mDSC spectrum.

[1081] Exemplary Embodiment 221. The composition as described in any of the foregoing exemplary embodiments, wherein the composition exhibits a weight loss of about 0.5% to about 5% at temperatures ranging from about 32±20°C to about 100±20°C, as measured by TGA.

[1082] Exemplary Embodiment 222. The composition as described in any of the foregoing exemplary embodiments, wherein the polymer is sold as HPMC E3.

[1083] Exemplary Embodiment 223. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by a Tg at about 104°C as measured by mDSC.

[1084] Exemplary Embodiment 224. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by being substantially similar to Figure 93 The mDSC spectrum shown is the mDSC spectrum.

[1085] Exemplary Embodiment 225. The composition as described in any of the foregoing exemplary embodiments, wherein the composition exhibits a weight loss of about 0.5% to about 5% at temperatures ranging from about 33±20°C to about 100±20°C, as measured by TGA.

[1086] Exemplary Implementation 226. A composition comprising the combination as described in Exemplary Implementation 207, wherein the polymer comprises a polymethacrylate-based copolymer.

[1087] Exemplary Embodiment 227. The composition as described in any of the foregoing exemplary embodiments, wherein the polymer is Eudragit ® E100 for sale.

[1088] Exemplary Embodiment 228. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by a Tg at about 48°C as measured by mDSC.

[1089] Exemplary Embodiment 229. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by being substantially similar to Figure 94 The mDSC spectrum shown is the mDSC spectrum.

[1090] Exemplary Embodiment 230. The composition as described in any of the foregoing exemplary embodiments, wherein the composition exhibits a weight loss of about 0.1% to about 5% at temperatures ranging from about 33±20°C to about 100±20°C, as measured by TGA.

[1091] Exemplary Embodiment 231. The composition as described in any of the foregoing exemplary embodiments, wherein the polymer is Eudragit ® L100-55 for sale.

[1092] Exemplary Embodiment 232. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by a Tg at about 181°C as measured by mDSC.

[1093] Exemplary Embodiment 233. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by being substantially similar to Figure 95 The mDSC spectrum shown is the mDSC spectrum.

[1094] Exemplary Embodiment 234. The composition as described in any of the foregoing exemplary embodiments, wherein the composition exhibits a weight loss of about 0.5% to about 10% at temperatures ranging from about 32±20°C to about 100±20°C, as measured by TGA.

[1095] Exemplary embodiment 235. A composition comprising the combination as described in Exemplary embodiment 207, wherein the polymer comprises a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

[1096] Exemplary Implementation 236. The composition as described in any of the foregoing exemplary implementations, wherein the polymer is Soluplus ® sell.

[1097] Exemplary Embodiment 237. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by a Tg at about 72°C as measured by mDSC.

[1098] Exemplary Embodiment 238. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by being substantially similar to Figure 97 The mDSC spectrum shown is the mDSC spectrum.

[1099] Exemplary Embodiment 239. The composition as described in any of the foregoing exemplary embodiments, wherein the polymer is Kollidon ® 12 PF for sale.

[1100] Exemplary Embodiment 240. The composition as described in any of the foregoing exemplary embodiments, wherein the composition is characterized by a Tg at about 107°C as measured by mDSC.

[1101] Exemplary Embodiment 241. The composition as described in any one of the foregoing exemplary embodiments, wherein the composition is characterized by being substantially similar to Figure 98 The mDSC spectrum shown is the mDSC spectrum.

[1102] Exemplary Embodiment 242. Use of the crystal form as described in any of the foregoing exemplary embodiments in the manufacture of a medicament for treating or preventing cancer in a subject.

[1103] Exemplary Implementation 243. A combination comprising: (i) a crystal form as described in any of the foregoing exemplary implementations; and (ii) one or more MAPK pathway inhibitors.

[1104] Exemplary Implementation 244. A method of treating or preventing cancer in a subject, the method comprising administering to the subject a combination comprising: (i) a crystal form as described in any of the foregoing exemplary implementations; and (ii) one or more MAPK pathway inhibitors.

[1105] Exemplary Implementation 245. A combination for treating or preventing cancer in a subject, the combination comprising: (i) a crystal form as described in any of the foregoing exemplary implementations; and (ii) one or more MAPK pathway inhibitors.

[1106] Exemplary Implementation 246. Use in the manufacture of a medicament for treating or preventing cancer in a subject, the combination comprising: (i) a crystal form as described in any of the foregoing exemplary implementations; and (ii) one or more MAPK pathway inhibitors.

[1107] Exemplary Implementation 247. The method, crystal form, combination, or use as described in any of the foregoing exemplary implementations, wherein the subject is a human.

[1108] Exemplary Implementation 248. The method, crystal form, combination, or use as described in any of the foregoing exemplary implementations, wherein the cancer is characterized by BRAF At least one oncogenic mutation in a gene.

[1109] Exemplary Implementation 249. The method, crystal form, combination or use as described in any of the foregoing exemplary implementations, wherein the cancer is characterized by at least one carcinogenic variant of B-Raf.

[1110] Exemplary Implementation 250. The method, crystal form, combination, or use as described in any of the foregoing exemplary implementations, wherein the subject has BRAF At least one oncogenic mutation in a gene.

[1111] Exemplary Implementation 251. The method, crystal form, combination, or use as described in any of the foregoing exemplary implementations, wherein the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of B-Raf.

[1112] Exemplary Implementation 252. The method, crystal form, combination or use as described in any of the foregoing exemplary implementations, wherein the oncogenic mutation of said B-Raf is any B-Raf mutation listed in Table 6.

[1113] Exemplary Implementation 253. The method, crystal form, combination or use as described in any of the foregoing exemplary implementations, wherein the carcinogenic variant of B-Raf can be any B-Raf variant listed in Table 7.

[1114] Exemplary Implementation 254. The method, crystal form, combination, or use as described in any of the foregoing exemplary implementations, wherein the cancer is characterized by KRAS At least one oncogenic mutation in a gene.

[1115] Exemplary Implementation 255. The method, crystal form, combination or use as described in any of the foregoing exemplary implementations, wherein the cancer is characterized by at least one carcinogenic variant of K-Ras.

[1116] Exemplary Implementation 256. The method, crystal form, combination, or use as described in any of the foregoing exemplary implementations, wherein the subject has KRAS At least one oncogenic mutation in a gene.

[1117] Exemplary Implementation 257. The method, crystal form, combination, or use as described in any of the foregoing exemplary implementations, wherein the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of K-Ras.

[1118] Exemplary Implementation 258. The method, crystal form, combination, or use as described in any of the foregoing exemplary implementations, wherein the cancer is characterized by NRAS At least one oncogenic mutation in a gene.

[1119] Exemplary Implementation 259. The method, crystal form, combination or use as described in any of the foregoing exemplary implementations, wherein the cancer is characterized by at least one carcinogenic variant of N-Ras.

[1120] Exemplary Implementation 260. The method, crystal form, combination, or use as described in any of the foregoing exemplary implementations, wherein the subject has NRAS At least one oncogenic mutation in a gene.

[1121] Exemplary Implementation 261. The method, crystal form, combination, or use as described in any of the foregoing exemplary implementations, wherein the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of N-Ras.

[1122] Exemplary Implementation 262. The method, crystal form, combination, or use as described in any of the foregoing exemplary implementations, wherein the cancer is characterized by NF1 At least one oncogenic mutation in a gene.

[1123] Exemplary Implementation 263. The method, crystal form, combination or use as described in any of the foregoing exemplary implementations, wherein the cancer is characterized by at least one carcinogenic variant of NF1.

[1124] Exemplary Implementation 264. The method, crystal form, combination, or use as described in any of the foregoing exemplary implementations, wherein the subject has NF1 At least one oncogenic mutation in a gene.

[1125] Exemplary Implementation 265. The method, crystal form, combination or use as described in any of the foregoing exemplary implementations, wherein the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of NF1.

[1126] Exemplary Implementation 266. The method, crystal form, combination, or use as described in any of the foregoing exemplary implementations, wherein the cancer is carcinoma, lymphoma, blastoma, sarcoma, leukemia, brain cancer, breast cancer, blood cancer, bone cancer, lung cancer, skin cancer, liver cancer, ovarian cancer, bladder cancer, kidney cancer, stomach cancer, thyroid cancer, pancreatic cancer, esophageal cancer, prostate cancer, cervical cancer, uterine cancer, gastric cancer, soft tissue cancer, laryngeal cancer, small intestine cancer, testicular cancer, anal cancer, vulvar cancer, joint cancer, oral cancer, pharyngeal cancer, or colorectal cancer.

[1127] Exemplary Implementation 267. The method, crystal form, combination, or use as described in any of the foregoing exemplary implementations, wherein the cancer is adrenocortical carcinoma, bladder urothelial carcinoma, invasive breast cancer, cervical squamous cell carcinoma, cervical adenocarcinoma, bile duct carcinoma, colon adenocarcinoma, lymphoma, diffuse large B-cell lymphoma, esophageal cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, renal chromophobe, renal clear cell carcinoma, renal papillary cell carcinoma, acute myeloid leukemia, low-grade glioma of the brain, hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, mesothelioma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma, paraganglioma, prostate adenocarcinoma, rectal adenocarcinoma, sarcoma, skin melanoma, gastric adenocarcinoma, testicular germ cell tumor, thyroid cancer, thymoma, uterine carcinosarcoma, and uveal melanoma. Other examples include breast cancer, lung cancer, lymphoma, melanoma, liver cancer, colorectal cancer, ovarian cancer, bladder cancer, kidney cancer, or stomach cancer. Other examples of cancer include neuroendocrine carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer, thyroid cancer, endometrial cancer, bile duct cancer, esophageal cancer, anal cancer, salivary cancer, vulvar cancer, cervical cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenal tumors, anal cancer, bile duct cancer, bladder cancer, bone cancer, colorectal cancer, brain tumors, breast cancer, cancer of unknown primary origin (CUP), cancer spread to bone, cancer spread to brain, cancer spread to liver, cancer spread to lung, carcinoid tumors, cervical cancer, childhood cancer, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), colorectal cancer, ear cancer, endometrial cancer, eye cancer, follicular dendritic cell sarcoma, gallbladder cancer, gastric cancer, gastroesophageal junction cancer, germ cell tumors, gestational trophoblastic disease (GIT), hairy cell leukemia, head and neck cancer, Hodgkin's lymphoma. Kaposi's sarcoma, kidney cancer, laryngeal cancer, leukemia, leptiform stomach, liver cancer, lung cancer, lymphoma, malignant schwannoma, mediastinal germ cell tumor, melanoma, skin cancer, male cancer, Merkel cell skin cancer, mesothelioma, hydatidiform mole, oropharyngeal cancer, myeloma, nasal and paranasal sinus cancer, nasopharyngeal carcinoma, neuroblastoma, neuroendocrine tumors, non-Hodgkin's lymphoma (NHL), esophageal cancer, ovarian cancer, pancreatic cancer, penile cancer, persistent venereal disease. Trophoblastic diseases and choriocarcinoma, pheochromocytoma, prostate cancer, pseudomyxoma peritonei, rectal cancer, retinoblastoma, salivary gland cancer, secondary cancers, signet ring cell carcinoma, skin cancer, small bowel cancer, soft tissue sarcoma, gastric cancer, T-cell childhood non-Hodgkin lymphoma (NHL), testicular cancer, thymic cancer, thyroid cancer, t...

Claims

1. A compound 1: The crystal form of its solvate, its hydrate, or its pharmaceutically acceptable salt.

2. The crystal form as described in claim 1, wherein the crystal form is a crystalline form.

3. The crystal form as described in claim 1 or 2, wherein the crystal form is form A, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof.

4. The crystal form as claimed in any of the preceding claims, wherein form A is characterized by an X-ray powder diffraction ("XRPD") pattern using Cu Kα radiation containing signals (e.g., peaks) at 13.2±0.2, 22.3±0.2, and 25.3±0.2 °2θ (e.g., 13.2±0.1, 22.3±0.1, and 25.3±0.1 °2θ (e.g., 13.2, 22.3, and 25.3 °2θ)).

5. The crystal form as claimed in any of the preceding claims, wherein the XRPD pattern of form A further comprises at least one signal (e.g., a peak) using CuKα radiation selected from 12.8±0.2, 18.5±0.2, 19.4±0.2 and 24.8±0.2 °2θ (e.g. 12.8±0.1, 18.5±0.1, 19.4±0.1 and 24.8±0.1 °2θ (e.g. 12.8, 18.5, 19.4 and 24.8 °2θ)). Optionally, the XRPD plot of form A further includes at least two signals (e.g., peaks) selected from 12.8±0.2, 18.5±0.2, 19.4±0.2 and 24.8±0.2 °2θ (e.g. 12.8±0.1, 18.5±0.1, 19.4±0.1 and 24.8±0.1 °2θ (e.g. 12.8, 18.5, 19.4 and 24.8 °2θ)) using Cu Kα radiation. Optionally, the XRPD plot of form A further includes a signal (e.g., a peak) at 12.8±0.2, 18.5±0.2, 19.4±0.2 and 24.8±0.2 °2θ (e.g. 12.8±0.2, 18.5±0.1, 19.4±0.1 and 24.8±0.1 °2θ (e.g. 12.8, 18.5, 19.4 and 24.8 °2θ) using Cu Kα radiation.

6. The crystal form as claimed in claim 1 or 2, wherein the crystal form is form B, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof.

7. The crystal form as claimed in claim 1 or 2, wherein the crystal form is form C, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

8. The crystal form as claimed in claim 1 or 2, wherein the crystal form is form D, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

9. The crystal form as claimed in claim 1 or 2, wherein the crystal form is form E, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

10. The crystal form as claimed in claim 1 or 2, wherein the crystal form is form F, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

11. The crystal form as claimed in claim 1 or 2, wherein the crystal form is form G, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

12. The crystal form as claimed in claim 1 or 2, wherein the crystal form is form H, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

13. The crystal form as claimed in claim 1 or 2, wherein the crystal form is form I, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

14. The crystal form as claimed in claim 1 or 2, wherein the crystal form is form J, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

15. The crystal form as claimed in claim 1 or 2, wherein the crystal form is form K, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

16. The crystal form as claimed in claim 1 or 2, wherein the crystal form is form L, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

17. The crystal form as claimed in claim 1 or 2, wherein the crystal form is form M, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

18. The crystal form as claimed in claim 1 or 2, wherein the crystal form is form N, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

19. The crystal form as claimed in claim 1 or 2, wherein the crystal form is form O, its solvate, its hydrate, or a pharmaceutically acceptable salt thereof.

20. The crystal form as claimed in claim 1 or 2, wherein the crystal form is form P, its solvate, its hydrate or a pharmaceutically acceptable salt thereof.

21. A combination comprising: Compound 1, its salts, its solvates, its hydrates or pharmaceutically acceptable salts in amorphous form; and polymer.

22. A composition comprising the combination as described in claim 21.

23. The composition of claim 22, wherein the polymer comprises a copolymer of N-vinylpyrrolidone and vinyl acetate.

24. The composition of claim 22, wherein the polymer comprises hydroxypropyl methylcellulose.

25. The composition of claim 22, wherein the polymer comprises a polymethacrylate-based copolymer.

26. The composition of claim 22, wherein the polymer comprises a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

27. The composition of any of the preceding claims, wherein the composition is prepared by a method comprising mixing form A of compound 1 with one or more solvents.

28. The composition of any of the preceding claims, wherein the composition is prepared by a method comprising mixing form A of compound 1 with a polymer.

29. The composition of any of the preceding claims, wherein the XRPD spectrum of the composition is substantially similar to one or more of the XRPD spectra shown in FIG100.

30. Use of the crystal form as described in any of the preceding claims in the manufacture of a medicament for treating or preventing cancer in a subject.

31. A combination comprising: (i) a crystal form as described in any of the preceding claims; and (ii) one or more MAPK pathway inhibitors.

32. A method of treating or preventing cancer in a subject, the method comprising administering to the subject a combination comprising: (i) a crystal form as described in any of the preceding claims; and (ii) one or more MAPK pathway inhibitors.

33. A combination for treating or preventing cancer in a subject, the combination comprising: (i) a crystal form as described in any of the preceding claims; and (ii) one or more MAPK pathway inhibitors.

34. Use of a combination in the manufacture of a medicament for treating or preventing cancer in a subject, said combination comprising: (i) a crystal form as described in any of the preceding claims; and (ii) one or more MAPK pathway inhibitors.

35. The method, crystal form, combination or use as claimed in any of the preceding claims, wherein the subject has at least one oncogenic mutation in the BRAF gene.

36. The method, crystal form, combination or use as described in any of the preceding claims, wherein the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of B-Raf.

37. The method, crystal form, combination or use as claimed in any of the preceding claims, wherein the subject has at least one oncogenic mutation in the KRAS gene.

38. The method, crystal form, combination or use as claimed in any of the preceding claims, wherein the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of K-Ras.

39. The method, crystal form, combination or use as described in any of the preceding claims, wherein the subject has at least one oncogenic mutation in the NRAS gene.

40. The method, crystal form, combination or use as claimed in any of the preceding claims, wherein the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of N-Ras.

41. The method, crystal form, combination or use as claimed in any of the preceding claims, wherein the subject has at least one oncogenic mutation in the NF1 gene.

42. The method, crystal form, combination or use as claimed in any of the preceding claims, wherein the subject has at least one tumor and / or cancer cells expressing an oncogenic variant of NF1.

43. The method, crystal form, combination, or use as claimed in any of the preceding claims, wherein the cancer is carcinoma, lymphoma, blastoma, sarcoma, leukemia, brain cancer, breast cancer, blood cancer, bone cancer, lung cancer, skin cancer, liver cancer, ovarian cancer, bladder cancer, kidney cancer, stomach cancer, thyroid cancer, pancreatic cancer, esophageal cancer, prostate cancer, cervical cancer, uterine cancer, gastric cancer, soft tissue cancer, laryngeal cancer, small intestine cancer, testicular cancer, anal cancer, vulvar cancer, joint cancer, oral cancer, pharyngeal cancer, or colorectal cancer.

44. The method, crystal form, combination, or use as described in any of the preceding claims, wherein the cancer is insensitive to or resistant to treatment with one or more MAPK pathway inhibitors.

45. The method, crystal form, combination or use as claimed in any of the preceding claims, wherein the cancer is insensitive to or resistant to treatment with BRAF inhibitors, MEK inhibitors or combinations thereof.